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resumo 
 
Terapia Fotodinâmica, Cancro da bexiga, Porfirinas, Ftalocianinas 
 
A terapia fotodinâmica (PDT) é uma metodologia emergente no tratamento de 
diversas doenças oncológicas, tendo por base o uso de oxigénio, luz e um 
fotossensibilizador (PS) para gerar reações citotóxicas no tecido tumoral. 
Reconhecendo a potencialidade de PSs conjugados com diferentes 
biomoléculas para serem reconhecidos especificamente por antigénios ou 
recetores sobrexpressos nas células tumorais, este estudo pretendeu avaliar o 
potencial fotodinâmico de PSs conjugados com moléculas de galactose (Gal), 
com a albumina humana e bovina, e com o anticorpo monoclonal anti-CD104.  
Numa primeira fase (Parte I) foram avaliadas as propriedades foto-químicas e -
físicas de uma porfirina (PorGal8) e de uma ftalocianina (PcGal16) conjugadas 
com moléculas de galactose. Estes compostos mostraram-se solúveis em meio 
aquoso, fluorescentes, foto-estáveis, geradores de espécies reativas de oxigénio 
(ROS) após foto-ativação e apresentaram interação com a albumina humana. 
Nas Partes II e III deste trabalho, foram realizados estudos in vitro de PDT com 
as linhas celulares de cancro da bexiga HT-1376 e UM-UC-3, para avaliar o 
potencial fotodinâmico da PorGal8 e PcGal16. Os conjugados demonstraram 
toxicidade após foto-ativação, por um mecanismo dependente da formação de 
ROS. Após PDT, a PorGal8 induziu alterações ao nível do citoesqueleto das 
linhas celulares e apresentou-se mais eficaz com a linha celular UM-UC-3. 
Posteriormente foi demonstrado que a resistência das células HT-1376 à PDT 
com a PorGal8 é explicada pela baixa expressão de galectina-1 (proteína capaz 
de reconhecer a PorGal8) e pela presença de células que sobrexpressão a 
proteína ABCG2 (proteína capaz de bombear a PorGal8 para fora das células). 
A PcGal16 apresentou também, inesperadamente, um modo de ação não 
dependente da sua foto-ativação, sendo capaz de diminuir os níveis de 
galectina-1 após o seu uptake pelas células. A síntese e o potencial biológico, 
usando as células UM-UC-3, dos conjugados porfirina-albuminas e porfirina-
anti-CD104 são descritos na última parte deste trabalho (Parte IV). Estes 
conjugados induziram reações citotóxicas após foto-ativação, sendo o 
conjugado com o anticorpo mais eficaz que os conjugados com as albuminas. 
Estes resultados obtidos com experiências in vitro demonstraram que os 
conjugados exibem propriedades bio-físico-químicas promissoras e são 
potenciais PSs para tratamento do cancro da bexiga. 
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Photodynamic therapy (PDT) is a promising method, which has been studied 
and applied to improve the treatment of several tumour types. PDT combines 
molecular oxygen, light and a photosensitizer (PS) to generate cytotoxic 
reactions in cancer cells. The potential of PSs conjugated with biomolecules 
which will be recognized by antigens or receptors overexpressed in cancer 
cells prompted us to validate the photodynamic activity of PSs conjugated 
with galactose units, human and bovine serum albumins, and the monoclonal 
antibody anti-CD104. 
In Part I, the photo-chemical and -physical properties of a porphyrin 
(PorGal8) and a phthalocyanine (PcGal16) conjugated with galactose 
molecules were evaluated. The galacto-conjugates demonstrated to be water 
soluble, fluorescents, photo-stable, generators of reactive oxygen species 
(ROS) and able to interact with human serum albumin. The photodynamic 
potential of PorGal8 and PcGal16 against human bladder cancer cell lines, 
HT-1376 and UM-UC-3 is demonstrated in the parts II and III of this thesis. 
The galacto-conjugates induced phototoxicity in both bladder cancer cell lines 
by a ROS-mediated mechanism. After photo-activation, PorGal8 induces 
changes in actin organization of bladder cancer cells and it was more photo-
active against UM-UC-3 cells. The resistance observed in HT-1376 cells after 
PDT with PorGal8 was due to the low expression of galectin-1 (able to 
recognize galactose molecules) and to the presence of cells overexpressing the 
multi-drug resistant pump ABCG2. Unexpectedly, PcGal16 exhibited also a 
“dark” mode of action by decreasing galectin-1 after its uptake in cancer cells. 
In Part IV, the synthesis of a porphyrin conjugated with bovine and human 
serum albumins and the monoclonal antibody anti-CD104 is reported, as well 
as their biological potential against the human bladder cancer cell line UM-
UC-3. These conjugates demonstrated high efficacy in destroying the cancer 
cells, with the mAb anti-CD104 efficacy overruling the albumins one. 
The in vitro results demonstrated that the conjugates exhibit excellent bio-
physic-chemical properties and prompted us to envisage them as novel 
anticancer drug candidates for bladder cancer treatment. 
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1. General overview 
Let’s suppose that you could have a cancer treatment that maintains your bladder and its physiological 
function, instead of a surgery that removes a part or your entire organ… 
Let’s suppose that you could have a cancer treatment made only once, not months of chemotherapy, 
radiotherapy or surgery… 
The choice is pretty objective!!! 
Photodynamic Therapy will never be the right or only answer for every type of cancers, but it has a 
great potential… 
 
Cancer is the term used for describe malignant diseases in which abnormal cells 
divide without control and are able to invade the tissues and the organs of the body. In 
European Union, in 2008, over two million (2 457,610) incident cancer cases (all sites but 
non-melanoma skin) and over one million cancer deaths (1 231,220) were registered [1]. 
Cancer is an important public health problem and its incidence is likely to increase in the 
future due to European population ageing. Cancer-associated problems (pain, depression, 
economic spending, fear, and anxiety) have impact on individuals, families and our society 
as a whole, making this an alarming situation.  
 The cancer treatment with conventional modalities, including surgery, radiotherapy 
and chemotherapy, result in serious side effects caused by the loss of physiological organ 
function. The advances reported in cancer scientific research imply methods that allow the 
early detection of the disease, and techniques that avoid the surgical removal of an organ. 
Photodynamic Therapy (PDT) is a promising and rather non-invasive method, which has 
been studied and applied to improve the treatment of several tumour types, especially the 
ones occurring in accessible cavities like the bladder. In PDT, the selective uptake of a 
photoactive agent by cancer cells followed by light irradiation can result in Reactive 
Oxygen Species (ROS) production. ROS can trigger chemical and biochemical processes 
that can lead to in situ cell death. Nowadays, the development of compounds for PDT 
those specifically accumulate in cancer tissues is a lively research field. 
 
 
 
 
 
Introduction 
3 
 
2. Bladder cancer 
When cancer touches the life, many things can change... 
 
Bladder cancer is one of the most common malignancies in population worldwide 
and it is characterized by frequent recurrences. This section provides information about the 
development, incidence, diagnosis and therapy of bladder cancer. Herein, the use of PDT 
as an emerging modality for bladder cancer treatment is highlighted. 
 
2.1. Bladder cancer development 
The bladder is a hollow, balloon shaped organ in the pelvic floor and due to its 
function (storage of urine) it has flexible and muscular walls [2]. The inside of the bladder 
is lined with transitional cells (transitional epithelium or urothelium) and squamous cells. 
Next is lamina propria (a layer of loose connective tissue) that is covered by the bladder 
muscle. Outside of the bladder is a layer of fat (Figure 1.1). 
Bladder cancer progression is characterized by four stages [3]. The tumour arises on 
the inside of the bladder wall (stage 0). Stage 0 tumours can penetrate the lamina propria 
layer (stage I), spread into the muscular layer (stage II), extend beyond the bladder muscle 
and into the outer layer (stage III) or spread toward the abdominal or pelvic wall (stage IV) 
[3, 4]. Cancers confined to the urothelium (stage 0) or lamina propria (stage I) are called 
superficial bladder cancers or non-muscle invasive. Muscle invasive cancers correspond to 
cancers that grow into the muscular wall of the bladder [5] (Figure 1.1). 
 
Figure 1.1. Bladder layers and bladder cancer progression (Superficial tumours: stages 0 and I; 
Invasive tumours: stages II, III, and IV). Adapted from [3]. 
Muscle invasive cancer may extend through the bladder wall and grow into a nearby 
organ such as the uterus or vagina (in women) or the prostate gland (in men). It may also 
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invade the wall of the abdomen. When bladder cancer spreads outside the bladder, cancer 
cells are often found in nearby lymph nodes. If the cancer reaches these nodes, cancer cells 
may have spread to other lymph nodes or other organs, such as the lungs, liver, or bones. 
Metastatic bladder cancer is the term used when cancer extends from its original place to 
another part of the body [3].  
Actually, bladder cancer staging is based on tumour penetration degree into the 
bladder wall. Table 1.1 lists penetration stages using the Tumour-Node-Metastases (TNM) 
classification system, which is the most commonly used and universally accepted 
classification [6]. 
 
Table 1.1. Staging of primary bladder cancer tumours (Tumour-Node-Metastases Classification) [6]. 
Ta Non invasive papillary tumour (confined to urothelium) 
Tis CIS carcinoma (high grade "flat tumour" confined to urothelium) 
T1 Tumour invades lamina propria 
T2 Tumour invades bladder muscle 
T2a Tumour invades superficial bladder muscle 
T2b Tumour invades deep bladder muscle 
T3 Tumour invades perivesical fat 
T3a Microscopic perivesical fat invasion 
T3b Macroscopic perivesical fat invasion 
T4 Tumour invades prostate, uterus, vagina, pelvic wall or abdominal wall 
T4a Tumour invades adjacent organs (uterus, ovaries, prostate) 
T4b Tumour invades pelvic wall and/or abdominal wall 
 
Ta and Tis (in the urothelium) and T1 (in the lamina propria) are the non-muscle 
invasive stages. Tis classification is applied for a high grade non-muscle invasive stage 
known as carcinoma in situ (CIS). The CIS is difficult to remove and if untreated will 
likely progress to muscle invasive disease [5, 6]. Most Ta tumours are low grade and do 
not progress to invade the bladder muscle. Stage T1 tumours may be much more likely to 
become muscle invasive. These tumours must be carefully monitored due to their 
recurrence in a higher and potentially lethal stage [6].  
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2.2. Bladder cancer statistics 
Bladder cancer is the second most common cancer of the genitourinary tract (Figure 
1.2), with rates of incidence and mortality in European Union of 14.6 and 4.8 per 100,000, 
respectively [1]. In Portugal, it is the fifth most common cancer among men [1]. Although 
the improvements seen in the last years, the bladder cancer incidence and mortality rates 
vary widely across the continents and between sexes [1, 7], with men and those from 
undeveloped countries at a distinct disadvantage (Table 1.2) [8]. Bladder cancer can occur 
at any age [1], however more than 90% of all patients diagnosed with this type of disease 
are 55 years of age and older. 
 
Figure 1.2. Most frequent cancers in European Union (2008). The values correspond to estimated 
incidence and mortality (both sexes) [1]. 
 
 
Table 1.2. Bladder Cancer in European Union and Portugal (2008) [1]. The values correspond to 
estimated incidence and mortality. Age standardized rate (European) per 100,000. 
  Incidence Mortality 
Portugal 
Man 22.6 7.3 
Woman 4.8 1.7 
European Union 
Man 28.3 8.8 
Woman 5.8 2.0 
Fortunately, the majority of bladder cancers diagnosed remains superficial and 
approximately 75-85% of those are low grade tumours [9]. The probabilities for recurrence 
of superficial bladder tumours range from 15% to 61% at 1 year and from 31% to 78% at 5 
year, according to the European Organisation for Research and Treatment of Cancer [10]. 
While the majority of superficial bladder tumours does not progress, up to 20% can 
proceed to muscle invasive or metastatic disease. The rates for progression range from 
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<1% to 17% at 1 year and from 1% to 45% at 5 year [10]. Due to its frequent recurrence 
and significant progression risk, patients with non-muscle invasive bladder cancers need to 
be under medical surveillance. This situation contributes to a large financial expenditure 
[11]. 
 
2.3. Bladder cancer treatment  
Transurethral resection and intravesical therapy are used in the treatment of bladder 
cancer. Cystoscopy, urine cytology and excretory urograms are used as tools for bladder 
tumours diagnosis [12]. These conventional modalities might cause unwanted side effects 
and in some cases they are not completely effective [9]. There is an urgent necessity for 
novel and effective cancer therapies. Identification followed by complete and selective 
destruction of tumours is the most desirable outcome and may reduce recurrence and 
progression rates [9], with postulated benefits for both patients and the health care 
economics.  
The clinical urological interest in PDT is focused on the preservation of the bladder 
and its function. Current scientific research on PDT for bladder cancer treatment is based 
on the development of tumour selective drugs. Bladder cancers are suitable targets for PDT 
because their interior can be assessed by endoscopy. The bladder geometry allows a 
homogeneous light delivery and the bladder tissue is relatively more translucent when 
compared to other human tissues. 
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3. Photodynamic Therapy  
In oncology, PDT is an emerging modality of cancer treatment. Firstly, a photoactive 
drug is administrated and accumulated selectively in cancer cells. The exposure of the 
tumour to light can result in cytotoxicity induced by ROS. This section provides a brief 
history about PDT and its photoactive component. The clinical applications of PDT in the 
oncologic field, as well as the mechanisms of cell death induced by PDT are also 
described. 
 
3.1. Brief history 
Perhaps the best way to start is the beginning… A detailed description of the PDT history is too 
complex to be encompassed here. Nevertheless, some key findings are important to understand the urgent 
necessity for new and effective PSs. 
 
The idea of combining light and a chemical compound has ancient beginnings. 
Scientific records of the therapeutic effect of sunlight activation of psoralens extracts date 
back to approximately 3,000 years ago when this early photochemotherapy was used for 
repigmentation of vitiligo [13, 14]. The most important discoveries in the history of PDT 
are described in the following topics, focusing those who encouraged the medical 
applications of PDT in the oncologic field (Figure 1.3). 
 
Figure 1.3. Timeline showing selected milestones in the historical development of PDT in oncology. 
 
The first application of PDT in cancer treatment was described by von Tappeiner and 
Jesionek in 1903 [15], who applied eosin to basal cell carcinomas prior to illumination. 
Porphyrins (Pors), the most explored class of drugs in PDT, were initially investigated by 
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Meyer-Betz in 1913 [16]. In these investigations, the PDT effects with Hematoporphyrin 
(HP) in rat tumours are reported. Meyer-Hertz also performed a heroic self-experiment: he 
injected himself with HP and irradiated a small area at his forearm. Consequently, 
exposure to direct sunlight led to phototoxic reactions with swelling and burning sensation 
[17]. Modern time of PDT applications was stimulated after Schwartz [18] and Lipson´s 
findings in which the acid treatment of HP yielded a mixture of Pors and other chemical 
species, termed Hematoporphyrin Derivative (HpD). HpD after red light activation 
demonstrated better PDT effect than that of HP [14]. Although the chemical 
characterization of HpD was not completely clear, in 1975 Dougherty [19] reported that 
the combination of this drug and red light results in mammary tumour eradication. This 
exciting result encouraged the first clinical experiments with HpD to treat patients with 
bladder cancer and skin tumours [20, 21]. In the late 1980s, Quadra Logic Technologies 
Photo Therapeutics (Vancouver, British Columbia, Canada) and Lederle Laboratories 
(American Cyanamid, Pearl River, NY) formed a partnership to achieve approvals for the 
clinical use of PDT [14]. The first PDT approval occurred in 1993 (in Canada) using 
Photofrin® (PF) - a more purified and better characterized version of HpD - for the 
treatment of bladder cancer [22]. The first Food and Drug Administration approval of PDT 
in the United States was also obtained with PF, in 1995, for palliation of obstructive 
esophageal cancer [22]. The results obtained with PF and the PDT approvals generated 
curiosity in the scientific community, as a brief search on Web of Science for the keyword 
“photodynamic” for the period 1900-2010. The number of papers increased from 113 in 
the first half of the century (1900-1955) to more than 10,119 in the second half (1955-
2010), with more than 4,000 papers in the last 5 years.  
The new recent time of clinical PDT is stimulating organic chemists to develop 
synthetic pathways that make possible the production of potential PSs.  
 
3.2. Photophysics and Photochemistry 
Photosensitization reactions are applied in a wide variety of medical areas. However the photophysical 
and photochemical mechanisms by which a photo-activated PS induces cytotoxicity are challenges in 
photobiological and photochemical researches… 
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From photophysical and photochemical points of view, PDT is not completely clear. 
Nevertheless, a general overview about the photo-processes involved in PDT will be 
addressed in the next two points. 
 
3.2.2. Photophysics 
A PS molecule in its normal state is in a configuration named ground-state, 
1
PS. This 
state corresponds to the lowest possible energy in PS molecule. The absorption of light (at 
a specific wavelength) by the PS causes its promotion from ground-state to the excited-
singlet-state, 
1
PS
*
. The excited-singlet-state is extremely unstable with a half time in the 
range of 10
-6
 seconds to 10
-9
 seconds. 
1
PS
*
 can decay back to the 
1
PS emitting fluorescence 
[23]. However, to obtain the PDT effect, the 
1
PS
*
 must undergo intersystem crossover to 
an electronically different excited state (10
-2 
seconds), the excited-triplet-state, 
3
PS
*
 [24, 
25]. After PS restores its ground-state the cycle is repeated (Figure 1.4). The electronic 
excitation of the PS, after light absorption, can elicit cytotoxic effects by PDT or 
fluorescence emission which permits to detect the malignant tissue (Figure 1.4). 
 
 
Figure 1.4. The principle of PDT, under photo-chemical and -physical points of view. 
 
 Depending on the PS chemistry, visible light at the wavelength range of 400-800 
nm can originate the biochemical processes relevant to PDT [23]. However, blue light 
penetrates less efficiently through tissue than red and infrared radiations. Thus, the 
maximum absorption of the PS for PDT should correspond to the wavelength range of 650-
850 nm, where the light penetration through the tissue is quite high (Figure 1.5) and the 
interference by endogenous chromophores within the body is avoided [23, 26]. Moreover, 
PDT
1PS
1PS* 1PS* 3PS*
Type-I reaction
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1O2
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with this wavelength range, the energy required for the production of ROS is maintained 
[23, 26].  
 
Figure 1.5. Correlation between the absorption of light by the PS molecule and the propagation of 
light through the tissues. Adapted from [27]. 
 
3.2.3. Photochemistry 
A light excited PS molecule has a high probability of triplet-state formation (3PS
*
) 
[26]. In general, 
3
PS
*
 is longer lived than the 
1
PS
*
, thus the cytotoxic processes induced by 
PDT are often mediated by this state. 
3
PS
*
 can induce chemical changes in a neighbour 
molecule via two competing pathways: type-I and type-II photochemical reactions [28] 
(Figure 1.5). Type-II is the most predominant process and it is better described in the 
literature than Type-I.  
Type-I photochemical reaction means the transfer of electrons (or protons) to a 
biological substrate forming radicals and radical ions [26]. These radicals can react with 
molecular oxygen producing ROS [26].  
Type-II reaction results in the 
3
PS
* 
energy transference to oxygen molecular, causing 
the excitation of triplet-state oxygen (
3
O2) to form singlet oxygen (
1
O2) that is a highly 
reactive chemical specie. The role of 
1
O2 in the photodynamic effect is controversial 
between researchers. However, for most PSs currently in investigation, the 
1
O2-mediated 
photodynamic mechanism is the model of cytotoxic action usually accepted. In most 
cellular systems, the 
1
O2 has a short lifetime [29], ranging from 10 ns to 320 ns. Therefore, 
its diffusion range is confined to approximately 10-55 nm in cellular media [30, 31]. The 
diameter of human cells ranges from 10-100 µm, thus 
1
O2 cannot diffuse more than a 
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single cell length [32]. The site of the primary 
1
O2 generation determines which sub 
cellular structures may be accessed and attacked.  
 
3.3. Advances in PSs chemistry (first, second and third generation PSs) 
PS is the key element in PDT. Nowadays, none of the existing PSs can be seen as an ideal one. 
 
The design of new PSs with excellent photophysical and biological properties is a 
lively research field in medicinal chemistry [33-35]. PSs are different in terms of chemical 
and biological characteristics and are classified in first-, second- and third-generation PSs 
[36]. An ideal oncologic PS should fulfil the requirements presented in Table 1.3 [25, 32, 
33, 37]. Not only the chemical, physical and biological properties, but also characteristics 
that meet the patient’s needs, have to be taken into account.  
 
Table 1.3. The requirements of an ideal oncologic PS [25, 32, 33, 37]. 
Toxicity 
Able to produce singlet oxygen 
Not able to produce dark toxicity 
Pharmacokinetic elimination Able to be eliminated itself 
Selectivity Able to be selectively and quickly accumulated in tumour tissue 
Activation Able to be activated at the wavelengths that allow optimal tissue penetration 
Sunlight precautions Not able to produce a high degree of skin photosensitivity 
Administration 
Able to be dissolved in injectable solvents 
Not able to produce aggregates in biological environments 
Photostability Able to be photostable and with chemical purity 
Reliability Able to get where you need it and activated when you need it 
Pain-free therapy Not able to induce pain during and after therapy 
Availability 
Able commercially (and not expensive) 
Able to be reconstituted by a local pharmacy 
Safety Able to be administrated without patient significant worry 
Integrative ability Able to be used in conjunction with other forms of treatment 
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3.3.1. First generation PSs 
The first family of PSs discovered is based on HP and its derivatives, HpD. After 
purification and manipulation, HpD was transformed into commercial products like PF (the 
first approved PS) [38]. PF is the main Por-based drug in both pre-clinical and clinical 
trials, but it still contains a non homogeneous chemical constitution. By adding, subtracting 
or substituting Pors structures, new porphyrinic PSs with well characterized composition 
are being created and they are entitled as first generation PSs.  
Pors are aromatic heterocyclic macrocycles composed of four modified pyrrole 
subunits, interconnected via methane bridges. They constitute an important group of 
pigments (Figure 1.6) [39]. The typical absorption spectrum of Pors is characterized by 
five peaks (Figure 1.6), the strongest known as Soret band (about 400 nm) and a set of 
four progressively smaller absorption bands (as the spectrum moves into the red 
wavelengths) known as Q-bands (Figure 1.6) [40]. Although these compounds are the 
most commonly used PSs [41] in the oncological clinic, they present three main 
disadvantages [37, 42]:  
- Biological effects after irradiation occur only to a tissue depth of about 5 mm, due 
to the longest-wave absorption band that appears at 630 nm (with a low extinction 
coefficient);  
- Non-selective accumulation in the tumour due to low specificity to the cancer 
tissue; 
- Long skin photosensitivity due to cutaneous accumulation and slow clearance from 
the skin. 
0
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Figure 1.6. Porphyrin structure and absorption spectrum. 
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3.3.2. Second generation PSs 
The limitations of first generation PSs arouse interest amongst organic chemists for 
the development of second generation PSs with new and improved characteristics based on 
PF. These new compounds include benzoporphyrin derivates, chlorins, phthalocyanines 
(Pcs), texaphyrins and naturally occurring compounds such as hypericin and 
protoporphyrin IX (PPIX) [43]. These PSs absorb light in the red and near-infrared regions 
of the electromagnetic spectrum (600-800 nm), allowing the treatment of deep tumours. 
Furthermore, with second generation PSs, the 
1
O2 production is markedly improved 
compared with first generation PSs [44]. 
Pcs consist of a ring with four isoindole units (Figure 1.7). The pyrrole groups in Pcs 
are conjugated to benzene rings, but in contrast to Por, these unities are bridged by 
nitrogen atoms [43]. Pcs structure causes a strong absorbance in red light with a maximum 
around 670 nm (Figure 1.7) that results in increased tissue light penetration. It has been 
proved that Pcs are very effective in a variety of cancers [45, 46]. Despite of the 
improvements referred above, the majority of second generation PSs does not show a 
localized distribution in the tumour area. 
 
 
Figure 1.7. Phthalocyanine structure and absorption spectrum. 
 
 
3.3.3. Third generation PSs 
Considering the limitations of first and second generation PSs, the third generation 
PSs has been developed. These compounds are first or second generation PSs conjugated 
to/or introduced into biochemical devices that allow biological specificity to deliver/target 
such PSs to cancer cells [44, 47-49]. Many hypotheses have been proposed for the 
development of third generation PSs. Although liposomes and nanoparticles can improve 
tumour accumulation, the biomolecules with specificity for structural motifs overexpressed 
or enhanced in tumour-associated tissue are being conjugated to PSs showing promising 
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results [48]. The publications involving third generation PSs refer to PSs conjugated to 
monoclonal antibodies (mAbs) directed against tumour antigens [50], sugars [51], 
oligonucleotides to enhance photogenotoxicity [52], hormones, metabolites, cellular 
signalling species to selectively target an overexpressed enzyme or receptor [53], and also 
to peptides [54], proteins [55] and amino acids [56]. The tumour selectivity achieved with 
these PSs is desired in the treatment of bladder tumours, since they have large surface areas 
to be illuminated [27].  
 
3.3.3.1. Third generation PSs: Immunoconjugates 
The conjugation of PSs with monoclonal antibodies (mAbs) is an exciting approach 
in molecular-targeted PDT. A mAb is a large immunoglobulin molecule with a weight of 
150 kDa and is developed specifically against a particular antigen by hybridoma 
technology [57]. Nowadays, mAbs are being used in a variety of ways in the cancer 
management, including diagnosis, monitoring, and treatment of the disease. These several 
applications are due to their unique abilities to recognize and bind to tumour-associated 
antigens. Antigens can only be present on tumour cells (a rarity) or overexpressed as 
compared to normal tissue [58, 59]. The main advantages of mAbs employment are their 
homogeneity and the fact that they can be produced endlessly [60]. The principal 
disadvantage is that mAbs production can take up to a year or longer, being also 
considerably expensive [60].  
The conjugation of PSs to mAbs has led to some of the most promising results for 
PDT [48, 61]. The advantages claimed for this approach include mAb specificity (highly 
specific for their target antigens) and PS specificity (non-toxic to normal organs which did 
not receive light). The major obstacle is the high PS-to-mAb ratios required, which makes 
the synthesis and purification steps complicated. The goal of any PS-mAb synthesis should 
be to retain mAb immunoreactivity and PS phototoxicity.  
In Table 1.4, are described some results obtained with PS-mAb immunoconjugates.  
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Table 1.4. Reported experiments of PDT with immunoconjugates. 
 
 Photosensitizer mAb Cancer type Results 
Malatesti [62] 
Porphyrin 
derivates 
EpCAM 
CD104 
Colon 
Lung 
Conjugates produced cytotoxic effect in 
lower doses than unconjugated PS 
Goff [63] 
Chlorin 
derivative 
OC125 Ovarian 
After PDT, control mice died and 40% of 
the treated animals were alive for 50 days 
Animals treated exhibited a substantial 
reduction in the amount of ascites 
Hudson [64] 
Porphyrin 
derivates 
35A7 
FSP 77 
Colon 
Ovarian 
Conjugates had tumour uptake values and 
phototoxicity higher than unconjugated PSs 
Smith [65] 
Porphyrin 
derivates 
CD104 
CD146 
CD326 
Colon 
Lung 
Conjugates caused suppression of tumour 
growth at lower doses than the commercial 
PF 
Mitsunaga [50] 
Phtalocyanine 
derivate 
Trastuzu 
Panitumu 
Subcutaneously 
xenografted 
tumours 
Conjugates induced rapid cell death in vitro 
by necrosis and were most effective when 
bound to the target 
In vivo studies showed target specific 
tumour shrinkage by the conjugates 
 
Malatesti [62] conjugated a Por with the mAbs anti-EpCAM and anti-CD104, which 
are specific for a human epithelial adhesion molecule and human integrin β4, respectively. 
These immunoconjugates were tested in human colon adenocarcinoma and human lung 
carcinoma cell lines and demonstrated ability to bind and photodynamically inactivate 
cancer cells that expressed the correspondent antigen. Goff [63] reported a study with a 
chlorin conjugated with a monoclonal than recognizes an antigen expressed in non-
mucinous ovarian cancers. The in vivo results showed that after PDT, 40% of the treated 
animals were still alive 50 days and all control animals died between 30 and 50 days. 
Hudson [64] reported a study with Pors conjugated with mAb anti-FSP 77 directed against 
the extracellular domain of the erb-B2 receptor (a member of the epithelial growth factor) 
overexpressed in colon adenocarcinomas, and with mAb anti-35A7 that binds to 
carcinoembryonic antigen overexpressed in breast and ovarian cancers. Overall, 
conjugating the Por to mAbs increased the potential for in vitro phototoxicity. Smith [65] 
reported the conjugation of Por with three different mAbs (anti-CD104, anti-CD146 and 
anti-CD326). In vivo studies demonstrated that these conjugates produce suppression of 
human tumour growth, similar to Photofrin®, but at administered PS doses that were more 
than two orders of magnitude lower. Mitsunaga [50] reported the conjugation of a Pc with 
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mAbs targeting epidermal growth factor receptors. The conjugates were effective when 
bound to the cell membrane and produced no phototoxicity when not bound. 
 
3.3.3.2. Third generation PSs: glycoconjugates 
The concept behind PSs conjugated with sugars is quite stimulating in the 
development of third generation PSs. The carbohydrates can increase therapeutic 
selectivity because they interact with glycoprotein-based membrane receptors that have 
carbohydrate recognition domains. Carbohydrates play important roles in biological 
processes, although carbohydrate and carbohydrate-derived drugs cover only a limited 
therapeutic area [66].  
In our group, at the University of Aveiro, several Por glycoconjugates have been 
developed [67-72]. Some of these Por glycoconjugates have demonstrated antiviral activity 
against herpes simplex virus type 1 and 2, after PDT [68, 71]. The corresponding Pc 
glyconjugates are, however, rather uncommon being thus of great interest to study [72-74]. 
Additional advantages with glycoconjugates are that the presence of carbohydrates 
modifies the PS macrocycle amphilicity and specific sugar transporters exist for different 
monosaccharides in cancer cells [58]. Moreover, the production and characterization of 
glycoconjugates are easier and cheaper than immunoconjugates. Many glycoconjugates 
have been synthesized to specifically target the lectin family receptors which are 
overexpressed in certain malignant cells, since they are involved in cell growth [75], cell 
adhesion [76], immune response [77] and angiogenesis [78]. Galectins are sugar-binding 
proteins with a weight of 15-kDa and known to show high affinity for galactose [79, 80]. 
Extracellular galactose-binding lectins are expressed on the surface of certain cancer cells 
and actually are one of the most investigated molecular targets for drug development [66]. 
Galectin-1 (a prototype, dimeric galectin with two identical carbohydrate recognition 
domains) mRNA levels are increased in most high-grade bladder tumours compared with 
normal or low-grade tumours and this lectin is able to bind α-galactoside [81, 82]. 
Therefore, it seems that this may be a valuable cellular target for galactose-based PSs.  
The glycoconjugates have demonstrated promising in vitro results (Table 1.5) and 
are currently being tested in vivo. Maillard reported the synthesis of a glycoconjugated 
chlorin [83]. This compound displayed good in vitro PDT efficacy. Fujimoto [84] reported 
the conjugation of a porphyrin with galactose and its molecular delivery to hepatocytes 
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(liver cells). Experiments indicated that the conjugate has a selective uptake by cancer 
cells. Zheng [85] reported the synthesis and biological evaluation of a β-galactose-
conjugate. Laville [86] reported the photoactivity of asymmetric and symmetric 
glucoconjugated chlorins. The asymmetric glucoconjugated chlorin exhibited superior 
phototoxicity compared with symmetric glucoconjugated chlorin and sugar-free chlorin. 
Chen reported the synthesis of Por-saccharide conjugates and their selective uptake to 
several cancer cells, followed by an investigation of their PDT properties [87]. In a recent 
study, Tanaka [51] compared the PDT efficacy of a newly developed glycoconjugated 
chlorin, with Talaporfin, which is clinically used in Japan. The in vitro studies showed that 
this new conjugate was 30 times more cytotoxic to gastric and colon cancer cell lines than 
Talaporfin. The in vivo studies showed that the conjugate accumulation was higher in 
tumours and this conjugate significantly suppressed tumour growth when compared with 
Talaporfin.  
 
Table 1.5. Reported experiments of PDT with glycoconjugates. 
 
 Photosensitizer Sugar 
Cancer 
type 
Results 
Maillard [83] Chlorin derivate Maltose Colon 
Conjugates showed phototoxicity as opposed to 
unconjugated PS 
Fujimoto [84] 
Porphyrin 
derivate 
Galactose 
Glucose 
Liver 
Galactose conjugate was selectively captured by 
cancer cells 
Zheng [85] Chlorin derivate 
Galactose 
Lactose 
Leucemy 
Conjugates produced an increase in photodynamic 
activity compared with unconjugated PS 
Laville [86] Chlorin derivate Glucose Colon 
Asymmetric conjugates showed stronger 
phototoxicity than unconjugated and symmetric 
conjugates 
Chen [87] 
 
Porphyrin 
derivate 
Galactose 
Glucose 
Breast 
Glucose conjugate was preferentially accumulated in 
cancer cells over galactose conjugate 
Tanaka [51] Chlorin derivate Glucose 
Gastric 
Colon 
Conjugates demonstrated a selective accumulation in 
cancer cells and higher toxicity than Taloporfin 
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3.4. Clinical applications 
Clinical PDT is a two-stage and a dual selective process with the first stage corresponding to the 
administration of the PS. After a certain period of time, the PS is preferentially retained in tumour (first time 
selective). The tumour is illuminated with light (second time selective) at a specific wavelength, a process 
which constitutes the second and final stage in the therapy… 
 
In clinical cancer settings, the PS is typically administered intravenously or topically, 
followed by light illumination of the anatomical site being treated (Figure 1.8).  
Initially, there is an uptake of the PS by most normal and hyper-proliferating cells, 
but it is retained longer in the last ones [88]. After maximum PS accumulation in cancer 
cells, the tumour is irradiated. The period of time between PS administration and the start 
of illumination varies from 5 min to 24 h, or more. The combination of PS and light at a 
specific wavelength can result in 
1
O2 production which is believed to be responsible for 
tumour destruction [89]. Total healing of the area after PDT may take from 2 to 6 weeks. 
During this time, the patient will be light sensitive (due to PS accumulation) and must be 
protected from direct light. Depending on the PS used, light sensitivity may take from 4 
hours to 6 weeks. The rapid cytotoxic reaction resulting in specific tumour destruction 
makes this therapy attractive to both patient and clinician. 
 
Figure 1.8. Schematic illustration of the mechanism of PDT in oncology. 
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3.5. Mechanisms of cell death in PDT 
Because of short lifetime and limited migration of 1O2 from the site of its formation, sites of damage 
are closely related to the localization of the PS… 
 
The therapeutic effects of PDT are thought to occur by three different ways: (i) 
cytotoxic reaction - direct lethal effects on tumour cells, (ii) vasculotoxic reaction - 
vascular impairment which limits blood supply to the tumour region and (iii) acute 
inflammation that can stimulate the immune system to recognize and destroy tumour cells 
[90, 91]. Although PDT can induce many cellular and molecular signalling pathways in 
cancer cells, its main purpose is to induce cell death (cytotoxic reaction) by apoptosis and 
necrosis [91, 92]. In these processes, the 
1
O2 is the fundamental cytotoxic species as 
outlined in the photochemical section. Singlet oxygen has a very short lifetime in cells and 
limited migration [29], thus the type of response triggered by activation of the PSs depends 
on their intracellular localization [93, 94].  
 
3.5.1. Modes of cell death in PDT 
Under PDT, cells can undergo at least two distinct types of cell death: necrosis and 
apoptosis (Figure 1.9). Among other factors, the type of cell death induced after PDT 
depends on the intracellular localization of the PS and on the PDT dose.  
Necrosis is a violent and quick form of cell death, characterized by in vitro 
cytoplasm swelling, devastation of organelles and disruption of the plasma membrane, 
leading to the release of intracellular contents and in vivo inflammation. Necrosis has been 
referred as an accidental cell death way or unprogrammed process [95]. The mechanisms 
involved in this process are much less studied than in apoptosis [96, 97]. 
 
Figure 1.9. The two distinct types of cell death induced by PDT, necrosis and apoptosis. 
 
Apoptosis can be identified in single cells and is characterized by cell shrinkage. 
Recently, researchers have described many pathways whereby mammalian cells can 
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undergo apoptosis, and have proposed some of the ways that PDT can initiate these 
processes in vitro [92]. This highly regulated form of cell death results in fast cell 
destruction, and requires transcriptional activation of specific genes, including the 
activation of endonucleases, following DNA degradation into fragments, and activation of 
caspases [92]. Two major apoptotic pathways have been characterized: the death receptor-
mediated apoptosis, also referred as extrinsic pathway, and the mitochondria-mediated 
apoptosis, also named intrinsic pathway [98]. Both events eventually lead to activation of 
caspase cascades, known as “effector caspases” [99]. Caspases are synthesized as 
zymogens and these precursors are transformed into active enzymes via oligomerization-
induced autoprocessing for initiator caspases (numbers 1, 2, 4, 5, 8, 9, 10, and 14) while 
effector caspases (numbers 3, 6, and 7) are activated by other proteases and play a key role 
in initiating and executing apoptotic mechanisms [37].  
In the extrinsic pathway, cell death surface receptors from the TNF (Tumour 
Necrosis Factor) gene family are stimulated after ligand binding, activating the initiator 
caspase-8 via adaptor and scaffolding proteins. The caspase-8 cleaves Bid (a BH3 only 
member of the Bcl-2 family). 
In the intrinsic pathway, PDT induces release of cytochrome c [100], which occurs as 
a result of mitochondria outer membrane permeabilization after PDT [99] and is controlled 
by Bcl-2 family members [27]. The Bcl-2 family includes four anti-apoptotic proteins: 
BclXL, Bcl-w, A1, Mcll and Bcl-2, and two protein groups that promote apoptosis: the 
Bax and the BH3-only families pro-apoptotic proteins [99]. Released cytochrome C binds 
Apaf-1 (apoptosis activating factor-1) and induces its oligomerization, in the presence of 
dATP. This complex, termed apoptosome, recruits and activates the initiator caspase-9 
[101].  
In both pathways, the activation of initiator caspases (caspase-8 or caspase-9) leads 
to the activation of effector caspases (Figure 1.10). During apoptosis the cells shrink, the 
nuclear chromatin becomes pyknotic (irreversible condensation of chromatin), the nuclear 
membrane condenses and the nucleus break up into apoptotic bodies. Although the 
cytoplasmic organelles remain intact, DNA is digested at internucleosomal sites, giving 
rise to fragments [98]. Apoptotic cells and apoptotic bodies are engulfed and cleared by 
phagocytes [102]. 
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3.5.1.1. Involvement of Bcl2 family of proteins in PDT 
 There are several reports in the literature showing the involvement of anti-apoptotic 
and pro-apoptotic proteins in cell death induced by PDT [103-106, 108]. The role of Bcl-2 
in the apoptotic response caused by PDT is controversial. In some reports it has been 
described that cells overexpressing Bcl-2 [103], are sensitive to apoptosis after PDT. It has 
been demonstrated that PDT induces direct degradation of Bcl-2 without affecting Bax, 
and the enhanced apoptotic response to PDT is attributed to high Bax:Bcl-2 ratio after PDT 
[103]. Other studies [104], have described that the Bcl-2 overexpression protects cells 
against PDT-induced phototoxicity, namely against PDT-induced apoptosis by blocking 
the activity of caspases 3 and 6. The RIF 1 (radiation-induced fibrosarcome cells), a type 
of cells resistant to PDT, treated with the antisense oligonucleotide, directed against the 
coding region of Bcl-2 protein demonstrated an increase of phototoxicity after PDT [105]. 
Moreover, it was observed that the treatment of these cells with PDT resulted in a 
significant induction of apoptosis with induction of caspase activity.  
The localization of the anti-apoptotic protein Bcl-2 in the endoplasmic reticulum 
(ER) suggests that this protein controls the intracellular calcium fluxes. It has been 
reported that after PDT, there are alterations of the Ca
2+
-binding proteins in the ER [106] 
leading to Ca
2+
 release and induction of the Ca
2+
 apoptotic processes. The ER stress allows 
Ca
2+
 to flow from ER stores to the cytosol and mitochondria, leading to induction of 
apoptosis. In fact, it has been reported that PSs localized in the ER stimulate a rapid 
increase in calcium concentration after PDT. Moreover, the decrease in ER activity 
(folding, modifying and sorting newly synthesized proteins) induced after PDT results in 
the accumulation of unfolded or misfolded proteins activating the adaptive unfolded 
protein response (UPR) [92]. The excessive accumulation of unfolded or misfolded 
proteins in ER results in excessive ER stress that can overwhelm the adaptive UPR, 
triggering cell death. The ALA-based PDT [107] decreased the levels of the ER calcium-
binding proteins as well as of Bcl-2, which served to amplify the mechanism ensuring 
apoptotic cell death. 
The role of the pro-apoptotic protein Bax in PDT-induced apoptosis is well reported 
in [108]. The cells DU-145 (human prostate cancer cells) demonstrated to be resistant to 
PDT due to the absence of Bax, since apoptosis was restored by the expression of Bax in 
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these cells. It was observed that in the absence of Bax, the downstream events of the 
mitochondrial pathway of apoptosis were completely blocked after PDT.  
 
Figure 1.10. Some PDT-associated apoptosis pathways involving mitochondria, ER and Bcl-2 family 
protein. PS-Photosensitizer, MT-Mitochondria, ER-Endoplasmic Reticulum. 
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4. PDT in bladder cancer: state of the art 
PDT for bladder cancer treatment remains largely investigational with limited use. 
PDT for bladder cancer is approved in Canada and in some EU nations but has not been 
approved by the US FDA [27].  
Early response rates (from 2-3 months) after PDT have been observed in 
approximately 50-80% of patients with bladder cancer, with longer term (from 1 year to 2 
years) durable responses noted in 20-60% of patients [27]. PF is the most commonly used 
PS in bladder cancer treatment and its clinical use dates to the late 1970s, when HpD 
effects in 5 patients were published [21]. PDT with HpD was used to treat 50 transitional 
cell carcinomas in 37 patients and a 74% complete response rate was achieved [109]. 
Another study reported the PDT effects with HpD in 34 patients with CIS. In this trial a 
73.5% complete response rate at 3 months was achieved [110]. However, by 2 years, 
77.8% of these patients had recurrence. In these studies, treatment of superﬁcial bladder 
cancer with PDT was generally well tolerated, with dysuria (painful urination), hematuria 
(blood in the urine), and skin photosensitivity being the most common acute toxicities. 
Bladder wall ﬁbrosis and diminished bladder capacity have been and continue to be 
problems in some PDT treated patients. It was demonstrated that PDT with sulfonated Pc 
in a rat bladder cancer produces a superficial necrosis without muscle damage [111]. With 
the use of PF as a PS, researchers observed complete response rates as high as 60% for 
patients with CIS or superﬁcial bladder cancer [112, 113]. Several experiments have 
demonstrated that suitable results can be achieved by combination of PDT to another 
therapeutic modality. Namely, studies combining intravesical immunotherapies or 
chemotherapies with PDT demonstrated that these therapies may significantly enhance the 
treatment of bladder tumours [114, 115]. In a recent small pilot study performed by Lee 
[116], 5 patients with non-muscle invasive bladder cancer were treated by PDT using a 
chlorin derivative. At a median follow-up of 29 months, 2 patients where disease free, 2 
patients developed recurrence and 1 patient progressed to muscle invasive disease.   
In terms of immunoconjugates for bladder cancer therapy, promising results were 
obtained with the conjugation of the monoclonal antibody Erbitux (cetuximab), that binds 
to an antigen overexpressed in bladder cancer cells [117]. In terms of glycoconjugates for 
bladder cancer therapy, no experiments have been reported. 
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5. Objectives of this thesis  
The objectives of this thesis were: 
- Study the photo-physical and -chemical properties of new galacto-conjugates, already 
synthesized: a porphyrin conjugated with eight galactose molecules (PorGal8) and a 
phthalocyanine conjugated with sixteen galactose molecules (PcGal16); 
- Conjugate a porphyrin with human and bovine albumins, and with an mAb against 
CD104;  
- Validate the photodynamic potential of the aforementioned conjugates against two human 
bladder cancer cell lines, UM-UC-3 and HT-1376: 
- Determine the uptake of the bioconjugates by cells, 
- Verify the toxicity of the conjugates in darkness and after light activation, 
- Quantify the levels of ROS after PSs-PDT, 
- Clarify the nature of the phototoxicity for each bioconjugates, 
- Identify the molecular mechanisms underlying cell death induced after PorGal8-
PDT. 
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1. Galacto-conjugated porphyrin PorGal8 and phthalocyanine 
PcGal16: photo-chemical and -physical characterization 
 
1.1. General overview 
Porphyrins (Pors) and phthalocyanines (Pcs) are well known first and second 
generation PSs, respectively. The conjugation of PSs with galactose units increases their 
water solubility [1-8] and provides the possibility for specific interaction of the resulting 
galacto-conjugate with galectins overexpressed in cancer cells. In this thesis, Pors and Pcs 
conjugated with galactose units (already synthesized) were evaluated as new PSs for PDT 
of bladder cancer cells. The photo-chemical and -physical properties (mentioned below) of 
these galacto-conjugates were assessed before their in vitro validation, since these are 
important parameters in the development of new PSs.  
This section includes the UV-Visible and fluorescence characterization, water 
solubility, 
1
O2 production ability, photostability and interaction with human serum albumin 
(HSA) (Figure 2.1) of a Pc conjugated with sixteen galactose units PcGal16 and a Por 
conjugated with eight galactose units PorGal8. These results are already published [9].  
 
Figure 2.1. Schematic overview of this section including the photo-chemical and -physical 
characterization of two galacto-conjugates, PcGal16 and PorGal8. The galacto-conjugates were synthesized 
and gently provided by Doctor Sandrina Silva [9]. 
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1.2. UV-Visible characterization, water solubility and fluorescence emission 
of galacto-conjugates 
The electronic absorption spectra of the galacto-conjugates were measured in DMF 
and DMSO (Figure 2.2) and their extinction coefficients (ɛ) in these two organic solvents 
are summarized in Table 2.1. PcGal16 and PorGal8 at 2 µM (in DMSO or DMF) exhibit a 
very sharp Soret band (at 415 nm) and Q band (at 720 nm), respectively, which is typical 
of non-aggregated PSs. To determine the solubility of the galacto-conjugates in aqueous 
buffered solution, their absorption spectra were also acquired in PBS. In this solvent, 
PorGal8 and PcGal16 demonstrated a lowering intensity and a broadening of the Soret and 
Q bands (Figure 2.2), which are related with reasonable water solubility. 
 
Figure 2.2. Electronic absorption spectra of PorGal8 (A) and PcGal16 (B) at 2 μM in DMF, DMSO, 
and PBS. 
 
To evaluate the water solubility range of the galacto-conjugates, UV-Visible studies 
with increasing concentrations of the conjugates in PBS solution (PcGal16: 0 µM to 9 µM, 
PorGal8: 0 µM to 19 µM) were performed (Figure 2.3). The galacto-conjugates strictly 
follow the Beer-Lambert law at the studied concentrations (Figure 2.3 B and D) 
suggesting no aggregation in PBS at concentrations below 19 µM for PorGal8 and 9 µM 
for PcGal16. The PSs´ solubility in aqueous solution is a critical parameter for their PDT 
application, since PSs´ aggregation compromises their ROS production and their uptake by 
cells [8].  
These results demonstrate that concentrations of PorGal8 and PcGal16 in PBS below 
19 µM and 9 µM, respectively, can be used for the in vitro PDT assays without 
compromising their phototoxic effectiveness. 
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Figure 2.3. UV-Visible spectra of PorGal8 (A) and PcGal16 (C) in PBS at different concentrations 
(PcGal16: 0 µM to 9 µM, PorGal8: 0 µM to 19 µM). The inset plots the PorGal8-Soret band (B) at 415 nm 
and PcGal16 Q-band (D) at 673 nm versus concentration of the respective galacto-conjugate in PBS. 
 
 The steady-state fluorescence emission spectra of PorGal8 and PcGal16 were 
acquired in DMF and the fluorescence quantum yields (ΦF) were determined (Table 2.1) 
using meso-tetraphenylporphyrin (TPP) as standard (ΦF = 0.11 in DMF [10]). These 
studies demonstrated that the galacto-conjugates shown fluorescence emission bands in the 
red spectral region - PcGal16: 734 nm and 805 nm, PorGal8: 659 nm and 703 nm - which 
can be used to determine the concentration of these PSs inside the cells.  
 
Table 2.1. UV-Visible data of the galacto-conjugates in DMF and DMSO. Fluorescence data of 
PorGal8 and PcGal16 in DMF. 
alog ε M-1.cm-1 
bReference: TPP in DMF ФF = 0.11 [10] excitation at 601 nm 
c∆Stokes is the Stokes shift, corresponding to the difference between wavelengths of maxima absorption and 
emission 
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λemission 
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ФF 
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(nm) 
PcGal16 
DMF 391 (5.34), 649 (5.30), 722 (5.45) 734, 805 0.13b 12 
DMSO 399 (5.16), 650 (5.26), 723 (5.40) ___ ___ ___ 
PorGal8 
DMF 413 (5.10), 504 (3.39), 577 (3.27), 655 (2.30) 659, 703 0.09b 4 
DMSO 415 (5.24), 505 (4.20), 575 (3.80), 655 (2.00) ___ ___ ___ 
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1.3. Photostability and singlet oxygen production of galacto-conjugates 
To evaluate the potentiality of the galacto-conjugates as new PSs, their photostability 
and ability to generate 
1
O2 (the main cytotoxic specie involved in PDT) were determined. 
For the photobleaching studies, the intensity of the Soret band of PorGal8 and Q band of 
PcGal16 was monitored after irradiation with white light at a fluence rate of 150 mW.cm
-2
 
(Table 2.2).  
These results demonstrate that the galacto-conjugates are photostable when exposed 
to UV-Visible light and molecular oxygen over the investigated irradiation period (30 
min). 
 
Table 2.2. Photostability of 19 µM of PorGal8 and 9 µM of PcGal16 in PBS, after irradiation with 
white light at a fluence rate of 150 mW.cm-2 for different periods of time (0-30 min). The results are 
presented in percentage calculated by the ratio of residual absorbance (at 673 nm for PcGal16 and at 415 nm 
for PorGal8) at different periods of time and absorbance before irradiation. 
Galacto-conjugate Irradiation time (min) 
 0 1 3 4 5 10 15 20 25 30 
PcGal16 100 100 100 99 99 98 98 98 98 97 
PorGal8 100 99 99 99 99 99 98 98 97 97 
 
 
The generation of 
1
O2 by galacto-conjugates was determined in DMF:H2O (9:1) 
using DPBF (1,3-diphenylisobenzofuran) as 
1
O2 scavenger [11]. The well known 
1
O2 
generators, TPP and ZnPc (zinc phthalocyanine) were used as references [12] for PorGal8 
and PcGal16, respectively. PorGal8 and TPP (both at 0.67 µM), PcGal16 and ZnPc (both at 
0.1615 µM) were able to photo-oxidize DPBF (at 16.15 µM) (Figure 2.4). 
The galacto-conjugates demonstrated to be potent generators of 
1
O2 and at 0.67 µM 
PorGal8 was able to decompose 77.5% of DPBF, after 20 min of irradiation. For PcGal16 
at 0.1615 µM, the DPBF breakdown was about 96.1%, after 5 min of irradiation. The 
galacto-conjugates have shown similar ability to photo-oxidize DPBF when compared to 
the corresponding references TPP and ZnPc.  
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Figure 2.4. Photo-oxidation of DPBF (16.15 µM) in DMF:H2O (9:1) with or without PorGal8 or TPP 
at 0.67 µM (A); PcGal16 or ZnPc at 0.1615 µM (B), after irradiation with white light filtered through a cut-
off filter for wavelengths <540 nm (4.5 mW.cm-2). The DPBF absorbance was recorded at 415 nm. 
 
 
1.4. Affinity of galacto-conjugates to Human Serum Albumin 
To elucidate the pharmacological properties of the galacto-conjugates [13], their 
interaction with the abundant plasma protein HSA was studied. The fluorescence 
quenching of tryptophan residues in 2.0 µM of HSA samples, after addition of PorGal8 
and PcGal16 at increasing concentrations (0-30 µM) was determined. PSs´ addition to HSA 
samples produced fluorescence quenching of the tryptophan residues (Figure 2.5). The 
effects of DMSO on HSA fluorescence quenching were tested, since the stock solutions of 
the galacto-conjugates were prepared in this solvent. Over a concentration range of 0-0.5 
% (v/v), DMSO did not quench HSA fluorescence (data not shown). The binding constant 
(Ka) and the number of binding sites (n) of galacto-conjugates to HSA were determined as 
described in the literature [14]. The values of Ka and n for PorGal8 were 1.544 x 10
4
 M
-1
 
and 1.2, respectively. For PcGal16 were 2.351 x 10
5
 M
-1 
and 1.4, respectively. These results 
indicate that there is only one binding site for the galacto-conjugates closes to the 
tryptophan residues of HSA. 
 
Figure 2.5. Fluorescence quenching curves of 2 µM of HSA, after addition of the galacto-conjugates 
at several concentrations (between 0 µM to 30.0 µM). Quenching (%)=(F0-F)/F0, where F0 and F are the 
HSA fluorescence intensities in the absence and presence of the conjugates (λexcitation at 280 nm and 
wavelength emission range between 300 nm to 400 nm). 
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2. Galacto-conjugated porphyrin PorGal8: photoactive agent against 
bladder cancer cells 
 
2.1. General overview  
Porphyrins are the most commonly used drugs in cancer treatment by PDT. 
Porphyrins decorated with carbohydrates, like galactose units, should allow for improved 
PDT treatment. Galactose-binding lectins, especially galectin-1 and galectin-3 are 
overexpressed in the surface of bladder tumours [15] and can be exploited in the 
development of new molecular-targeted PSs for cancer treatment. As demonstrated in part 
I, PorGal8 is water soluble up to 19 µM, stable after light irradiation, efficient generator of 
1
O2 and binds to HSA protein [9]. In this part of the work (Figure 2.6), the effectiveness of 
PorGal8 to induce phototoxicity in two human bladder cancer cell lines HT-1376 and UM-
UC-3 will be reported. Due to the presence of carbohydrate moieties in the PS, the 
involvement of galecin-1 target specificity of the PorGal8 was addressed. Additionally, the 
presence of cancer stem cells (CSCs) in these cell lines was exploited. The ROS generation 
after PorGal8-PDT (in the presence and absence of quenchers) was evaluated. The 
alterations of F-actin and the cell death pathways induced after PorGal8-PDT were also 
addressed. 
 
 
 Figure 2.6. Schematic overview of this section including the in vitro results obtained with PorGal8 
against the human bladder cancer cell lines, UM-UC-3 and HT-1376. 
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2.2. Galectin-1 protein levels in HT-1376 and UM-UC-3 bladder cancer cells 
The in vitro validation of the compounds studied in this thesis, namely PorGal8, was 
performed in bladder cancer cell lines (HT-1376 and UM-UC-3, Figure 2.7 A and B) 
derived from transitional cell carcinoma, which is the most common malignant tumour 
arising from the urothelium. The morphology of HT-1376 is defined by tightly adherent 
cuboidal cells growing as colonies. The morphology of UM-UC-3 cells is defined by 
poorly adherent cells displaying a stellate morphology. UM-UC-3 cells have been 
associated with the epithelial to mesenchimal phenotype, which is an event implicated in 
neoplastic progression [16]. It has been reported that UM-UC-3 cells have an invasive 
phenotype, while HT-1376 cells have an epithelial morphology associated with a non-
invasive phenotype [16]. 
For the PSs conjugated with galactose units it was thought that galactose around the 
core of PSs has interaction with galactose-binding lectins (galectins) overexpressed on the 
surface of certain types of cancer cells, promoting somehow its uptake [16]. Among 
galectins, the expression of galectin-1 is correlated with the cancer staging and cell 
metastatic potential [15] and can be exploited in the development of new conjugated PSs 
for cancer treatment.  
The galectin-1 protein levels were determined in both cell lines by western blotting 
and they were significantly higher in UM-UC-3 than in HT-1376 cells (Figure 2.7 C and 
D). The expression of galectin-1 is known to be correlated with the degree of malignancy 
in rat thyroid cell lines transformed with several viral oncogenes [17]. The mRNA 
(messenger ribonucleic acid) levels of galectin-1 were 20-fold higher in low tumourigenic 
and 100-fold higher in highly tumourigenic cells, than in normal cells [17]. 
These results demonstrate that UM-UC-3 and HT-1376 cells have a different 
morphology and galectin-1 protein levels. UM-UC-3 cells seem to correspond to a more 
aggressive and invasive phenotype. 
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Figure 2.7. Bright field images of monolayer culture of HT-1376 (A) and UM-UC-3 (B) human 
bladder cancer cell lines. Original magnification: 200x. (C) Western blotting analysis of galectin-1 protein 
levels in HT-1376 and UM-UC-3 cells. β-actin was blotted as loading control. (D) Quantitative analysis of 
galectin-1 (normalized to β -actin) expressed as a ratio of the levels found in HT-1376 cells. Data represents 
mean ± S.D. of five independent experiments. *Significantly different from HT-1376 cells (p<0.05). 
 
 
2.3. Uptake of PorGal8 by HT-1376 and UM-UC-3 bladder cancer cells 
The concentration of PorGal8 inside the HT-1376 and UM-UC-3 cells was measured 
by fluorescence spectroscopy, in order to determine the optimum concentration of PorGal8 
and incubation time to be used in the following assays. Bladder cancer cell lines were 
incubated in the dark at various periods of time (0.5, 1, 2, and 4 h) with increasing 
concentrations of water soluble PorGal8 (0.5, 2.5, 5, 10, and 12.5 µM) in PBS.  
In both cell lines a fast uptake of PorGal8 occurred during the first 1.5 h, followed 
by a slower steady increase (Figure 2.8). PorGal8 uptake profile as a function of the 
incubation time was higher in UM-UC-3 cells than in HT-1376 cells. Thus, the higher 
uptake of PorGal8 by UM-UC-3 cells when compared with HT-1376 cells can in some 
way be attributed to the protein levels of galectin-1 (Figure 2.7 C and D). Galectin-1 may 
serve as docking sites for PorGal8 on the cell membrane and probably, facilitating entry of 
PorGal8.  
The results can support our hypothesis, that the presence of galactose units in 
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PorGal8 should allow for improved uptake of this PS in cancer cells and galectin-1 may 
have an important role in that process.  
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Intracellular uptake of PorGal8 by HT-1376 (A) and UM-UC-3 (B) cells, at various 
concentrations (0.5, 2.5, 5, 10, and 12.5 µM) in function of the uptake time (0, 1, 2, 3, and 4 h). PorGal8 
concentration was determined using fluorescence spectroscopy and the results were normalized to protein 
quantity. Data are the mean ± S.D. of at least three independent experiments performed in triplicates.  
 
The intracellular uptake of PorGal8 in bladder cancer cells was also confirmed by 
confocal fluorescence microscopy (Figure 2.9). The cells were incubated with PorGal8 at 
10 µM for 1.5 h (in darkness) and cell nuclei were stained with DAPI. In both cell lines, 
the fluorescence of PorGal8 was clearly observed throughout the cytoplasm of cancer cells 
with some small bright spots. The strong fluorescent signal of PorGal8 inside the UM-UC-
3 cells (Figure 2.9) confirms its higher uptake in these cells than in HT-1376 cells, as 
previously obtained by fluorescence spectroscopy (Figure 2.8). 
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Figure 2.9. Representative fluorescence images of HT-1376 and UM-UC-3 cells incubated for 1.5 h 
with 10 µM of PorGal8 in darkness (red) with nucleus stained with DAPI (blue). Control fluorescence 
images (no PorGal8 fluorescence) were acquired after cells´ incubation with PBS for 1.5 h in the dark and 
staining the nucleus with DAPI (blue). Scale bars are indicated on images. Original magnification: 400x.  
 
 
2.4. Dark toxicity and phototoxicity of PorGal8 in HT-1376 and UM-UC-3 
bladder cancer cells 
The current PSs, at the working concentrations, are non-toxic unless and until 
activation by light at a specific wavelength. Thus, after confirming the uptake of PorGal8 
by bladder cancer cells, its cytotoxicity in darkness was determined. Bladder cancer cell 
lines, HT-1376 and UM-UC-3, were incubated in darkness at various periods of time (0.5, 
1, 2, and 4 h) with increasing concentrations of PorGal8 (0.5, 2.5, 5, 10, and 12.5 µM) in 
PBS. The cells viability was determined 24 h after treatment by MTT colorimetric assay. 
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In this assay, the yellow-colored MTT is reduced by mitochondrial dehydrogenases in 
living cells to a blue-colored formazan precipitate. The absorption of dissolved formazan 
correlates with the number of live cells.  
In both cell lines, incubation concentrations up to 12.5 µM and uptake time up to 4 h 
did not induce dark toxicity (Figure 2.10). 
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Figure 2.10. Non-dark toxicity of PorGal8 in HT-1376 (A) or UM-UC-3 (B) cells. Cells were 
incubated with PorGal8 at various concentrations (0.5, 2.5, 5, 10, and 12.5 µM) for increasing uptake times 
(0, 0.5, 1, 2, and 4 h) in dark conditions. Cytotoxicity was assessed using MTT colorimetric assay 24 h after 
treatment. The percentage of cytotoxicity was calculated relatively to control cells (cells incubated with PBS 
in darkness) at therespective uptake time. Data are the mean value ± S.D. of at least three independent 
experiments performed in triplicates. 
 
The non dark toxicity of PorGal8 prompted us to perform the PDT studies. The cells 
were incubated with PorGal8 at the same concentrations in the dark (0.5, 2.5, 5, 10, and 
12.5 µM) for 1.5 h. After PorGal8 uptake in darkness, cells were irradiated with white 
light at a potency of 8.4 mW.cm
-2
 for various irradiation times (5, 10, 20, and 40 min). The 
cell viability was assessed by MTT colorimetric assay 24 h after PDT assays. To test the 
effect of white light irradiation alone on cell viability, control experiments using irradiated 
cells (previously incubated with PBS for 1.5 h in the dark) were performed. These 
conditions did not induce toxicity in both cell lines. However, when cells were pre-
incubated with PorGal8 and then irradiated, there was an increase of the phototoxicity in a 
concentration- and irradiation time-dependent manner (Figure 2.11). Incubation with 10 
µM of PorGal8 and irradiation for 40 min induced a percentage of phototoxicity of 33.20 ± 
1.84 and 55.45 ± 4.96 for the cell line HT-1376 and UM-UC-3, respectively. 
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Figure 2.11. Photocytotoxic effects of PDT with PorGal8 in HT-1376 (A) and UM-UC-3 (B) cells. 
Cells were incubated in the dark with PorGal8 at various concentrations (0.5, 2.5, 5, 10, and 12.5 µM) for 1.5 
h and irradiated with white light at a fluence rate of 8.4 mW.cm-2 for various times (5, 10, 20, and 40 min). 
Cytotoxicity was assessed 24 h after PDT using the MTT assay. The percentage of photocytotoxicity was 
calculated relatively to control cells (cells incubated with PBS for 1.5 h and then irradiated) at the respective 
irradiation time. Data are the mean value ± S.D. of at least three independent experiments performed in 
triplicates. *(p<0.05).and **(p<0.001) significantly different from control cells (incubated with PBS for 1.5 
h) at the same irradiation time  
 
Theoretically, in the MTT assay, the color intensity of the formazan dye is correlated 
to the number of viable cells. However, this assay is dependent of the cell metabolism to 
reduce MTT in formazan. To confirm the results obtained using the MTT assay, 
additionally studies using the trypan blue staining assay were performed. The trypan blue 
is excluded by live cells with intact cell membranes and it is retained in dead cells (for 
more detail about these two methods, see chapter IV). 
MTT and trypan blue exclusion assays were performed 48 h and 72 h after PorGal8-
PDT, in order to evaluate whether cells could recover for a time superior to 24 h after PDT. 
A significant reduction of mitochondrial activity in HT-1376 cells was still found 48 h 
after PDT for the concentrations 0.5, 2.5, and 5 µM (Figure 2.12 A) when compared with 
the respective concentrations 24 h after treatment. For the concentrations 2.5, 10, and 12.5 
µM the HT-1376 cells recover, at least in part their mitochondrial metabolic function 72 h 
after treatment. An increase of mitochondrial activity was also observed 72 h after PDT for 
UM-UC-3 cells, when PorGal8 was used at concentrations of 0.5 µM or 5 µM (Figure 
2.12 B). No significant differences were seen in the proportion of membrane-damaged 
cells 48 h and 72 h after PDT with respect to 24 h after PDT, for both cells lines (Figure 
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2.12 C and D). Both MTT and trypan blue exclusion demonstrated that PDT with PorGal8 
is more active against UM-UC-3 cells than HT-1376 cells (Table 2.3). Based on these 
results, as well as in the uptake results, the next experiments were performed by incubation 
of the cells with 10 µM of PorGal8 for 1.5 h in darkness and irradiating for 40 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.12. Photocytotoxic effects of PorGal8 in HT-1376 (A and C) and UM-UC-3 (B and D) 
cells as function of the PorGal8 concentration. Cytotoxicity was assessed 24, 48, and 72 h after PorGal8-
PDT using the MTT (A and B) and the trypan blue exclusion (C and D) assays. The percentage of 
cytotoxicity was calculated relatively to control cells (cells incubated with PBS and then irradiated) at the 
respective time after PDT. Data are the mean value ± S.D. of at least three independent experiments 
performed in triplicates. The symbols *(p<0.05), **(p<0.001), *(p<0.0001) represent significant differences 
in phototoxicity comparing with MTT reduction (%) or excluded trypan blue (%) of PorGal8-24 h after PDT 
for the respective concentration. 
 
 
Table 2.3. Percentage values of cell toxicity after treat human bladder cancer cell lines, HT-1376 and 
UM-UC-3, with PorGal8 at 10 µM for 1.5 h and irradiate for 40 min. The results were obtained 24, 48, and 
72 h after PorGal8-PDT using the MTT and trypan blue exclusion assays. The symbol * represents 
significant (p<0.05) differences in cell toxicity comparing with HT-1376 cells at the respective time after 
PDT. 
 HT-1376 cell line UM-UC-3 cell line 
Hours after PDT 24 48 72 24 48 72 
Cell toxicity 
(% mean ± 
S.D.) 
MTT 
assay 
33.30 ± 1.47 30.54 ± 1.88 27.19 ± 1.07 54.57 ± 4.71* 54.47 ± 0.48* 44.87 ± 0.83* 
Trypan 
blue 
exclusion 
31.83 ± 1.30 34.33 ± 1.47 26 ± 0.68 53.24 ± 6.04* 53.50 ± 1.73* 49.67 ± 2.64* 
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2.5. Galectin inhibition studies in HT-1376 and UM-UC-3 bladder cancer 
cells  
To clarify the role of galectins in the uptake of PorGal8, the binding sites of galectin 
to galactose, in UM-UC-3 and HT-1376 cells, were “blocked” with a pre-incubation of 50 
nM galactose for 1.5 h before incubation with 10 µM of PorGal8 for 1.5 h.  
The pre-incubation with galactose did not completely inhibit the uptake of PorGal8 
in both bladder cancer cells (Figure 2.13 A). In fact, there are no significant differences in 
the PorGal8 uptake when HT-1376 cells were pre-incubated with galactose. Interestingly, 
for the cell line UM-UC-3 (which expresses high levels of galectin-1, Figure 2.7 C and D) 
there was about 40% decrease in PorGal8 cell uptake when the cells were pre-incubated 
with galactose.  
The PDT assays during 40 min were also performed after the galactose “blocking” 
assays and the cell viability was determined 24 h after treatment by MTT colorimetric 
assay. It was observed an increase of cell viability of about 15% and 53% in HT-1376 and 
UM-UC-3 cells, respectively (Figure 2.13 B).  
These results demonstrate the involvement of galactose-binding proteins, namely 
galectin-1, on increased intracellular accumulation of PorGal8 in the bladder cancer cells, 
which after PDT leads to cytotoxicity and that was more evident for the cell line UM-UC-
3.  
 
 
 
 
 
 
Figure 2.13. Decrease on the uptake of PorGal8 by UM-UC-3 and HT-1376 cells after pre-incubation 
with galactose (A). Photocytotoxic decrease in HT-1376 and UM-UC-3 cells after PDT in cells pre-incubated 
with galactose (B). PorGal8 uptake was determined using fluorescence spectroscopy after cells´ incubation 
with 50 nM of galactose for 1.5 h and then with 10 µM of PorGal8 for 1.5 h. Cytotoxicity was assessed 24 h 
after treatment using the MTT colorimetric assay. The percentage of cytotoxicity was calculated relatively to 
control cells (cells incubated with PBS) at the respective condition. Data are the mean value ± S.D. of at least 
three independent experiments performed in triplicates. The symbol * represents significant differences in 
uptake or phototoxicity comparing with uptake or MTT reduction (%) of cells without pre-incubation with 
galactose (p<0.05). 
0
750
1500
2250
3000
U
p
ta
k
e
 (
n
m
o
l 
P
S
/m
g
 p
ro
te
in
)
A
Galactose         +          -           +               +         -             +
PorGal8 -          +           +               -         +             +
HT-1376 UM-UC-3
*
0
25
50
75
100
M
T
T
 r
e
d
u
c
ti
o
n
(%
 f
ro
m
 c
o
n
tr
o
l)
B
Galactose         +          -           +               +         -             +
PorGal8 -          +           +               -         +             +
HT-1376 UM-UC-3
*
Results and Discussion                                                                        Galacto-conjugated porphyrin PorGal8:  
Photoactive agent against bladder cancer cells 
51 
 
2.6. PorGal8-induced reactive oxygen species after PDT in HT-1376 and 
UM-UC-3 bladder cancer cells 
To confirm whether phototoxicity (Figures 2.11 and 2.12) is related with an increase 
of oxidative stress after PorGal8-PDT, the generation of ROS was evaluated immediately 
after PDT using the probes DHE (dihydroethidium) and H2DCFDA (2´,7´-
dichlorohydrofluorescin) [18, 19]. The probe H2DCFDA quantitatively reacts with various 
ROS to yield the fluorescent product DCF. DHE reacts mainly with superoxide anion 
being oxidized to ethidium, staining the nucleus with bright red fluorescence (for more 
detail about these two probes, see chapter IV).  
HT-1376 and UM-UC-3 cells were incubated in darkness for 1.5 h with PBS 
(control) or 10 µM of PorGal8 for 1.5 h and then irradiated for 40 min. The images 
obtained by confocal microscopy demonstrated for both cell lines an increase of 
intracellular DHE and DCF fluorescence when compared to control cells (Figure 2.14 A 
and B). Additionally, quantitative analysis also demonstrated a significant increase of 
DHE and DCF intracellular fluorescence after PorGal8-PDT when compared to control 
cells (Figure 2.14 C and D). The DHE fluorescence was not significantly different 
between cell lines (Figure 2.14 C) and the DCF fluorescence was about two-fold higher 
for UM-UC-3 than for HT-1376 cells, when 5 µM of H2DCFDA was used (Figure 2.14 
D).  
DCF is frequently used as an overall sensor of oxidative stress in the cells, which 
demonstrate that the higher ROS levels observed inside the UM-UC-3 cells, can explain 
the higher phototoxicity in these cells than in HT-1376 cells (Figures 2.11 and 2.12). 
Moreover, it has been reported that a weaker accumulation of PSs inside the cells can 
enhance the antioxidant response after PDT [20]. Based on that evidence and on the fact 
that PorGal8 is lesser accumulated in HT-1376 cells, the possible enhancement of an 
antioxidant response after PorGal8-PDT can be a plausible explanation for the lower ROS 
generation inside these cells, and consequently lower toxicity.  
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Figure 2.14. Representative fluorescence images (A and B) and quantification (C and D) of DHE and 
DCF fluorescence increase (as a measure of ROS production) after PorGal8-PDT. Human bladder cancer cell 
lines HT-1376 and UM-UC-3 were incubated with PBS (control) or 10 µM of PorGal8 for 1.5 h in the dark. 
After PDT during 40 min, the images were acquired on a confocal microscope demonstrating an increase of 
intracellular oxidative stress in HT-1376 (A) and UM-UC-3 cells (B) when compared to control cells. The 
fluorescent signals of DHE (C) and DCF (D) were quantified by fluorescent spectroscopy for both cell lines. 
*Significantly different from irradiated-control cells (incubated with PBS for 1.5 h) and then incubated with 
DHE or H2DCFDA probes (p<0.05). 
#Significantly different from treated HT-1376 cells (p<0.05). 
 
To analyze the contribution of particular ROS in PorGal8-mediated cell death, 
specific quenchers of 
1
O2 (sodium azide [21] and histidine [22]) and free radical 
scavengers (cysteine [23]) were used. HT-1376 and UM-UC-3 cells loaded with 10 µM of 
PorGal8 for 1.5 h in darkness were pre-incubated with 50 nM of 
1
O2 quenchers and ROS 
scavengers and were then exposed to the light. The cell viability evaluated 24 h after 
PorGal8-PDT was dependent on the used scavenger and on the cell type (Figure 2.15). In 
both cell types, sodium azide, histidine and cysteine were effective as 
1
O2 quenchers and 
free radical scavenger, respectively. These results demonstrate once more the involvement 
of several ROS-induced after PDT with PorGal8 in HT-1376 and UM-UC-3 cells.   
 
HT-1376
Control PorGal8-PDT                                                    
A UM-UC-3
Control PorGal8-PDT                                                    
B
H
2
D
C
F
D
A
 p
ro
b
e
D
H
E
 p
ro
b
e
HT-1376 UM-UC-3
0
1
2
3
4
5
Control
DHE 2M
DHE 5M
*
*
*
*
C
R
O
S
 l
e
v
e
ls
(F
lu
o
re
s
c
e
n
c
e
 f
o
ld
 in
c
re
a
s
e
/m
g
 p
ro
te
in
)
HT-1376 UM-UC-3
0
20
40
60
80
Control
H2DCFDA 2M
H2DCFDA 5M
*
*
*
*
#
D
R
O
S
 l
e
v
e
ls
(F
lu
o
re
s
c
e
n
c
e
 f
o
ld
 in
c
re
a
s
e
/m
g
 p
ro
te
in
)
Results and Discussion                                                                        Galacto-conjugated porphyrin PorGal8:  
Photoactive agent against bladder cancer cells 
53 
 
 
 
 
 
 
 
 
  
Figure 2.15. Photocytotoxicity after PorGal8-PDT in the presence of specific quenchers of 
1O2 
(sodium azide - NaN3- and histidine) and free radical scavengers (cysteine) in HT-1376 (A) and UM-UC-3 
(B) cells. Cytotoxicity was assessed 24 h after PorGal8-PDT in the presence of 50 nM of ROS quenchers, 
using the MTT assay. The percentage of cytotoxicity was calculated relatively to control cells (untreated 
cells). Data are the mean value ± S.D. of at least three independent experiments performed in triplicates. The 
symbol * represents significant differences in phototoxicity comparing with MTT reduction (%) of PorGal8-
24 h after PDT (p<0.05). 
 
 
2.7. The role of cancer stem cells in determination of the cell demise after 
PDT with PorGal8 
 The results previously described demonstrated that HT-1376 cells are lesser 
sensible after PorGal8-PDT than UM-UC-3 cells (Figures 2.11 and 2.12). Based on the 
putative interaction between galactose units around the Por core and cell surface galectins 
[24], the presence of higher galectin-1 protein levels in UM-UC-3 cells (Figure 2.7 C and 
D) may enhance the accumulation of PorGal8 inside the cells and, conquently, increase the 
phototoxicity. Additionally, we hypothesized that the resistance of HT-1376 cells after 
PorGal8-PDT may be due to the presence of cancer stem cells (CSCs). It has been reported 
that bladder tumours contain a subset of cells expressing the ATP binding cassette 
transporter ABCG2 [25]. In fact, these cells referred as CSCs are able to survive after 
cancer therapy and are responsible for initiating tumour regrowth. It has been reported that 
porphyrins (as well as other conventional drugs used in the treatment of cancer) are not 
able to target CSCs, because they are substrates for ABCG2, being effluxed by these 
pumps [26, 27]. This idea is also supported by experiments showing that porphyrins 
accumulate in tissues of an ABCG2-knockout mice [28]. It has been suggested that the 
tetrapyrrole porphyrin structure plays an important role in interaction of protoporphyrin IX, 
hematoporphyrin, and pheophorbide with human ABCG2 [29]. Thus, the overexpression 
of ABCG2 in CSCs, which is considered to be a cancer stem cell marker [30], can protect 
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them from many structurally different anti-cancer compounds leading to drug resistance 
[31].  
To assess the presence of putative CSCs in HT-1376 cell line, cells were allowed to 
grow in serum-free medium in anchorage-independent conditions [32]. After two or three 
days of cells´ culture in the aforementioned conditions, the cells started to form floating 
spherical colony-like structures (Figure 2.16 A). The sphere-forming efficiency 
determined by the number of colonies formed per total number of HT-1376 cells plated 
was of 3.2 ± 0.5% (n = 6). A second generation of spheres, designated as CSCs HT-1376, 
was obtained with similar sphere-forming efficiency and it was used in the experiments.  
Immunofluorescence studies showed the presence of the cancer stem cell surface 
marker CD44 [33] in isolated CSCs HT-1376 (Figure 2.16 B). We investigated whether 
CSCs HT-1376 have increased levels of the drug efflux transporter ABCG2. Western 
blotting analysis revealed that ABCG2 increased approximately three-fold in CSCs HT-
1376 compared to HT-1376 cells (Figure 2.16 C). Using the same experimental 
conditions, UM-UC-3 cells did not form floating spherical colony-like structures (like 
observed to HT-1376 cells) and their ABCG2 protein levels were negligible (Figure 2.16 
C).  
The putative lower percentage of CSCs (and lower ABCG2 protein levels) in UM-
UC-3 relatively to that for HT-1376 cells can be an explanation for their higher sensitivity 
after PorGal8-PDT. Moreover, it has been reported that after cancer therapy, stem cell-
enriched subpopulations contain low levels of ROS and increased expression of free 
radical scavenging systems, when compared with the non-stem counterparts [34]. Since the 
photocytotoxic effects after PorGal8-PDT result from ROS-induced cell damage, we 
thought that the presence of a subpopulation with stem like properties in HT-1376 cells 
should increase their anti-oxidative defense after PorGal8-PDT. 
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Figure 2.16. (A) CSCs HT-1376 derived by the sphere-formation assay with HT-1376 cells. Spherical 
colonies were generated from single-cell suspensions of HT-1376 cells cultured in serum-free medium 
supplemented with growth factors in non-adherent conditions during 7 days. Original magnification: 400x. 
(B) Representative fluorescence images of the cancer stem cell marker CD44 (red) in CSCs HT-1376, with 
DAPI staining the nucleus (blue). Scale bars are indicated on images. Original magnification: 400x. (C) 
Western blotting analysis of ABCG2 in HT-1376, UM-UC-3, and CSCs HT-1376. β-actin was blotted as 
loading control. The bellow panel shows the quantitative analysis of the ABCG2 protein (normalized to β-
actin). Values are presented as mean ± S. D. of three independent experiments. The symbol * represents 
significant differences in ABCG2 comparing with HT-1376 or UM-UC-3 cells (p<0.05). 
 
It has been described that cells expressing ABCG2 in high levels are resistant after 5-
aminolevulinic acid-PDT, which demonstrates the role of ABCG2 in the efflux of the PS 
from those cells [35]. Next, we examined the phototoxicity after PorGal8-PDT in isolated 
CSCs HT-1376 expressing ABCG2 in high levels (Figure 2.17). The CSCs HT-1376 were 
treated in darkness with several concentrations of PorGal8 (5, 10, and 12.5 µM) for 1.5 h 
and then irradiated for 40 min. After 24 h, cell viability assays demonstrated that CSCs 
HT-1376 are lesser photosensible when compared to HT-1376 cells. These results 
strengthen the hypothesis that the presence of high levels of ABCG2 in CSCs (in the cell 
line HT-1376) decreases the phototoxicity of PorGal8 in this cell line.  
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Figure 2.17. Photocytotoxic effects after PorGal8-PDT in CSCs HT-1376 comparing with those for 
HT-1376 cells. Cells were incubated with PorGal8 at various concentrations (5, 10, and 12.5 µM) for 1.5 h in 
darkness and irradiated with white light for 40 min. Cytotoxicity was assessed 24 h after PDT using the MTT 
assay. The percentage of photocytotoxicity was calculated relatively to control cells (cells incubated with 
PBS for 1.5 h and then irradiated). Data are the mean value ± S.D. of at least one independent experiment 
performed in triplicates. *Significantly different from HT-1376 cells treated with PorGal8 at the same 
concentration (p<0.05). 
 
 
2.8. Photo-effects of PDT with PorGal8 on actin microfilaments of HT-1376 
and UM-UC-3 bladder cancer cells 
The effects induced by PorGal8 after PDT, on the actin microfilaments of HT-1376 
and UM-UC-3 cells were examined using a specific F-actin fluorescent probe, TRICT-
phalloidin. Actin microfilaments in combination with microtubules, and intermediate 
filaments form the cytoskeleton systems of vertebrate cells. Cytoskeleton is a potential 
target in the development of new anti-cancer drugs, due to its role in cell morphology and 
membrane integrity. The results obtained by trypan blue exclusion assays demonstrated 
that the cell membrane integrity is affected after PorGal8-PDT and it was more evident for 
the cell line UM-UC-3 (Figure 2.12). The involvement of caspases (in cell death by 
apoptosis) and ROS on the degradation of some cytoskeletal proteins has been reported 
[36]. The changes in cytoskeletal proteins provide information about the molecular 
mechanisms of apoptosis induced after PDT [37]. In fact, it has been reported that PDT 
with targeted PSs induces actin degradation (by caspases) at early stages of apoptosis [37]; 
while in PDT with non-targeted PSs, actin is cleaved during the later execution phase of 
apoptosis [38].  
The HT-1376 and UM-UC-3 cells were incubated with PBS (control) or 10 µM of 
PorGal8 for 1.5 h in darkness and then irradiated for 40 min. In control HT-1376 cells, F-
actin was found mainly in plasma membrane, exhibiting a well-organized distribution 
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(Figure 2.18 A). It was also observed a cortex-specific staining inside the HT-1376 cell 
colonies in the proximity of intercellular contacts. In contrast, thirty minutes after 
PorGal8-PDT there was a reduction of the actin staining, which appears diffusely 
distributed around the nucleus of the cells (Figure 2.18 A). At this time point, HT-1376 
cells seem to lose the contact to each other. Twenty-four hours after PDT, it was observed 
a reorganization of the actin filaments in HT-1376 cells with distribution similar to that 
observed in control cells (Figure 2.18 A).  
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Figure 2.18. Representative fluorescence images demonstrating the changes of F-actin after PorGal8-
PDT in HT-1376 (A) and UM-UC-3 (B) cells. The cells were incubated for 1.5 h with PBS (control cells) or 
10 µM of PorGal8 in darkness and then irradiated for 40 min. After treatment, the nucleus was stained with 
DAPI (blue) and F-actin was stained with TRICT-Phalloidin. Scale bars are indicated on images. Original 
magnification: 400x.   
 
The UM-UC-3 cells do not form dense colonies as HT-1376 cells and establish 
intercellular contacts by cytoplasmic protrusions (Figure 2.18 B). In untreated UM-UC-3 
cells, intracellular actin is manifested as organized stress fibres and cortex filaments 
localized at cell periphery (Figure 2.18 B). Thirty minutes after PorGal8-PDT, the UM-
UC-3 cells are retracted, the stress fibers are lost, the actin collapses and it is reorganized 
into a peripheral ring-like structure (Figure 2.18 B). Twenty-four hours after PDT, the 
pattern distribution of F-actin increases in the sites of cell protrusions, which indicates a 
reduction of cell-cell interaction. At this time point, UM-UC-3 cells are trying to establish 
DAPI                         TRICT-PHALLOIDIN                      Merge
C
O
N
T
R
O
L
3
0
 M
IN
2
4
 H
B
Results and Discussion                                                                        Galacto-conjugated porphyrin PorGal8:  
Photoactive agent against bladder cancer cells 
59 
 
contact with their neighbor cells by long protrusions. The UM-UC-3 cells also contained 
filopodia and small actin spots (Figure 2.18 B).  
These results demonstrated that the changes induced in actin organization after 
PorGal8-PDT depend on the cell types. In HT-1376 cells, which are less photosensible 
after PorGal8-PDT, the actin photodamage was transient for those cells. The actin 
distribution and morphology was restored 24 h after photosensitization in these cells. Thus, 
we hypothesize that cytoskeletal structures like F-actin can be involved in the mechanism 
of resistance to PDT in HT-1376 cells. In UM-UC-3 cell line, cells are completely 
retracted 30 min after treatment. Twenty four hours after PorGal8-PDT the UM-UC-3 cells 
demonstrated an elongated shape, alteration of the actin pattern and lost stress fibers. 
Taking into account that ROS generated after PorGal8-PDT can be involved on the 
degradation of actin microfilaments [36], the higher alteration in actin of UM-UC-3 cells 
can be explained by the higher accumulation of ROS inside these cells (as previously 
demonstrated, Figure 2.14). 
 
 
2.9. Timing the cell death pathways in HT-1376 bladder cancer cells after 
PDT with PorGal8 
The evidence that the cell death mechanisms induced after PDT are dependent on the 
PS employed is a relevant clue in the design of new PSs. There has been a growing interest 
in exploiting the mechanisms of cell death at different time points after PDT, in an attempt 
to improve the phototoxic effects at the molecular level. In this context, we explored the 
temporal activation of different cell death pathways induced after PorGal8-PDT in HT-
1376 cells.  
It has been reported that the proteins of the Bcl-2 family play an important role in the 
intrinsic pathway of apoptosis-mediated PDT where mitochondria has a central role. In 
Bcl-2 family, Bcl-2 and Bax are anti-apoptotic and pro-apoptotic proteins, respectively 
[40]. The overexpression of the anti-apoptotic protein Bcl-2 has been associated with 
resistance in cancer therapy by chemotherapy and radiotherapy [41]. However its role in 
PDT is unclear. In some studies it is demonstrated that the overexpression of Bcl-2 protects 
cells from photodynamic treatment [42], while in other studies the increased levels of Bcl-
2 make cancer cells more sensitive to apoptosis-mediated PDT [43]. The role of the pro-
apoptotic protein Bax in apoptosis-mediated PDT is being well described. In cells 
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suppressing or not expressing Bax that are treated with PDT, there was a complete 
inhibition of the release of cytochrome c from mitochondria, of the caspase activation and 
of the nuclear fragmentation [44].  
It has been reported that PDT can target and induce changes of Bcl-2 and related 
anti-apoptotic proteins and activate the pro-apoptotic members of the family [45] in 
various cell lines and tumours. The apoptotic cell death induced by the conventional 5-
aminolevulinic acid demonstrated a suppression of Bcl-2 mRNA levels and an elevation of 
Bax mRNA in cervical cancer cell line [46] and esophageal cancer cells [47]. In vivo 
studies also demonstrated that after 5-aminolevulinic acid-PDT there are a significant 
decrease in mRNA expression of Bcl-2 and an increase on the levels of Bax, in cervical 
cancer [48]. PDT studies with hypericin involving upregulation of Bax in human breast 
adenocarcinoma cell line [49] have shown that Bcl-2 levels in colorectal cancer cells were 
not affected [50]. Furthermore it is being plausible that ROS generated after 
photoactivation of the PS can trigger by itself activation of the pro-apoptotic protein Bax 
[43]. 
The HT-1376 cells were treated with PBS (control) or 10 µM of PorGal8 for 1.5 h in 
darkness and then irradiated for 40 min. The Bcl-2 protein levels and Bax fluorescence 
were then evaluated by western blotting and immunofluorescence, respectively. Western 
blotting results indicated that Bcl-2 did not respond significantly at several time points 
(0.25, 0.5, 1, 2 and 24 h) after PorGal8-PDT (Figure 2.19 A). The immunofluorescence 
results at 30 min and 24 h after PorGal8-PDT demonstrated an increase of the levels of 
Bax, when compared with control cells (Figure 2.19 B). 
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Figure 2.19. (A) Western blotting analysis of Bcl-2, at several time points (0.25, 0.5, 1, 2, and 24 h) 
after HT-1376 cells had been incubated with 10 µM of PorGal8 for 1.5 h and irradiated during 40 min. 
Control (CT) corresponds to irradiated cells (incubated with PBS for 1.5 h). β-actin was blotted as loading 
control. The graphic shows the quantitative analysis of the Bcl-2 protein (normalized to β-actin). Values are 
presented as mean ± S. D. of three independent experiments. (B) Representative fluorescence images of Bax 
immunofluorescence (green) in HT-1376 cells, at 0.5 h and 24 h after PorGal8-PDT. Scale bars are indicated 
on images. Original magnification: 400x.  
 
PDT is known to activate the PI3K/Akt signaling pathway in several cell lines [51, 
52]. Akt/PKB is a serine/threonine kinase that plays an important role in cell survival and 
is activated downstream of the phosphatidylinositol-3-kinase (PI3-K) upon stimulation of 
numerous receptors for growth factors [53]. The phosphorylation of Akt (pAkt) in two 
conserved residues, Thr-308 and Ser-473 [54] activates this molecule and can provide 
survival cell signals those protect them from apoptotic stimuli. Numerous studies have 
shown that oxidative stress stimulates Akt phosphorylation and that proteins activated by 
phosphorylated Akt promote cell survival [55, 56]. Exposure of fibroblasts 
to 
1
O2 (generated by rose bengal-mediated photosensitization) induced a strong 
phosphorylation of Akt [56]. Surprisingly it was reported that PS alone (Photofrin) and 
light alone, as well as the PDT procedure can activate the Akt signaling pathway in mouse 
and human breast cancer cells, as well as in mouse and human-derived breast cancer 
tumours growing in mice [56].  
The HT-1376 cells were treated with PBS (control) or 10 µM of PorGal8 for 1.5 h 
and then irradiated for 40 min. The western blotting studies demonstrated 
immunoreactivity for pAkt in untreated cells and a significant decrease in pAkt protein 
levels at 15 min, 30 min and 24 h after PDT when compared to control cells (Figure 2.20). 
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Knowing that pAkt can significantly down-regulate the expression of Bax [57], the 
increase in immunofluorescence of Bax at 30 min and 24 h after PorGal8-PDT (Figure 
2.19) can be, in part, caused by dephosphorylation of Akt at these time points. In the 
present study, one and two hours after PorGal8-PDT induced a significant increase in pAkt 
protein levels when compared to 30 min after PorGal8-PDT (Figure 2.20). This seems to 
indicate that the increased pAkt levels can promote cell survival and block apoptosis at 
these time points. The total Akt band showed a similar signal density in control and treated 
cells. Thus, PDT with PorGal8 changed the level of phosphorylation but not the amount of 
Akt protein.  
 
Figure 2.20. Western blotting analysis of total Akt and phosphorylated Akt (pAkt), at several time 
points (0.25, 0.5, 1, 2, and 24 h) after HT-1376 cells had been incubated with 10 µM of PorGal8 for 1.5 h 
and irradiated during 40 min. Control (CT) corresponds to irradiated cells (incubated with PBS for 1.5 h). β-
actin was blotted as loading control. The graphic shows the quantitative analysis of the pAkt protein 
(normalized to β-actin). Values are presented as mean ± S. D. of three independent experiments. The symbols 
*(p<0.05), ** and $$ (p<0.001), *** and $$$ (p<0.0001)  represent significant differences in pAkt protein 
levels comparing with control cells or treated cells at 30 min after PorGal8-PDT, respectively. 
 
It has been suggested that PDT can induce oxidative damage to the endoplasmic 
reticulum (ER), which can be further propagated to the mitochondrial cell death machinery 
[45, 53]. There are studies indicating that alterations in the Ca
2+
 homeostasis into the ER 
and alterations in the principal functions of the ER (folding, modifying and sorting newly 
synthetized proteins) induces ER stress and activation of the unfolded protein response 
(UPR) [58]. Initially, the UPR is a pro-survival process that reduces the accumulation and 
aggregation of unfolded or misfolded proteins and restores the ER function. However, if 
ER stress persists and cannot be repaired, the UPR can activate a cell death pathway, 
which generally converges into the caspase-activation cascade. The UPR process can lead 
to the translation of genes encoding for activating the transcription factor 4 (ATF4) [58]. 
ATF4 promotes cell survival through the induction of genes involved in restoring ER 
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homeostasis, but it can also induces apoptosis through the induction of the transcription 
factor C/EBP homologous protein (CHOP). Thus, in cases of ER stress, the CHOP 
induction is an important element of the switch from pro-survival to pro-death signaling in 
cases of ER stress [59]. Moreover, PDT-mediated apoptosis with a mitochondrial and ER-
localizing porphyrin was reduced in CHOP-deficient cells, thereby confirming CHOP 
contribution to the induction of apoptosis in photosensitized cells [60]. 
In irradiated HT-1376 cells that had been previously incubated with 10 µM of 
PorGal8 for 1.5 h it was observed an increase in the protein levels of CHOP at 0.5, 1, 2, 
and 24 h after treatment (Figure 2.21). These results demonstrated an ER stress at these 
time points which can induce cell death by apoptosis.  
 
Figure 2.21. Western blotting analysis of CHOP protein, at several time points (0.25, 0.5, 1, 2, and 24 
h) after HT-1376 cells had been incubated with 10 µM of PorGal8 for 1.5 h and irradiated during 40 min. 
Control (CT) corresponds to irradiated cells (incubated with PBS for 1.5 h). β-actin was blotted as loading 
control.  
 
Apoptosis is also controlled at the ER by the pro-apoptotic protein Bax, since it has 
been reported that overexpression of Bax promotes Ca
2+ 
mobilization from the ER to the 
mitochondrion during apoptosis [61]. Thus, the increase in immunofluorescence of Bax at 
30 min and 24 h after PDT can be associated with the ability of ROS-induced after 
PorGal8-PDT to induce ER stress. Moreover, Akt activity is important in ER stress-
induced apoptosis and ER stress may induce mitochondrial-mediated apoptosis. In fact, it 
was reported that inactivation of PI3K-Akt induces CHOP expression in ER-stressed cells 
[62]. It was also reported that CHOP induces apoptosis by increasing Tribble 3 (TRB3) 
expression, a pseudokinase that inhibits AKT [63].  
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3. Galacto-conjugated phthalocyanine PcGal16: decrease of 
galectin-1 protein levels and phototoxicity in bladder cancer cells 
 
3.1. General overview  
Phthalocyanines are PSs with remarkable photo-chemical and -physical properties [4, 
8, 9]. The most important characteristics of these compounds are their ability to produce 
high levels of 
1
O2 and their markedly greater absorbance of red light near of 700 nm, 
where the tissues are more transparent to visible radiation. As demonstrated in part I, 
PcGal16 is water soluble up to 9 µM, stable after light irradiation, efficient generator of 
1
O2 
and binds to HSA protein [9]. In this section it will be described the use of PcGal16 as a 
potential PS in PDT, looking at: uptake by cancer cells, decrease of galectin-1 after uptake, 
phototoxicity and ROS production after PDT in human bladder cancer cell lines HT-1376 
and UM-UC-3 (Figure 2.22). 
 
Figure 2.22. Schematic overview of this section including the in vitro results obtained with PcGal16 
against the human bladder cancer cell lines UM-UC-3 and HT-1376. 
 
 
3.2. Uptake of PcGal16 by HT-1376 and UM-UC-3 bladder cancer cells 
The uptake of PcGal16 by cancer cells is a crucial factor for its application as a PDT 
agent. Bladder cancer cell lines, HT-1376 and UM-UC-3 (Figure 2.7 A and B), were 
incubated in dark conditions at various periods of time (0.5, 1, 2, and 4 h) with increasing 
concentrations of PcGal16 (0.5, 2.5, 5, and 9 µM) in PBS. The fluorescent properties of 
PcGal16 (part I, Table 2.1) - two emission bands in the red spectral region (734 nm and 
805 nm) - allow the quantification of its intracellular concentration. The uptake of PcGal16 
Results and Discussion                                                               Galacto-conjugated phthalocyanine PcGal16:  
Decrease of galectin-1 protein levels and phototoxicity in bladder cancer cells 
66 
 
was concentration-dependent and time-dependent, and reached a plateau after 2 h of 
incubation (Figure 2.23). In spite of the higher levels of galectin-1 in UM-UC-3 cells 
when compared with HT-1376 cells (part II, Figure 2.7 C and D), the uptake of PcGal16 
was similar in both cell lines. This result seems to indicate that there is not a specific 
recognition or an involvement of the PcGal16 by galectin-1 present in cell membranes.  
The amphiphilic structure of PcGal16 allowing its localization in the hydrophobic-
hydrophilic interfaces of membranes can be an explanation for the uptake of these PS by 
bladder cancer cells. It has been reported that a suitable combination of hydrophilic and 
hydrophobic substituents or structural elements improves the tumour uptake of the 
resulting conjugates [8].  
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Figure 2.23. Intracellular uptake of PcGal16 by HT-1376 (A) and UM-UC-3 (B) cells. Cells were 
incubated in darkness with various concentrations of PcGal16 (0.5, 2.5, 5, and 9 µM) for different uptake 
times (0, 1, 2, 3, and 4 h). The concentration of PcGal16 was determined by fluorescence spectroscopy and 
the results were normalized to protein quantity. Data are the mean ± S.D. of at least three independent 
experiments performed in triplicates.  
 
The intracellular accumulation of PcGal16 in bladder cancer cells was also confirmed 
by confocal fluorescence microscopy (Figure 2.24). The cells were incubated with 5 µM 
of PcGal16 for 2 h (in darkness) and nuclei were stained with DAPI. The fluorescence 
signal of PcGal16 was observed inside the cells throughout the cytoplasm.  
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Figure 2.24. Representative fluorescence images of HT-1376 and UM-UC-3 cells incubated in 
darkness for 2 h with 5 µM of PcGal16 (red) with nucleus stained with DAPI (blue). Control fluorescence 
images were acquired after cells´ incubation with PBS for 2 h and staining the nucleus with DAPI (blue). 
Scale bars are indicated on images. Original magnification: 400x. 
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3.3. Galectin-1 protein levels in HT-1376 and UM-UC-3 bladder cancer cells 
after PcGal16 uptake 
Immunofluorescence staining of galectin-1 was carried out on HT-1376 and UM-
UC-3 cells before and after PcGal16 uptake (Figure 2.25). These studies enabled us to 
determine the subcellular localization of galectin-1 (that is present in higher levels in UM-
UC-3 cells than in HT-1376 cells, part II Figure 2.7 C and D) and PcGal16 in bladder 
cancer cells, and their possible co-localization. HT-1376 and UM-UC-3 cells were 
incubated with 5 µM of PcGal16 for 2 h (in dark conditions) and immunostained with a 
specific antibody against galectin-1. In UM-UC-3 cells, galectin-1 is abundant in the 
nucleus (with some bright spots) and in HT-1376 cells it is diffusely distributed through 
the cytoplasm with some nuclear localization (Figure 2.25). The incubation of cancer cells 
with PcGal16 induces a decrease in galectin-1 immunofluorescence signal (Figure 2.25). 
For the HT-1376 cell line, it was observed co-localization of PcGal16 with galectin-1 in 
vesicular structures, mainly concentrated perinuclearly. In UM-UC-3 cells, there is also 
some co-localization of PcGal16 with galectin-1, which seems to accumulate more 
diffusely in vesicles located in the cytoplasm.  
Although significant progress has been made in research related with the role of 
galectins in cancer, the information concerning the molecular mechanisms and exogenous 
stimuli that regulate the expression of these proteins in tumour cells is scarce. There are 
some reports indicating that galectin-1 expression in tumour cells can be modulated by 
chemotherapeutic and antimetastatic agents [64, 65]. Knowing that galectin-1 contributes 
to tumour progression and resistance after conventional cancer therapy [66], the ability of 
PcGal16 to reduce the levels of galectin-1 after its uptake prompted us to envisage PcGal16 
as a potential candidate for cancer treatment.   
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Figure 2.25. Representative fluorescence images of galectin-1 protein (green) in HT-1376 and UM-
UC-3 cells before and after cells´ incubation with 5 µM of PcGal16 (red) for 2 h in darkness, with DAPI 
staining the nucleus (blue). Arrows indicate co-localization of PcGal16 with galectin-1. Scale bars are 
indicated on images. Original magnification: 400x.  
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3.4. Dark toxicity and phototoxicity of PcGal16 in HT-1376 and UM-UC-3 
bladder cancer cells 
After confirmation of PcGal16 uptake by bladder cancer cells, the cytotoxic effect of 
PcGal16 in darkness was accessed. It is of utmost importance to ensure that PcGal16 
induces toxicity only after light activation. The dark cytotoxicity of PcGal16 at various 
periods of incubation time (0, 0.5, 1, 2, and 4 h) with increasing concentrations of PcGal16 
(0.5, 2.5, 5, and 9 µM) on HT-1376 and UM-UC-3 cells was estimated 24 h after 
treatment, using the MTT assay (Figure 2.26). No dark toxicity was observed in untreated 
cells (up to 4 h) in the presence of 0.45% or less DMSO (data not shown). Moreover, 
PcGal16 showed no significant cytotoxicity at concentrations up to 9 µM, since the MTT 
reduction did not decrease significantly below the levels measured at the concentration 
zero.  
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 Figure 2.26. Non-dark toxicity of PcGal16 in HT-1376 (A) and UM-UC-3 (B) cells. Cells were 
incubated in darkness with PcGal16 at various concentrations (0.5, 2.5, 5, and 9 µM in PBS) for increasing 
uptake times (0, 0.5, 1, 2, and 4 h). Cytotoxicity was assessed 24 h after treatment using the MTT 
colorimetric assay. The percentage of cytotoxicity was calculated relatively to control cells (cells incubated 
with PBS in darkness) at the respective uptake time. Data are the mean value ± S.D. of at least three 
independent experiments performed in triplicates. 
 
For the PDT assays, the cells were incubated with PcGal16 at various periods of time 
(0.5, 1, 2, and 4 h) with several concentrations in the dark (0.5, 2.5, 5, and 9 µM). After 
PcGal16 uptake in darkness, the cells were irradiated for 40 min and cell viability was 
evaluated 24 h after treatment by the MTT assay. To test the effect of light irradiation on 
cell viability, control experiments were performed in cells incubated with PBS and 
irradiated. These conditions did not induce toxicity in both cell lines. However, when cells 
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were incubated with PcGal16 and then irradiated, there was an increase of the phototoxicity 
in a concentration- and uptake time-dependent manner (Figure 2.27).  
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 Figure 2.27. Photocytotoxic effects after PcGal16-PDT in HT-1376 (A) and UM-UC-3 (B) cells. Cells 
were incubated in darkness with PcGal16 at various concentrations (0.5, 2.5, 5, and 9 µM in PBS) for 0, 0.5, 
1, 2, and 4 h and irradiated with white light for 40 min. Cytotoxicity was assessed 24 h after phototreatment 
using the MTT assay. The percentage of photocytotoxicity was calculated relatively to control cells (cells 
incubated in darkness with PBS and then irradiated) at the respective uptake time. Data are the mean value ± 
S.D. of at least three independent experiments performed in triplicates. *(p<0.05) and **(p<0.001) 
significantly different from control cells at the same uptake time. 
 
PcGal16 demonstrated to be more photoactive against UM-UC-3 cells, in spite of its 
similar accumulation in both cell lines. Among the conditions used, 5 µM and 9 µM of 
PcGal16 and incubation times of 2 h and 4 h showed the highest phototoxicity in both cell 
types. For example, when 5 µM of PcGal16 was used for 2 h there was a percentage in 
toxicity of 80.97 ± 4.53 and 26.94 ± 1.08 for UM-UC-3 and HT-1376 cells, respectively. It 
is important to note that for the cell line UM-UC-3, low concentrations of PcGal16 (0.5 µM 
and uptake time of 4 h) were enough to achieve a percentage in toxicity of 58.54 ± 1.67.  
MTT and trypan blue staining assays were performed 48 h and 72 h after PcGal16-
PDT, to investigate whether cells could recover for a time superior to 24 h after PDT. In 
both cell lines, the results obtained with the MTT colorimetric assay (cell metabolic 
activity) correlated well with the loss of cell membrane integrity (trypan blue staining) 
(Figure 2.28). UM-UC-3 cells were unable to recover from the photo-effects 48 h or 72 h 
after PcGal16-PDT, for concentrations of 5 µM and 9 µM (Figure 2.28 B) as evaluated by 
MTT and trypan blue assays. For concentrations of 0.5 µM and 2.5 µM, UM-UC-3 cells 
were able to recover in part their metabolic activity 48 h and 72 h after PDT (Figure 2.28 
B) as evaluated by the MTT assay. Regarding the trypan blue staining, cell membrane 
integrity is strongly affected 48 h and 72 h after PDT in both cell lines (Figure 2.28 C and 
D). The metabolic activity of HT-1376 cells was more affected 72 h after PDT than 24 h or 
48 h (Figure 2.28 A). As previously described for PorGal8, one plausible explanation for 
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the observed resistance of HT-1376 cells is the presence of CSCs in this cell line (part II, 
Figure 2.16). The possible ability of HT-1376 cells to produce an antioxidant adaptative 
response, activating antioxidant enzymes (like superoxide dismutase, catalase and 
glutathione peroxidase) and prosurvival mechanisms, can also explain the resistance 
observed 24 h after PcGal16-PDT. 
The concentrations of PcGal16 necessary to inhibit the proliferation of HT-1376 and 
UM-UC-3 cells in 50% can be estimated from Figure 2.28. These values, hereafter 
referred to as ‘‘photocytotoxic concentrations’’ (IC50) are reported in Table 2.4, which also 
includes another photocytotoxic index, the ‘‘intracellular phototoxic concentration’’ 
(IPC50) representing the intracellular concentration that produces a 50% decrease in cell 
viability.  
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Figure 2.28. Cytotoxic effects of PcGal16 at various concentrations in HT-1376 (A and C) and UM-
UC-3 (B and D) cells as function of the uptake time. Cytotoxicity was assessed 24, 48, and 72 h after 
PcGal16-PDT using the MTT (A and B) and trypan blue staining (C and D) assays. The percentage of 
cytotoxicity was calculated relatively to control cells (cells incubated with PBS in darkness and then 
irradiated) at the respective uptake time. Data are the mean value ± S.D. of at least three independent 
experiments performed in triplicates. The symbol **(p<0.001) represents significant differences in 
phototoxicity comparing with MTT reduction (%) or excluded trypan blue (%) of PcGal16-24 h after PDT for 
the respective concentration. 
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Table 2.4. Values for photocytotoxic concentration (IC50, µM) and intracellular phototoxic content 
(IP50, nmol PS per mg of protein) of PcGal16 on human bladder cancer cell lines, HT-1376 and UM-UC-3. 
IC50 values were calculated using the MTT dose response curves (24, 48, and 72 h after PDT), obtained for 
cells incubated with PcGal16 at various concentrations for 2 h.  
 HT-1376 cell line UM-UC-3 cell line 
Hours after PDT 24 48 72 24 48 72 
IC50 (µM), CI95% - 3.3 [0.6;10.7] 2.5 [2.2;2.9] 2.1, [0.9;5.0] 2.8, [2.4; 3.2] 2.6, [2.6;2.7] 
IPC50 
(nmol PS/mg protein) 
- 3450.2 3225.0 2165.9 2444.1 2373.7 
IC50 is the incubation concentration that inhibits the proliferation of cultures in 50%, after cells  ´incubation with PcGal16 
and cells  ´irradiation for 40 min 
IPC50 is the intracellular phototoxic content corresponding to the IC50 
CI95%: 95% Confidence interval 
 
Pcs conjugated with carbohydrates are rare, thus the photodynamic potential of this 
type of compounds is of great interest between PDT researchers. Recently, it was reported 
that Pcs conjugated with galactose units are accumulated inside HeLa carcinoma cells and 
produce higher toxicity in HeLa cells than in non-malignant HaCaT cells [8].  
 
 
3.5. Reactive oxygen species induced by PcGal16 in HT-1376 and UM-UC-3 
bladder cancer cells after PDT 
In an attempt to correlate the observed photocytotoxicity with the ability of PcGal16 
to generate ROS, a qualitative analysis by fluorescence microscopy and a quantitative 
evaluation by fluorescence spectroscopy using the H2DCFDA probe [18], were performed 
(for more detail, see part II). 
The PDT treatment with PcGal16 evidenced for the two bladder cancer cell lines, a 
significant increase in the DCF fluorescence (Figure 2.29) corresponding to ROS 
formation. The percentage of cells with DCF fluorescence was about 1.2-fold higher for 
the cell line UM-UC-3 than for the cell line HT-1376, when 5 µM of H2DCFDA was used. 
The presence of CSCs (part II, Figure 2.16) and an adaptative antioxidant response after 
PcGal16-PDT in HT-1376 cells can explain the less sensitivity of these cells to ROS and 
consequently less cell death. 
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Figure 2.29. Representative fluorescence images (A and C) and quantification (B and D) of DCF 
fluorescence increase (as a measure of ROS production) after PcGal16-PDT. Human bladder cancer cell lines, 
HT-1376 (A) and UM-UC-3 (B) were incubated with 5 µM of PcGal16 for 2 h in the dark. After PDT during 
40 min, an increase in intracellular oxidative stress was detected by oxidation of the fluorescent probe 
H2DCFDA. *Significantly different from irradiated-control cells (p<0.05). 
 
To elucidate the role of ROS generated after PcGal16-PDT in cell phototoxicity, 
specific quenchers of 
1
O2 (sodium azide [21] and histidine [22]) and free radical 
scavengers (cysteine [23]), were added before the PDT treatment. Figure 2.30 shows how 
the presence of 50 nM of NaN3, histidine or cysteine in the solution is able to reduce the 
cell toxicity after PcGal16-PDT. All the quenchers were non-toxic for the concentration 
used.  
For the cell line UM-UC-3, all the quenchers were able to reduce significantly but 
did not totally eliminate the phototoxicity induced after PcGal16-PDT. These results 
demonstrated that sodium azide, histidine and cysteine have a significant protection against 
PDT with PcGal16 in UM-UC-3 cells, suggesting that both 
1
O2 and hydroxyl radical are 
involved in the induction of cytotoxicity after PcGal16-PDT.  
The free radical scavenger (cysteine) was the only one able to reduce significantly 
the cell toxicity in HT-1376 cells.  
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Figure 2.30. Photocytotoxicity after PcGal16-PDT in the presence of specific quenchers of 
1O2 
(sodium azide and histidine) and free radical scavengers (cysteine) in HT-1376 (A) and UM-UC-3 (B) cells. 
Cytotoxicity was assessed 24 h after PcGal16-PDT in the presence of 50 nM of ROS quenchers, using the 
MTT assay. The percentage of cytotoxicity was calculated relatively to control cells (untreated cells). Data 
are the mean value ± S.D. of at least three independent experiments performed in triplicates. The symbol 
*(p<0.05) and ***(p<0.0001) represents significant differences in phototoxicity comparing with MTT 
reduction (%) after PcGal16-PDT. 
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4. Por 1-albumins and Por 1-mAb anti-CD104: Target-directed 
destruction of bladder cancer cells 
 
4.1. Por 1-BSA and Por 1-HSA bioconjugates  
4.1.1. General overview  
 Albumins are emerging as versatile protein carriers for target-directed drugs and for 
improving the pharmacokinetic profile of peptide- and protein-based treatments [67]. 
Conjugates of porphyrins (and their derivatives) with human and bovine serum albumin 
(HSA and BSA, respectively) have been successfully produced and characterized [68-70]. 
From an experimental point of view, the PS conjugated with HSA or BSA is a model for 
developing bioconjugation strategies and extensive structural characterization of the 
conjugates. From a biological point of view, albumin can be accumulated in tumour tissues 
due to the EPR effect (enhanced permeability and retention of macromolecules in tumour 
tissues) [71]. EPR is the result of two effects: firstly, blood vessels of tumour tissues have 
an enhanced vascular permeability for circulating albumin and secondly, it was 
demonstrated that macromolecules having a molecular weight higher than 40 kDa have a 
reduced clearance from the tumour tissue. These properties make albumin a good 
candidate as a photosensitizer carrier, as well as a good model in the development of 
bioconjugation strategies [67]. 
In this section it will be described the characterization of Por 1-BSA/HSA 
bioconjugates by UV-Visible, LC-UV-MS and MALDI-TOF-MS. At the end, in vitro 
results with these conjugates against UM-UC-3 human bladder cancer cell line after PDT 
are reported (Figure 2.31). 
 
Figure 2.31. Schematic overview of this section including the characterization of Por 1-BSA/HSA, as 
well as the biological assays against UM-UC-3 bladder cancer cell line. 
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4.1.2. Por 1-BSA and Por 1-HSA bioconjugates characterization 
4.1.2.1. UV-Visible 
The synthesis of porphyrins bearing an N-hydroxysuccinimide (NHS) activated ester 
group has been well documented [72] and sets the ground for the herein reported 
bioconjugation strategy. With this regard, the carboxyl functionality present on Por 1 was 
transformed into an NHS ester. Porphyrin was thereafter conjugated with the free amine 
groups of amino acids (usually lysines) of the albumins, in aqueous buffered medium with 
a slightly basic pH. The free amine groups of an amino acid attack the carbonyl carbon of 
porphyrin and initiate the ligation followed by elimination of NHS. 
Conjugation of both albumins (HSA and BSA) was successfully carried out with Por 
1 and these conjugates were named as Por 1-albumin bioconjugates. To optimize the 
conjugation strategy, variable molar amounts of Por 1 (30:1, 40:1, and 80:1 mole ratio per 
albumin) were used in the conjugation reaction. The degree of porphyrin labeling (DOL), 
after purification of the conjugates, was assessed using UV-Visible spectroscopy (Table 
2.5).  
 
Table 2.5. DOLs for Por 1-albumin bioconjugates at different initial molar ratios. DOL is the degree 
of labeling, i.e. moles of Por 1 per moles of albumin after conjugates purification. 
Conjugate Initial Molar ratios 
µmol after purification 
DOL 
Por 1 Albumin 
Por 1-BSA 30:1 12.30 10.10 1.22 
Por 1-BSA 40:1 11.50 10.40 1.11 
Por 1-BSA 80:1 11.00 10.90 1.01 
Por 1-HSA 30:1 10.80 5.19 2.08 
Por 1-HSA 40:1 11.10 6.46 1.72 
Por 1-HSA 80:1 10.80 6.39 1.69 
 
For the conjugates obtained after reaction of Por 1 with the albumins, it was 
observed that the DOL decreases with increasing initial molar ratios. These results suggest 
that for the ratios 40:1 and 80:1 the amount of albumin was insufficient to react with all 
Por 1 made available. Also, this outcome can be a consequence of the reduced solubility of 
these proteins when higher concentrations of Por 1 were employed for the higher ratios. 
Hence, the ratio 30:1 of Por 1 to proteins was considered to pursuit further studies. The 
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DOLs obtained for Por1-BSA (about 1) or Por 1-HSA (about 2) conjugates are in 
agreement with the literature for a chlorine6-BSA [68] and a methotrexate-HSA conjugate 
[73]. 
 
 
4.1.2.2. MALDI-TOF-MS and LC-UV-MS 
The conjugation of both albumins with Por 1 was successfully achieved as 
documented by the MALDI-TOF-MS spectra (Figure 2.32), obtained for both the non-
conjugated BSA or HSA (native proteins) and for the Por 1-albumin bioconjugates. The 
spectra displayed in Figure 2.32 are characterized by three main peaks: the molecular ion 
m/z [M-H]
+
 (M = BSA, HSA, Por 1-BSA or Por 1-HSA), the doubled charged molecular 
ion m/2z [M-H]
2+
 with half the m/z of the molecular ion, and the triply charged molecular 
ion m/3z ([M-H]
3+
) with 1/3 of the molecular ion m/z value.  
 
  
Figure 2.32. MALDI-TOF-MS spectra of native albumins (non-conjugated proteins) and of Por 1-
albumin bioconjugates.  
 
The characterization of Por 1-albumin bioconjugates was also accomplished by LC-
UV-MS and some chromatograms are depicted in Figure 2.33, using the Por 1-HSA 
conjugate as an example. Chromatographic fractions monitored at 280 nm (wavelength of 
albumin´s maximum absorbance) and at 415 nm (wavelength corresponding to Soret band 
of Por 1) showed a single peak of the bioconjugate. The peak of the HSA native protein 
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elutes at 17.8 min whereas the bioconjugate elutes slightly later, at 21.2 min. The mass 
spectra of these peaks eluting at 17.8 min and 21.2 min were obtained and reconstructed 
using the Bayesian Protein Reconstruction add-in feature from Analyst
TM
 software (Figure 
2.34). In Figure 2.33 (right-hand side) the presence of non-conjugated HSA in the sample 
was also detected at about 20.8 min elution time and the mass spectra of this peak was also 
obtained and reconstructed (Figure 2.34). 
 Figure 2.33. Chromatograms of non-conjugated HSA and Por 1-HSA conjugate. The 
chromatograms were obtained for the HSA absorption wavelengths range between 260 nm to 280 nm and for 
the Por 1 maximum absorption range between 410 nm to 420 nm. 
 
 
 
Figure 2.34. Reconstructed masses of native HSA, Por 1-HSA bioconjugate and non-conjugated 
HSA after Bayesian Protein Reconstruction.  
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4.1.3. Biological in vitro assays with Por 1-albumin bioconjugates against 
UM-UC-3 bladder cancer cells 
4.1.3.1. Uptake of Por 1-albumin bioconjugates by UM-UC-3 bladder cancer 
cells 
The ability of Por 1-albumin bioconjugates to be accumulated inside the cancer 
cells was evaluated using the human bladder cancer cell line UM-UC-3 (Figure 2.7 B). 
The structure of Por 1 generates a fluorescence signal, which allows the uptake 
determination of Por 1-albumin by fluorimetry. UM-UC-3 cells were incubated in 
darkness with 5 µM of bioconjugates in PBS buffer for 0.5, 1, 2, and 4 h (Figure 2.35). 
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Figure 2.35. Cellular uptake of Por 1-albumin bioconjugates by UM-UC-3 bladder cancer cells. 
Conjugates containing 5 µM of Por 1 were incubated in the dark for 0.5, 1, 2, and 4 h in PBS with UM-UC-3 
cells. The results are expressed as Por 1 concentration (nmol) per mg of intracellular protein against uptake 
time (h). Values are presented as mean ± S. D. of three independent experiments performed in triplicates. 
*Significantly different from Por 1-HSA at uptake time of 0.5 h (p<0.05). $Significantly different from Por 
1-BSA at uptake time of 0.5 h (p<0.05). The symbol # represents significant differences between Por 1-HSA 
and Por 1-BSA at the same uptake time (p<0.05). 
 
The uptake of Por 1-albumin bioconjugates was significantly increased for the 
uptake times of 1, 2, and 4 h when compared with the uptake value of the respective 
conjugate at 0.5 h. The uptake kinetics was statistically different between the Por 1-
albumin bioconjugates (when using the same uptake time) for the uptake times of 1, 2, and 
4 h (Figure 2.35). Due to the high homology between HSA and BSA [74], it is expected 
that the BSA conjugate is processed likewise the HSA conjugate. The uptake of Por 1-
albumin bioconjugates increased as a function of the incubation time. Four hours after 
incubation, the cellular uptake values were 868.7 ± 23.54 nmol per mg of protein, for the 
Por 1-HSA conjugate and 1066.0 ± 54.23 nmol per mg of protein for the Por 1-BSA one. 
The four hours uptake time was, therefore, selected for subsequent experiments.  
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It is expected that the albumin is accumulated in cells as a source of amino acids and 
energy under conditions of cellular stress, as observed in cancer cells [75]. It was 
demonstrated that albumin is accumulated through albumin-mediated endocytosis into the 
lysosomal compartment of cancer cells, where it is degraded [75]. It was also shown that 
the uptake of a methotrexate-HSA bioconjugate in cancer cells occurs by endocytosis [73], 
thus we also hypothesize the same for our bioconjugates. The membrane receptor 
responsible for the uptake of albumin inside the cancer cells, and whether the endocytosis 
process is dependent or not of a specific receptor is not clear [76]. 
 
 
4.1.3.2. Dark toxicity and phototoxicity of Por 1-albumin bioconjugates in 
UM-UC-3 bladder cancer cells 
To prove whether Por 1-albumin bioconjugates are toxic just after light activation, 
their cytotoxicity in darkness was evaluated. Por 1-albumin bioconjugates at various 
concentrations (0.5, 1, 5, and 10 µM in PBS) were incubated with UM-UC-3 cells for 4 h. 
The control experiments were performed by incubation of the cells in the dark with PBS 
for 4 h. The toxicity was estimated 24 h after treatment using the MTT colorimetric assay. 
No cytotoxicity was observed in the control cells. Moreover, the two Por 1-albumin 
bioconjugates did not exhibit dark cytotoxicity at incubation concentrations up to 10 µM, 
as the MTT reduction did not decrease significantly below the control levels, i.e. when 0 
µM of the conjugates is used (Figure 2.36 A). 
For the PDT assays, the cells were irradiated using white light for 40 min after 
incubation of the cells with the Por 1-albumin bioconjugates at 0.5, 1, 5, and 10 µM for 4 
h. As shown in Figure 2.36 B, an MTT gradual reduction was observed for both 
conjugates in a concentration dependent manner. 
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Figure 2.36. Por 1- albumin bioconjugates’ toxicity, after UM-UC-3 cells had been incubated in the 
dark with different concentrations of the conjugates (0.5, 1, 5, and 10 µM) for 4 h (A) and then irradiated for 
40 min (B). The cell survival fractions were determined 24 h after treatment by the MTT colorimetric assay. 
Values are presented as mean ± S. D. of three independent experiments performed in triplicates, using the 
respective controls (cells incubated with PBS and (A) non-irradiated or (B) irradiated) as reference value for 
cellular viability (100%). **(p<0.001) significantly different from 0 µM of Por 1-BSA. $$(p<0.001) 
significantly different from 0 µM of Por 1-HSA, #significantly different from Por 1-HSA at the same 
concentration (p<0.05).  
 
The MTT reduction was statistically different between Por 1-BSA and Por 1-HSA 
conjugates for the concentration of 1 µM. The best results were obtained when the cells 
were incubated with 5 µM and 10 µM solutions of the bioconjugates. Por 1-BSA and Por 
1-HSA at 5 µM resulted in cell toxicity percentages of 89.48 ± 1.98 and 90.02 ± 1.16, 
respectively. Combining the uptake results with the phototoxicicity outcome, further 
experiments were performed using 5 µM of Por 1-albumin bioconjugates and uptake time 
of 4 h. 
Accounting to other reported studies [73], we hypothesize that the accumulation and 
phototoxicity of Por 1-albumin bioconjugates will be succeeded in vivo because of the 
enhanced microvascular permeability, as well as specific cellular uptake mechanisms. As 
aforementioned, albumin conjugates can be accumulated inside the cancer cells due to the 
EPR effect [67]. The vasculature of the tumour tissue is permeable for macromolecules due 
to the leaky defective blood vessels, whereas in healthy tissues only small molecules can 
pass through the blood vessels. 
 
 
 
 
 
 
 
Results and Discussion                                                               Por 1-albumins and Por 1-mAb anti-CD104:  
Target-directed destruction of bladder cancer cells 
 
84 
 
4.1.3.3. Reactive oxygen species induced by Por 1-albumin bioconjugates in 
UM-UC-3 bladder cancer cells after PDT 
To ensure that the bioconjugation did not influence the ability of Por 1 to produce 
ROS after photoactivation and also to determine whether or not the phototoxicity observed 
in Figure 2.36 B is related to ROS production after PDT, the intracellular levels of ROS 
were measured using the probes H2DCFDA [77] and DHE [19] (for more detail, see part 
II).  
The ROS measurements are displayed in Figure 2.37. For both tested Por 1-
albumin bioconjugates, the ROS levels were significantly increased in comparison to cells 
without PS. The differences between the conjugates using the same probe, were 
statistically different for DHE probe.  
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Figure 2.37. ROS production inside the UM-UC-3 cells after cells´ incubation in darkness with 5 µM 
of Por 1-albumin bioconjugates for 4 h and irradiation with white light for 40 min. The intracellular ROS 
levels were determined after PDT treatment, by DHE and H2DCFA staining. Values are presented as the 
mean ± S. D. of three independent experiments performed in triplicates. *significantly different when 
compared with control cells (cells without conjugate, incubated with DHE or H2DCFDA) (p<0.05); 
#statistical differences between Por 1-HSA and Por 1-BSA using the DHE probe (p<0.05). 
 
The production of ROS after albumin bioconjugates-PDT demonstrates that the 
conjugation of Por 1 to BSA or HSA is not able to quench the porphyrin excited states by 
amino acid residues on the protein. Thus, the phototoxicity observed with the conjugates is 
related with their ability to generate ROS.  
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To correlate the 
1
O2 production by Por 1-albumin bioconjugates with their 
phototoxicity, after PDT, the 
1
O2 quencher - sodium azide (NaN3) - was used [21]. UM-
UC-3 cells were incubated with 5 µM of Por 1-albumin bioconjugates for 4 h in darkness 
and then with a non-toxic concentration of NaN3 (50 nM) before the PDT treatment. 
Figure 2.38 shows how the presence of NaN3 is able to reduce the cell toxicity. The 
effectiveness of the conjugates is not completely reversed with NaN3, which suggests that 
1
O2 generation is a minor part of the phototoxic effect. 
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Figure 2.38. Inhibition of cell phototoxicity induced by Por 1-albumin bioconjugates after PDT, 
using sodium azide (NaN3) as the quencher. After conjugates uptake at 5 µM for 4 h in darkness, the cells 
were incubated with 50 nM of NaN3 and irradiated with white light for 40 min. The cell viability was 
evaluated 24 h after treatment by the MTT colorimetric assay. Values are presented as the relative mean ± S. 
D. of three independent experiments performed in triplicates. *(p<0.05) and **(p<0.001) significantly 
different when compared with the respective conjugate (without quencher), after PDT. 
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4.2. Por 1-mAb anti-Caf and Por 1-mAb anti-CD104 immunoconjugates  
4.2.1. General overview  
The conjugation of PSs with specific antibodies allows the direct targeting of the PS 
to the correct cell type [72]. The mAb anti-CD104 recognizes the human antigen CD104, 
also known as integrin beta 4. The role of CD104 in tumourigenicity is well established 
and its overexpression in colorectal and bladder carcinomas has been reported [78, 79]. 
There are two reports about the synthesis and photodynamic activity of cationic 
isothiocyanato diphenyl porphyrins conjugated with mAb anti-CD104 [80, 81]. 
Since limited quantities of mAb anti-CD104 were available, the mAb anti-Caf was 
used as a model for the optimization of our bioconjugation strategy.  
In this section it will be described the characterization of Por 1-mAb anti-Caf and 
Por 1-mAb anti-CD104 by UV-Visible and the immunoreactivity of the conjugate Por 1-
mAb anti-Caf by ELISA assay. At the end, PDT in vitro results obtained with Por 1-mAb 
anti-CD104 against UM-UC-3 human bladder cancer cell line are reported (Figure 2.39). 
 
Figure 2.39. Schematic overview of this section including the characterization of Por 1-mAb anti-
Caf and Por 1-mAb anti-CD104 conjugates, as well as the biological assays with Por 1-mAb anti-CD104 
against UM-UC-3 bladder cancer cells. 
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4.2.2. Por 1-mAb anti-Caf and Por 1-mAb anti-CD104 immunoconjugates 
characterization 
4.2.2.1. UV-Visible and ELISA 
The efficient conjugation of Por 1 with albumins and the successful biological 
results obtained with these bioconjugates suggest that the adopted experimental procedure 
has general applicability. Thus, the conjugation of Por 1-mAb anti-Caf was performed 
using the same methodology. 
The DOL for the Por 1-mAb anti-Caf, i.e. moles of Por 1 per mole of mAb anti-
Caf, was calculated from two independent experiments, using initial molar ratios of 30:1 
and 80:1 (Table 2.6). It was observed that the DOL decreases with increasing initial molar 
ratios, like had been obtained for the conjugates Por 1-albumin bioconjugates (Table 2.5), 
an effect reported elsewhere for other photosensitizer-antibody conjugates [82]. 
Consequently, the conjugation of Por 1 with the mAb anti-CD104 was also performed 
using an initial molar ratio of 30:1, based on the obtained data with the albumins 
conjugates. For the Por 1-mAb anti-CD104 a DOL of 0.803 was obtained (Table 2.6), 
that is in accordance with the ratio described in the literature for cationic isothiocyanato 
diphenyl porphyrins conjugated with the same mAb anti-CD104 [80]. 
 
Table 2.6. DOLs of Por 1-mAb anti-Caf and Por 1-mAb anti-CD104 immunoconjugates at 
different initial molar ratios. DOL is the degree of labeling (i. e. moles of Por 1 per moles of antibody after 
conjugate purification). 
Immunoconjugate Initial Molar ratios 
nmol after purification 
DOL 
Por 1 mAb 
Por 1-mAb anti-Caf 30:1 0.165 0.204 0.809 
Por 1-mAb anti-Caf 80:1 0.919 2.750 0.334 
Por 1-mAb anti-CD104 30:1 0.191 0.238 0.803 
 
 
The conjugate Por 1-mAb anti-Caf was used in an attempt to confirm that the 
antibody binding specificity is not affected after conjugation, since it has been described 
that conjugated porphyrins can interfere with the antigen recognition by the antibody [83]. 
Thus, the immunoreactivity of Por 1-mAb anti-Caf was checked by ELISA assay (data 
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not shown). ELISA demonstrated that the immunespecificity of mAb anti-Caf is unaffected 
after conjugation with Por 1. 
    
 
4.2.3. Biological in vitro assays with Por 1-mAb anti-CD104 
immunoconjugate against UM-UC-3 bladder cancer cells 
The dark toxicity of Por 1 (control) and Por 1-mAb anti-CD104 on the UM-UC-3 
cell line was examined 24 h after treatment by the MTT colorimetric assay (Figure 2.40). 
Because of the reactive nature of the ester group, Por 1 containing a carboxylic group was 
used. The cells were incubated for 4 h in darkness with Por 1-mAb anti-CD104 
immunoconjugate at 0.0025, 0.005, 0.05, 0.5, and 1 µM for 4 h. Non-conjugated Por 1 was 
used as control, tested for concentrations between 0.0025 µM to 10 µM. The non 
conjugated Por 1 and Por 1-mAb anti-CD104 were not toxic to cells in the absence of 
light.  
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Figure 2.40. Non-dark toxicity of Por 1-mAb anti-CD104 immunoconjugate, after UM-UC-3 cells 
had been incubated in the dark with different concentrations of the immunoconjugate (0.0025, 0.005, 0.5, and 
1 µM) for 4 h. The cell survival fractions were determined 24 h after treatment by the MTT colorimetric 
assay. Values are presented as mean ± S. D. of three independent experiments performed in triplicates, using 
the control (cells incubated with PBS for 4 h) as reference value for cellular viability (100%). 
 
For the PDT assays, the cells were incubated with Por 1-mAb anti-CD104 at 
various concentrations (0.0025, 0.005, 0.05, 0.5, and 1 µM) for 4 h in darkness and then 
irradiated for 40 min. The cell toxicity obtained with Por 1-mAb anti-CD104 was 
statistically different for all studied concentrations in relation to untreated cells (Figure 
2.41). The IC50 values (concentration of porphyrin needed to kill 50% of UM-UC-3 cells 
after PDT) were 0.09, 0.14, and 0.53 µM for Por 1-mAb anti-CD104, Por 1-BSA and Por 
1-HSA, respectively. The immunoconjugate IC50 was lower when compared with that for 
reported photosensitizers conjugated with mAb anti-CD104 antibody against human colon 
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adenocarcinoma cell line LoVo and human caucasian lung large cell carcinoma CORL23 
[81]. These results show that the immunoconjugate is a potential target-directed 
photosensitizer. Knowing that anti-CD104 binds to a 205-kDa glycoprotein (integrin beta 
4) involved in cell-cell adhesion that is up-regulated in bladder carcinomas, future in vivo 
studies with higher quantities of the Por 1-mAb anti-CD104 are needed to validate the 
putative potential of this immunoconjugate against bladder tumours.  
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Figure 2.41. Phototoxicity of non conjugated porphyrin and Por 1-mAb anti-CD104 
immunoconjugate. UM-UC-3 cells were incubated in the dark with compounds at different concentrations for 
4 h and irradiated with white light for 40 min. The cell survival fractions were determined 24 h after 
treatment by the MTT colorimetric assay. Values are presented as mean ± S. D. of three independent 
experiments performed in triplicates, in relation to the control (concentration equal to zero), expressed in 
percentage. **(p<0.001) significantly different from Por 1-mAb anti-CD104 immunoconjugate at 0 µM. 
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Conclusions and future perspectives 
In the present study we intended to assess the photo-activity of three types of 
bioconjugates: PSs conjugated with galactose units, albumin proteins and mAb anti-
CD104. Although structurally different, all of these bioconjugates have a common purpose 
– molecular targeted photodynamic therapy of bladder cancer cells. PorGal8 and PcGal16 
are decorated with eight and sixteen galactose molecules, respectively, which can be 
recognized by galectins (galactose-binding proteins), overexpressed in bladder tumours. 
Por 1-albumin bioconjugates correspond to porphyrin conjugated with human and bovine 
serum albumin, which can be selectively accumulated in cancer cells, since the vasculature 
of the tumour tissue is permeable to macromolecules due to the leaky blood vessels, 
whereas in healthy tissues only small molecules can pass through the blood vessels. Por 1-
mAb anti-CD104 could have specificity to bladder cancer cells, since mAb anti-CD104 
binds to a 205-kDa glycoprotein (integrin beta 4) involved in cell-cell adhesion that is up-
regulated in bladder carcinomas. 
 
 The photophysical and -chemical characterization of the two new galacto-
conjugates, PorGal8 and PcGal16, demonstrated that the presence of galactose units in the 
periphery of Por and Pc improves their hydrophilicity. The interaction of these galacto-
conjugates with HSA and their high singlet oxygen production demonstrated high capacity 
for their use as PDT agents.  
 
 For the in vitro photodynamic assays two human bladder cancer cell lines, HT-
1376 and UM-UC-3, were used. UM-UC-3 cells correspond to a more invasive phenotype, 
while HT-1376 cells have an epithelial morphology associated with a non-invasive 
phenotype. The promising results obtained in vitro, encourages the move on to the next 
step: in vivo tests with all bioconjugates in tumour masses. 
 
 The uptake of PorGal8 was higher in UM-UC-3 cells than in HT-1376 cells and it 
can be somehow related to the higher protein levels of galectin-1 in UM-UC-3 cell line, 
which may serve as docking sites for PorGal8 on the cell membrane and probably, 
facilitating entry of PorGal8. Moreover, the pre-incubation of cells with galactose 
decreased the uptake and phototoxicity of PorGal8. Specific inhibition of galectin-1 
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expression by RNAi (interference) will be an approach to be used in future works, in an 
attempt to investigate the involvement of this lectin in the uptake of PorGal8 by bladder 
cancer cells.  
 In both cell lines, PorGal8 was inert until activation by light. The phototoxicity 
after PorGal8-PDT was higher for the cell line UM-UC-3 than for the cell line HT-1376, 
being mediated by ROS production. Using the sphere formation assay, the presence of 
CSCs expressing ABCG2 (multi-drug resistance pump) protein in HT-1376 cells was 
detected. Thus, it is possible that CSCs in HT-1376 offer some resistance after PorGal8-
PDT. The presence of CSCs in HT-1376 cell line can be validated, in future works, by 
flow cytometry approaches using for example violet-excited Dye Cycle Violet (a cell 
permeable DNA binding dye) that is effluxed via ABCG2 pump-dependent mechanism. 
 PDT with PorGal8 induced transient changes in actin organization in HT-1376 
cells. Therefore, it is plausible that cytoskeletal structures like F-actin can be involved in 
the mechanism of resistance to PDT in HT-1376 cells. For these cells, PDT with PorGal8 
increased the expression of the pro-apoptotic protein Bax and ER-stress associated protein 
CHOP. To determine whether the mechanisms of action of the PDT agent PorGal8 are 
different between the two cell lines, we intend to evaluate (in future works) in both cell 
lines the expression of proteins associated to cell death at different time points after PDT. 
 
 The uptake of PcGal16 was similar in both cell lines and fluorescence microscopy 
demonstrated its accumulation inside the cells throughout the cytoplasm. In dark 
conditions, PcGal16 was non toxic and induced a decrease in galectin-1 protein levels. 
Western blotting studies are needed to quantify the galectin-1 protein levels before and 
after cellular uptake of PcGall6. For the HT-1376 cell line, it was observed co-localization 
of PcGal16 with galectin-1 in vesicular structures often concentrated perinuclearly. For the 
UM-UC-3 cell line, it was also observed dispersed co-localization of PcGal16 with 
galectin-1 in the cytoplasm. After PcGal16-PDT, HT-1376 cell line was relatively resistant 
24 h and 48 h after PDT with PcGal16. However, 72 h after PDT there is a massive cell 
death. For the cell line UM-UC-3 there was a strong phototoxicity twenty-four hours after 
PDT without cell recovery until 72 h after PDT. The PDT treatment with PcGal16 
evidenced, for the two bladder cancer cell lines, a significant increase in ROS formation 
and it was higher for the cell line UM-UC-3 than for the cell line HT-1376. Determination 
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of the activity of antioxidant enzymes in UM-UC-3 and HT-1376 cells, like superoxide 
dismutase, catalase and glutathione peroxidase before and after PcGal16-PDT may be an 
attractive approach to investigate the involvement of these antioxidant enzymes in 
detoxification of ROS-induced by PcGal16. This approach is planned to take place in a 
near future in our laboratory. Regarding the phototoxicity and generation of ROS in the 
two bladder cancer cell lines, it is expected that the activity of antioxidant enzymes is 
higher in HT-1376 cells than in UM-UC-3 cells.  
 
 The conjugation of human and bovine albumin, and mAb anti-CD104 with 
porphyrin 1 was successfully achieved. The biological potential of these conjugates was 
evaluated against the human bladder cancer cell line UM-UC-3. No photodynamic effect 
was detected when the non-conjugated porphyrin was used. Yet, when it was coupled 
covalently with the mAb anti-CD104, BSA and HSA, the resulting conjugates 
demonstrated high efficacy in destroying the cancer cells, with the mAb anti-CD104 
efficacy overruling the albumin ones.  
 The porphyrin used in the synthesis of these bioconjugates has the longest-wave 
absorption band around 600 nm, thus the in vivo biological effects will occur only to a 
tissue depth of about 5 mm. Considering the limitations of Por 1-mAb anti-CD104 for in 
vivo studies, we intend to conjugate the mAb anti-CD104 with phthalocyanines whose may 
be particularly effective in treating deeply seated tumours due to their markedly greater 
absorbance of red light near of 650 nm.  
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1.1. Equipment and reagents 
 
1.1.1. General instrumentation 
1.1.1.1. Equipment and material for the UV-Visible absorbance and 
fluorescent measurements 
The fluorescence assays were performed on a computer controlled by FluoroMax-3 
spectrofluorimeter from Horiba Jobin Yvon. The data acquisition and post 
processing/analysis were performed using its software DataMax. 
The UV-visible assays were performed on the UVIKON 922 spectrophotometer from 
Biotek Instruments.  
 
1.1.1.2. Equipment for irradiation assays 
The illumination system used to determine the photostability and 
1
O2 generation of 
PSs was the Light Source Model Lc-122 from Lumacare, equipped with a halogen/quartz 
250 W lamp coupled to one optic fiber probe (400-800 nm). The fluence rates were 
determined with the energy meter Coherent FieldMaxII-Top with a Coherent PowerSens 
PS19Q energy sensor. 
 
1.1.2. Reagents, chemical products and buffers 
PorGal8, PcGal16, TPP and ZnPc were synthesized by Doctor Sandrina Silva in the 
Porphyrins and Phthalocyanines Materials Research Group, Department of Chemistry, 
University of Aveiro, Portugal.  
Dimethylsulfoxide (DMSO), dimethylformamide (DMF), 1,3-diphenylisobenzofuran 
(DPBF) were obtained from Sigma-Aldrich. Phosphate buffered saline (PBS) buffer was 
prepared in Milli-Q water at pH 7.60: 10 mM NaH2PO4, 70 mM Na2HPO4 and 145 mM 
NaCl. 
The Human Serum Albumin (HSA) lyophilized powder, essentially protease free; 
≥96% (agarose gel electrophoresis) was purchased from Sigma-Aldrich (Ref. A4327).  
 
1.1.3. Softwares 
Microsoft Excel was used for the displayed graphs and ChemDraw Ultra 12.00 from 
CambridgeSoft was the software used to draw the chemical structures. 
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1.2. Protocols 
 
1.2.1. Aggregation assays  
 Principle 
The aggregation behaviour of PorGal8 and PcGal16 in PBS buffer is studied at 
different concentrations by Lambert-Beer´s law plots, where the relation of absorbance and 
concentration is linear: 
              
where A is the absorbance, ɛ is the molar absorptivity of the compound (L.mol-1.cm-
1
), b is the length of the light path (cm) and c is the concentration of the compound in 
solution (mol.L
-1
) [1]. 
 
Protocol 
Stock solutions of the galacto-conjugates at a concentration of 20 mM were prepared 
in DMSO and stored in the dark at room temperature (RT). The working solutions were 
freshly prepared prior to use, by diluting the stock solutions in PBS buffer with the 
concentration of DMSO being always inferior to 1% (v/v). 
Two milliliters of working solutions (without air bubbles) was placed into quartz 
cuvettes and the absorbance was scanned for wavelengths between 300 to 800 nm for 
PcGal16 and 300 to 700 nm for PorGal8.
1 
The wavelengths of maximum absorption were 
determined and the molar absorptivity of the compounds was calculated by plotting the 
absorbance against the respective concentration, by Lambert-Beer´s law.
2
 
 
1.2.2. Fluorescence assays 
Principle 
The fluorescence quantum yields (ФF) of PorGal8 and PcGal16 can be calculated in 
DMF by comparison of the area below the corrected emission spectra (between 620 nm to 
850 nm) using 5,10,15,20-tetraphenylporphyrin (TPP) as standard (λexcitation at 601 nm, Фf 
= 0.11 in DMF) [2]. For that, the following equation is used: 
    
      
   
           
                        
                           
    
                                                             
1 The maximum absorbance was always inferior to 1.0, in all working solutions. 
2 It was considered that the length of the light path (b) is equal to 1 cm. 
Methods and Materials                                      Photo -Physical and -Chemical assays of galacto-conjugates 
106 
 
where AUC is the integrated area under the fluorescence curves for each sample and 
standard, and Abs is the absorbance of the samples and the standard at the excitation 
wavelength (λexcitation at 601 nm) [3]. 
 
Protocol 
PorGal8, PcGal16 and TPP working solutions were freshly prepared in DMF to give 
absorbance near of 0.03
3
 at 601 nm. The fluorescence emission spectra of PorGal8, 
PcGal16 and TPP were measured between 620 to 850 nm, after excitation at 601 nm. The 
excitation and emission slits width were set at 2.0 nm. Using the DataMax software, the 
emission spectra were corrected and the area under the fluorescence emission curves was 
calculated. 
 
1.2.3. Photostability assays 
Principle 
The photostability of PorGal8 and PcGal16 can be studied by monitoring, 
respectively, the decrease of the absorbance of Soret and Q bands, after different times of 
irradiation with white light (400-800 nm) delivered by an illumination system. 
 
Protocol 
Solutions of PorGal8 at 19 µM and PcGal16 at 9 µM were freshly prepared in PBS 
buffer (0.5% v/v DMSO) and kept in the dark at RT. The irradiation experiments were 
performed in magnetically stirred cuvette solutions (with 2 mL of sample) in a dark room, 
over a period of 30 min with white light (400-800 nm) at a fluence rate of 150 mW.cm
-2
. 
The absorbance at 415 nm or 722 nm
4
 for PorGal8 or PcGal16, respectively, was 
determined before irradiation and at 1, 3, 4, 5, 10, 15, 20, 25, and 30 min periods of time 
after irradiation. The results were expressed as follows:                    
                                  
                      
. 
 
 
                                                             
3 This condition minimizes reabsorption of radiation by the ground-state species. 
4 The wavelengths 415 nm and 722 nm correspond to the maximum absorbance of PorGal8 and PcGal16, 
respectively. 
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1.2.4. Singlet oxygen assays 
Principle 
Singlet oxygen (
1
O2) can be determined by a chemical method using 1,3-
diphenylisobenzofuran (DPBF) as 
1
O2 scavenger [4]. The yellow-colored DPBF reacts 
specifically with 
1
O2 in a [4+2] cycloaddition reaction, being oxidized to the colorless o-
dibenzoylbenzene (Figure 4.1). DPBF has an absorption maximum at 415 nm, thus it is 
possible to follow the ability of the PorGal8 and PcGal16 to generate 
1
O2 by measuring the 
DPBF absorption decay, at this wavelength. 
 
 
 
 
Figure 4.1. Reaction of DPBF with 1O2 by a Diels Alder reaction. 
 
Protocol 
Freshly prepared stock solutions of 50 µM DPBF, 10 µM of galacto-conjugates 
(DMF:H2O; 9:1, by volume) were maintained in the dark at RT until use. Solutions 
containing DPBF (16.15 µM) with or without PorGal8 or TPP at 0.67 µM; PcGal16 or 
ZnPc at 0.1615 µM were prepared in DMF:H2O (9:1, by volume) in a quartz cuvette. The 
solutions were irradiated at RT and under gentle magnetic stirring, with filtered
5
 white 
light (500 to nm 800 nm)
 
at a fluence rate of 4.5 mW.cm
-2
. The breakdown of DPBF was 
monitored by measuring the decrease in absorbance at 415 nm at pre-established 
irradiation intervals. The results were expressed by plotting the DPBF depletion against the 
irradiation time. The depletion of DPBF was calculated as follows:                
    
    
. 
Abs0 and Abst are the absorbance values at 415 nm before and after irradiation, 
respectively. 
 
1.2.5. Human Serum Albumin interaction assays 
Principle 
The interaction of the galacto-conjugates with HSA protein can be determined by 
measuring the intrinsic fluorescence quenching of tryptophan residues (excited at 280 nm) 
                                                             
5 The white light was filtered through a cut-off filter for wavelengths inferior to 550 nm. 
O
Ph
Ph
+
1
O2
O
Ph
Ph
O
O
O
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on HSA protein. If occurs interaction between conjugates and HSA, the binding constant 
(Ka) and the number of binding sites (n) can be determined by the following equation: 
    
 
             
F0 and F are the tryptophan fluorescence intensities in the absence and presence of 
the quencher (Q) [5]. 
 
Protocol 
Stock solutions of the galacto-conjugates at a concentration of 20 mM were prepared 
in DMSO and kept in dark conditions at RT. HSA was freshly prepared at a concentration 
of 2 µM in PBS buffer at RT. Two mL of HSA solution was titrated with increasing 
concentrations of galacto-conjugates, keeping always the final concentration of DMSO to 
no more than 0.15% (v/v).
6
 The final concentrations of the conjugates were 0, 0.5, 1.0, 1.5, 
2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 15.0, 20.0, and 30.0 µM.  
The fluorescence emission spectra of the HSA´s tryptophan residues were acquired 
for the wavelength range between 300 nm to 450 nm upon excitation at 280 nm. The 
excitation and emission slits width were set at 2.0 nm. The fluorescence quenching curves 
were obtained by plotting the tryptophan residues quenching (in percentage) against 
conjugates concentration. The tryptophan residues quenching (in percentage) was 
calculated, as follows: 
                                   
      
  
     
Ka and n values were determined by plotting the log((F0-F)/F) against log(PorGal8 
or PcGal16 concentration), giving a linear plot, where log(Ka) and log(n) are the ordinate at 
the origin and slope, respectively. 
 
                                                             
6 Over a concentration range of 0-0.5% (v/v), DMSO did not quench HSA fluorescence. 
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2.1. Equipment and common materials 
 
2.1.1. General equipment 
The plate shaker was a Titramax 101 from Heidolph. The plate washer was an 
automatic 96-channel plate washer, ELx405 Select™ from BioTek Instruments. 
 
2.1.1.1. Equipment for the UV-visible absorbance and fluorescence 
measurements 
The microplate spectrophotometer used was a SpectraMax Plus384 from Molecular 
Devices controlled by SoftMax Pro software (v.5.3, Molecular Devices).  
 
2.1.1.2. Liquid Chromatography (LC) coupled to Ultraviolet-Visible (UV) 
and Mass Spectrometric (MS) detection, LC-UV-MS 
The LC-UV-MS used for the Por 1-albumin bioconjugates characterization, was an 
Agilent 1100 liquid chromatography system from Agilent Technologies and an API 4000 
triple-quadrupole mass spectrometer from Applied Biosystems. Both instruments were 
controlled by Analyst TM software (v.1.4.2, Applied Biosystems). 
 
2.1.1.3. Matrix-Assisted Laser Desorption/Ionization-Time Of Flight-Mass 
Spectrometry, MALDI-TOF-MS)   
MALDI-TOF mass spectra of Por 1-albumin bioconjugates were acquired using a 
Bruker Reflex III MALDI mass spectrometer from Bruker-Daltonik, operated with a 
nitrogen laser and at 20 kV acceleration voltage. 
 
2.1.2. Materials 
The PD-10 Desalting Columns containing Sephadex G-25 Medium used for the 
purification of the immunoconjugates were from GE HealthCare.  
The MaxiSorp
TM
 transparent microtiter plates with 96 flat-bottom polystyrene wells 
(plates used for the ELISA) possessing high protein-binding capacity were purchased from 
Nunc. The UV-Star
TM
 transparent microtiter plates with 96 wells, with an optical window 
down to 230 nm, were from Greiner Bio-One.  
Methods and Materials                                                                                  Synthesis and characterization of  
bioconjugates and immunoconjugates 
111 
 
The Vivaspin 500 filters with a cut off 3 kDa used to concentrate the Por 1-albumin 
bioconjugates were supplied by Sartorius.  
The HPLC column used in the LC-UV-MS assays was a protein reversed-phase 
column, Prot RP 18S, UltraSep ESD 300, 125 mm x 3 mm, from SepServ. 
 
2.1.3. Reagents, antibodies and chemical products 
Bovine Serum Albumin (BSA), the lyophilised albumin fraction V (min. 99%, 
receptor grade) used for preparing the conjugates, was purchased from Serva 
Electrophoresis (Ref. 11924). Human serum albumin (HSA), essentially fatty acid free, 
used for preparing the conjugates, was obtained from Sigma-Aldrich (Ref. A1887).  
The mouse monoclonal antibody against caffeine (mAb anti-Caf) was purchased 
from USBiological (Ref. C0110-06) at a concentration of 1.0 mg.mL
-1
. The mouse 
monoclonal antibody against human CD104 (mAb anti-CD104), was obtained from AbD 
Serotec (Ref. MCA1456). The secondary antibody used in the ELISA was the polyclonal 
antibody anti-mouse IgG (whole molecule)-Peroxidase, produced in goat, provided as a 
solution from Sigma-Aldrich (Ref. A4416). The caffeine-BSA conjugate was synthesized 
and directly provided by the PhD student Julia Grandke in the Immunoanalytics Division, 
Analytical Chemistry; Reference Materials, BAM, Berlin.  
The porphyrin 1 (Por 1) containing an reactive ester group was synthesized and 
directly provided by Doctor Sandrina Silva of the Porphyrins and Phthalocyanines 
Materials Research Group, Department of Chemistry, University of Aveiro, Portugal. 
Hydrogen peroxide (H2O2) 30% Trace Select
 
and
 
tetrabutylammonium borohydride 
(TBAB) were obtained from Fluka. 3,3`,5,5´-tetramethylbenzidine (TMB) and sulphuric 
acid (H2SO4) were from Baker, Tween™ 20 was purchased from Serva. Trifluoroacetic 
acid was purchased from Merck. Ultrapure Sinapic matrix for MALDI was supplied by 
Protea Biosciences. All other reagents were from Sigma. 
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2.1.4. Buffers and solutions 
Table 4.1. Buffers used in the synthesis and characterization of bioconjugates (Por 1-albumins) and 
immunoconjugates (Por 1-mAb anti-Caf and Por 1-mAb anti-CD104). 
Buffer/Solution name Composition pH 
Sodium bicarbonate (NaHCO3) 
buffer 
0.1 M NaHCO3 
Prepared in Milli-Q water 
9.3 
Phosphate buffered saline (PBS) 
buffer 
10 mM NaH2PO4 
70 mM Na2HPO4 
145 mM NaCl 
Prepared in Milli-Q water 
7.60 
Washing buffer 
0.05% (v/v) Tween 20 
Prepared in PBS buffer 
7.60 
Substrate buffer 
220 mM Potassium dihydrogen citrate 
0.5 mM Sorbic acid potassium salt 
Prepared in Milli-Q water 
4.00 
3,3’,5,5’-Tetramethylbenzidine 
(TMB) solution 
40 mM TMB 
8 mM TBAB 
Prepared in N,N-dimethylacetamide 
___ 
Peroxidase substrate 
2.45% (v/v) TMB solution 
3 mM H2O2 
Prepared in substrate buffer 
___ 
 
2.1.5. Softwares 
Origin
TM
 8.0 software from OriginLab was used for most of the displayed graphs. 
ChemDraw Ultra 12.00 from CambridgeSoft was the software used to draw the chemical 
structures. 
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2.2. Protocols 
 
2.2.1. Bioconjugation of Porphyrin 1 (Por 1) with BSA, HSA, mAb anti-Caf 
and mAb anti-CD104 
Principle 
The conjugation of porphyrins with monoclonal antibodies (mAbs) or proteins (like 
albumin) can be carried out via activated ester derivatives [6]. A porphyrin bearing a N-
hydroxysuccinimide (NHS) activated ester (Por 1) [7] reacts with the amine groups of the 
albumin or mAb in aqueous medium and slightly basic pH, provoking the elimination of 
the NHS (Figure 4.2): 
 
Figure 4.2. Por 1-albumin and Por 1-mAbs synthesis. The amine-reactive ester of the porphyrin is 
coupled to the amine groups of the albumins or mAbs in aqueous medium and basic pH. 
 
Protocol: Preparation of Por 1 and BSA/HSA proteins for bioconjugation 
A stock solution of Por 1 at a concentration of 237 µM was prepared in anhydrous 
DMSO.
7
 Stock solutions of BSA and HSA at a concentration of 6.85 µM were prepared in 
0.1 M NaHCO3, pH 9.3. The Por 1-albumin bioconjugates were prepared by mixing 30, 
                                                             
7 Por 1 contains an amine-reactive NHS-ester, which is susceptible to hydrolysis when water is present. 
Thus, stock solutions of this porphyrin were prepared in anhydrous DMSO and under a nitrogen atmosphere. 
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60, or 80 moles of Por 1 with 1 mol of albumins, in a reaction volume of 2 mL in NaHCO3 
buffer (Table 4.2):
8
 
 
Table 4.2. Molar reaction ratios used in the bioconjugation of Por 1 with the albumins. 
 
 
 
 
 
 
 
 
 
 
Protocol: Preparation of Por 1, mAb anti-Caf and mAb anti-CD104 for 
bioconjugation 
As a first approach, conjugation of Por 1 with the mAb anti-Caf was performed. For 
that, a stock solution of Por 1 at 237 µM was prepared in anhydrous DMSO.
7
 The mAb 
anti-Caf was supplied at a concentration of 1 mg.mL
-1
.
9
 The Por 1-mAb anti-Caf 
conjugate was prepared by mixing 30 moles or 80 moles of Por 1 with 1 mol of the mAb 
anti-Caf in a total reaction volume of 100 µL in NaHCO3 buffer (Table 4.3):
8
 
 
Table 4.3. Molar reaction ratios used for bioconjugation of Por 1 with mAb anti-Caf. 
Molar reaction ratio 
(Por 1:mAb anti-Caf) 
Por 1 
concentration 
(µM) 
mAb anti-Caf 
concentration 
(µM) 
Reaction 
Volume 
(µL) 
30:1 66.36 2.21 100 
80:1 66.36 0.83 100 
 
For the Por 1-mAb anti-CD104 bioconjugation, a stock solution of Por 1 at a 
concentration of 660 µM was prepared in anhydrous DMSO.
7
 The mAb anti-CD104 was 
supplied at a concentration of 1 mg.mL
-1
.
10 
The Por 1-mAb anti-CD104 reaction ratio was 
                                                             
8 The solutions were prepared before use under a nitrogen atmosphere, in microtubes sealed with parafilm. 
9 Considering the molecular weight of mAb Caf (whole antibody) equal to 150 kDa, the concentration of the 
stock solution was 6.67 µM. 
10 Considering the molecular weight of the mAb anti-CD104 (whole antibody) equal to 166 kDa, the 
concentration of the stock solution was 6.02 µM. 
Molar reaction 
ratio  
(Por 1:Albumin) 
Por 1 
concentration 
(µM) 
Albumin 
concentration 
(µM) 
Reaction 
volume 
(mL) 
30:1 206 6.87 2 
40:1 206 3.43 2 
80:1 206 2.57 2 
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prepared using 30 moles of Por 1 per 1 mol of mAb anti-CD104 in 50 µL of NaHCO3 
buffer (Table 4.4):
8
 
 
Table 4.4. Molar reaction ratios used in the bioconjugation of Por 1 with the mAb anti-CD104. 
Molar reaction ratio 
(Por 1:mAb anti-
CD104) 
Por 1 
concentration 
(µM) 
mAb anti-
CD104 
concentration 
(µM) 
Reaction 
Volume (µL) 
30:1 180.60 6.02 50 
 
Protocol: Bioconjugation and purification 
The mixtures were gently agitated at RT for 3 h protected from light. The 
bioconjugates were then purified from remaining free Por 1 or free albumin/mAb over a 
gel permeation chromatography (GPC) and kept in NaHCO3 buffer. Four drops (about 100 
µL) were collected in each well of a microtitre 96-wells plate. The eluted fractions were 
monitored at 418 nm (Por 1 absorption at the wavelength of Soret band) and at 280 nm 
(albumin/mAb absorption wavelength), showing a single peak containing both the 
porphyrin and the albumin/mAb (i.e. the bioconjugate). The volumes of the wells with 
highest absorbance were pooled and stored at 4 ºC in darkness (Figure 4.3): 
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Figure 4.3. Bioconjugate recovery (Por 1-mAb anti-CD104) after clean-up on a Sephadex PD-10 
column. The microtitre plate was read at 280 nm and 418 nm and the top fractions were combined. 
 
 
 
Protocol: Characterization, degree of labeling  
The degree of labeling (number of moles of Por 1 per mole of conjugated 
albumin/mAb, DOL) was calculated using spectroscopic methods. The concentration of the 
albumins was determined considering the molar coefficient extinction (at 280 nm) 
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approximately equal to 47,000 cm
-1
.M
-1
. As for the antibodies, the concentration was 
determined as:                            
          
   
. 
The concentration of Por 1 was determined photometrically at 418 nm using Por 1 
dilutions to set up the calibration curve. The DOL was derived for each conjugate at all the 
initial molar ratios employed as follows: 
                          
              
                    
. 
 
 
2.2.2. Enzyme-Linked Immunosorbent Assays  
Principle 
The presence of the immunoconjugate Por 1-mAb anti-Caf in the sample collected 
after purification can be confirmed by an indirect ELISA [8]. Moreover, ELISA can be 
used to investigate whether the conjugation affects the immunoreactivity of the mAb anti-
Caf. Firstly, the Por 1 conjugated with the monoclonal antibody against caffeine is 
immobilized in a solid support. For that purpose, the solid support needs to be coated with 
a conjugate BSA-caffeine (Figure 4.4, Step 1). The BSA-caffeine conjugate has two 
functions: the BSA will be coated to the solid support and the caffeine will be recognized 
by the mAb anti-Caf, which, in turn, is conjugated with Por 1 (Figure 4.4, Step 2). Next, a 
specific antibody (secondary antibody) linked to an enzyme (peroxidase) is applied over 
the surface, recognizing the mAb anti-Caf (Figure 4.4, Step 3). In the final step, a solution 
containing the enzyme´s substrate is added producing a detectable signal at 450 nm 
(Figure 4.4, Step 4).  
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Figure 4.4. Illustration of the competitive indirect ELISA, used in this thesis. The reservoir (squared-
like shape) represents the wells of a microtitre plate well. 
 
Protocol 
Conjugate BSA-caffeine and secondary antibody dilutions (in PBS buffer previously 
equilibrated at RT) were optimized in order to provide an acceptable absorbance signal 
(between 0.5 and 1 at the wavelength of 450 nm after ELISA). A 1,000-fold dilution for 
the conjugate BSA-caffeine and a 10,000-fold dilution for the secondary antibody 
originated the optimal absorbance values. The transparent high-binding microtitre 96-wells 
plates were coated directly with the conjugate BSA-caffeine (100 µL per well) diluted 
1,000-fold in PBS buffer, covered with parafilm and incubated overnight (about 16 h at 
RT) on a microtiter plate shaker at 750 rpm. The plates were then washed once with 
washing buffer (PBS containing 0.05% (v/v) Tween 20).
 
After addition of 100 µL per well 
of the bioconjugate PS-mAb anti-Caf diluted in PBS buffer (1,000-fold or 10,000-fold), the 
plates were covered with parafilm to avoid evaporation and incubated for 3 h with shaking. 
Thereafter, the plates were washed once again with the washing buffer.
 
The secondary 
antibody diluted in PBS 1:10,000 was added to the plate (100 µL per well) and incubated 
for 1 h on the plate shaker at RT. After washing out the calibration standards, samples and 
unbound secondary antibody, 100 µL of peroxidase substrate (prepared prior to use) was 
added into the wells and incubated for 16 min with shaking, protected from light at RT.
11
 
                                                             
11 In the presence of peroxidase substrate, the solution becomes blue and after H2SO4 addition, it becomes 
yellow. 
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The reaction was stopped using 50 µL of 1 M H2SO4, per well. The optical density was 
measured at 450 nm using 650 nm as the reference wavelength. 
 
 
2.2.3. Matrix-Assisted Laser Desorption/Ionization-Time Of Flight-Mass 
Spectrometry assay, MALDI-TOF-MS 
Principle 
The Por 1-albumin bioconjugates can be characterized by mass spectrometry based 
techniques such as MALDI/TOF-MS [9]. 
In this technique, the sample is mixed with a chemical matrix which contains an 
organic molecule with a cromophore. After spot the mixture into a small plate it is allowed 
to dry, forming a crystal lattice into which the protein to be characterized is mixed. The 
plate is then placed into the source which has a laser that emits a beam of light to the 
sample. The organic molecule in the matrix absorbs energy at the wavelength of the laser 
radiation and transfers this energy to the protein in the matrix. With this energy, the protein 
is ejected from the target surface (without undergoing thermal degradation) to the gas 
phase and accepts a proton (gas-phase proton-transfer reactions), producing ions.  
Then, the TOF analyzer measures the time it takes for the ions to fly from one end of 
the analyzer to the other and strike the detector. The speed by which the ions fly down the 
analyzer tube is proportional to their mass-to-charge (m/z) ratios. 
In such way, with the MALDI interface it is possible the detection of the “full” 
molecule, since the process causes little or no fragmentation of the protein or protein 
conjugated with Por 1, allowing the detection of the molecular ion. The native and 
conjugated protein masses can be directly obtained from the spectra. 
 
Protocol 
The Por 1-albumin bioconjugates purified by GPC, were concentrated by 
ultrafiltration (diafiltration) using filters with a cut-off of 3 kDa (Vivaspin 500 µL).
12
 For 
that, 100 µL of the conjugate was placed in the concentrator of the Vivaspin. The 
assembled concentrator was centrifuged at 15,000 x g at 20 ºC for 5 min. After emptying 
                                                             
12 In this process it is important to remove salts and buffers (that will compete with the molecular ion peaks, 
affecting negatively MS analysis) and to concentrate the sample. 
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the filtrate container, the concentrate was refilled with 100 µL of Milli-Q water and the 
sample was centrifuged once more. The last step was repeated and the samples were kept 
at 4 ºC. 
The albumin´s solutions were freshly prepared at a concentration of 2 mg.mL
-1
 in 
Milli-Q water. 
Sinapic acid MALDI matrix was freshly prepared in aqueous solution at a 
concentration of 10 g.L
-1
 containing 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic 
acid. The concentrated sample was mixed up with the matrix 1:2 (by volume), added onto 
the plate
13
 and air-dried for at least 1 h. The data were assessed using Origin 8.0 software 
and the resulting mass spectra data were fitted by a Lorentzian function, assigning the 
centres of the resulting peaks to unconjugated albumins and Por 1-albumin bioconjugates 
masses (the m/z values). 
 
2.2.4. Liquid Chromatography (LC) coupled to Ultraviolet-Visible (UV) and 
Mass Spectrometric (MS) detection, LC-UV-MS assays 
Principle 
The Por 1-albumin bioconjugates can also be characterized by LC-UV-MS [10]. 
The LC-UV-MS encloses three interfaces: High Performance Liquid Chromatography 
(HPLC), Ultraviolet-Visible spectroscopy (UV) and Mass Spectrometry (MS). The HPLC 
separates the components present in the sample by reverse phase chromatography. The 
conjugate is detected first via a photodiode array (PDA), taking into account the 
absorbance of albumin and Por 1 at 280 nm and 418 nm, respectively. Then, on the mass 
spectrometer, the metabolites are ionized (by electrospray ionization, ESI) and the mass 
detector separates all ions that have different masses producing a high full resolution 
spectrum. The spectra obtained are then reconstructed, using the Bayesian Protein 
Reconstruction add-in feature from the Analyst™ software and the conjugate mass range 
can be determined. 
 
 
 
                                                             
13 This steep needs to be performed quickly, since the mixture can dry before its application in the sample 
plate. 
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Protocol 
After concentrating the samples, as aforementioned for the MALDI/TOF-MS, the 
Por 1-albumin bioconjugates characterization by LC-UV-MS was performed. The 
separation was performed on a reverse-phased protein column with a binary gradient 
consisting of eluent A (0.1% trifluoroacetic acid in Milli-Q water) and eluent B (0.1% 
trifluoroacetic acid in methanol), at a flow rate of 450 μL.min-1. The column oven 
temperature was set at 30 ± 2°C. The injection volume was 10 μL. The gradient profile is 
provided in Table 4.5. 
 
Table 4.5. Gradient profile used in LC-UV-MS assays for the Por 1-albumin bioconjugates 
characterization. 
t (min) % B 
0 60 
3 60 
12 90 
25 90 
25.1 60 
35 60 
 
For the diode array detection (DAD) the wavelength range 190 to 900 nm was 
chosen with a step width of 2.0 nm. The settings shown in Table 4.6 were used for the LC-
UV-MS measurements. 
 
Table 4.6. MS profile used in LC-UV-MS assays for the Por 1-albumin bioconjugates 
characterization. 
 
Ionization ESI in the positive ion mode 
Acquisition mode Scan from 200.0-3000.0 a.m.u 
Dwell time 2 sec 
Curtain gas 30 psi (207 KPa) 
Ion source gas #1 50 psi (345 kPa) 
Ion source gas #2 50 psi (345 kPa) 
Source temperature 500°C 
Entrance potential 10 V 
Declustering potential 70 V 
Ion spray voltage 5.0 kV 
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The conjugates were identified after extracting the chromatograms at the 
wavelengths 280 nm (for the albumins) and at 418 nm (for Por 1). The m/z range was 
extracted between 1,000 to 3,000 and the Bayesian Protein Reconstruction was applied, 
using the Bio tools extension of Analyst TM software (starting mass: 20,000 Da; stop 
mass: 70,000 Da; step mass: 1 Da; S/N threshold: 20; 20 iterations). 
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In vitro biological assays 
Part III 
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3.1. Equipment and common materials 
 
3.1.1. General instrumentation 
3.1.1.1. General equipment 
The centrifuge used was a SIGMA 2-16 and the microcentrifuge was a VWR 
MiniFuge Galaxy MiniStar C1413. The vortex was from VWR. The liquid aspirator 
system used was the Vacusip from Integra. The shaker used was a standard analog shaker 
from VWR. 
 
3.1.1.2. Equipment for the UV-visible absorbance and fluorescence 
measurements 
The UV-visible absorbance measurements were performed on a microplate reader 
Synergy™ HT (Biotek Instruments) controlled by BioTek's Gen5™ Data Analysis 
Software. For the porphyrin based photosensitizers, the fluorescence measurements were 
also performed on this equipment. For the phthalocyanine based photosensitizers, the 
fluorescence measurements were determined using the IVIS Lumina XR system (Caliper 
Life Sciences) in combination with its Living Image Software.  
 
3.1.1.3. Equipment for the cells irradiation 
A LED array was prepared by Mr. Cândido Casqueira, electromechanic technician of 
the Departement of Chemistry of the University of Abeiro, and it was used in the 
irradiation assays. It is composed of a matrix of 24 x 16 LEDs which makes a total of 384 
light sources, emitting white light with two emission peaks at λ = 450 ± 20 and λ = 550 ± 
50 nm (Figure 4.5). The regulated Plug-in adaptor with LED indicator 800 mA was 
purchased from MW. 
 
  
 
 
 
Figure 4.5. (Left) Image of the LED array used in the photodynamic experiments. (Right) Emission 
spectra of the LED array system. 
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3.1.1.4. Equipment for the Western Blotting 
The Mini Protean electrophoresis system and the Mini Trans-Blot system were from 
Bio-Rad Laboratories. The tube roller SRT6D was from Stuart. The chemiluminescence 
detection system used was the Chemi Doc
TM
 XRS from Bio-Rad controlled by the 
software Quantity One. 
 
3.1.1.5. Microscopes 
The fluorescence microscope was purchased from Leica Microsystems (Model 
DFC350) and the confocal microscope was from Zeiss (LSM 710, Carl Zeiss).  
 
3.1.2. Materials 
Canted neck cell culture flasks 75 cm
2
 with 0.2 µM vent cap were purchased from 
Corning. CyroPure tubes were purchased from SARSTEDT. The tissue culture testplates 
and the conical tubes of 15 mL or 50 mL were from Orange Scientific. Rubber spatulas, 
cell scrappers were purchased from Greiner Bio-One. The Coverslip Glasses with 
diameters of 5 mm were purchased from Warner Instruments. The Neubauer chamber was 
from VWR. The Immun-Blot PVDF membranes were purchased from Bio-Rad. The plates 
used were transparent (Orange Scientific) and black (Greiner Bio-One) 96-wells microtiter 
plates for the absorbance and fluorescence studies, respectively.  
 
3.1.3. Cell culture and trypsins 
UM-UC-3 (ATCC Number: CRL-1749
TM
) and HT-1376 (ATCC Number: CRL-
1472
TM
), human bladder transitional cell carcinoma cell lines, have been isolated from 
urinary bladder of a male and a female Caucasian aged 58 years, respectively, with a grade 
3 bladder carcinoma. 
EMEM medium: ATCC-formulated Eagle´s Minimum Essential Medium (EMEM) 
from ATCC (Ref. 30-2003) with Earle´s Balanced Salt Solution, Nonessential Amino 
Acids, Sodium pyruvate, 10% (v/v) heat-inactivated Fetal Bovine Serum (FBS) from 
Gibco (Ref. 10270-106) and 1% (v/v) antibiotic/antimicotic containing penicillin, 
streptomycin and amphotericin B from Sigma-Aldrich (Ref. 15240-062). 
N2 medium with 1% (m/v) of methylcellulose: Serum-free Dulbecco´s Modified 
Eagle Medium/Nutrient Mixture F-12 Ham (DMEM/F12 was purchased from Sigma-
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Aldrich (Ref. D2906) with 1% (m/v) of methylcellulose (Sigma-Aldrich, Ref. M0387) 
supplemented with 1% (v/v) antibiotic/antimicotic containing penicillin, streptomycin and 
amphotericin B from Sigma-Aldrich (Ref. 15240-062), 20 nM progesterone (Sigma-
Aldrich, Ref. P7556), 100 μM putrescine (Sigma-Aldrich, P5780), 1% (v/v) of the 
supplement insulin(20 µg.mL
-1
)-transferrin(25 µg.mL
-1
)-selenium(30 nM) (Gibco 
Invitrogen Life Technologies), 10 ng.mL
-1
 human basic fibroblast growth factor (bFGF, 
Peprotech EC) and 10 ng.mL
-1
 human recombinant epidermal growth factor (EGF, Sigma-
Aldrich, Ref. E9644). 
Trypsin-EDTA 0.25% (w/v) and Trypsin Tryple Express were purchased from Gibco 
(Refs. 25200-072 and 12605-010, respectively). Accutase
TM
 was purchased from Sigma-
Aldrich (Ref. A 6964). 
 
3.1.4. Proteins, molecular weight marker and antibodies 
Bovine Serum Albumin (BSA), the lyophilized albumin fraction V was purchased 
from Biochemical (Ref. 441554Y).  
The protein standard for the western blotting assays was the Precision Plus Protein
TM
 
Dual Color standard, containing ten protein bands (10, 15, 20, 25, 37, 50, 75, 100, 150, and 
250 kDa) from Bio-Rad (Ref. #161-0374). 
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Table 4.7. Primary antibodies used in the western blotting and immunofluorescence assays. 
 
Antibody 
Antigen 
Molecular 
Weight (kDa) 
Dilution Supplier 
  
Western 
Blotting 
Immunofluorescence  
Mouse Monoclonal Antibody 
against CD44 antigen (PGp-1) 
90 ___ 1:50 
Santa Cruz 
Biotechnology 
Rabbit Monoclonal Antibody 
against Galectin-1 antigen 
14 1:1000 1:100 Abcam 
Mouse Monoclonal Antibody 
Against CHOP antigen 
27 1:1000 ___ Cell Signaling 
Mouse Monoclonal Antibody 
against Bcl-2 antigen 
26 1:200 ___ 
Santa Cruz 
Biotechnology 
Rabbit Monoclonal Antibody 
against Phospho-Akt antigen 
60 1:2000 ___ Cell Signaling 
Rabbit Monoclonal Antibody 
against Akt antigen 
60 1:1000 ___ Cell Signaling 
Rabbit Polyclonal Antibody 
against Bax antigen 
20 ___ 1:50 
Santa Cruz 
Biotechnology 
Mouse Monoclonal Antibody 
against β-actin antigen 
43 1:20000 ___ Sigma-Aldrich 
Mouse Monoclonal Antibody 
against ABCG2 (BCRP) antigen 
70 1:500 ___ Millipore 
 
The horseradish peroxidase-conjugated secondary anti-rabbit (GAR-HRP) or anti-
mouse (GAM-HRP) antibodies, used in the western blotting assays, were purchased from 
Bio-Rad. 
The secondary anti-rabbit or anti-mouse antibodies, used in the immunofluorescence 
assays, were the Alexa Fluor 488 Goat Anti-Rabbit and Alexa Fluor 568 Goat Anti-Mouse, 
purchased from Molecular Probes.  
 
3.1.5. KITS and probes 
The Immun-Star
TM
 WesternC
TM
 Chemiluminescent Kit (containing the 
chemiluminescent substrate: luminol/enhancer and peroxide solution) used in the western 
blotting assays was from Bio-Rad. 
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The Pierce
 
BCA Protein Assay Kit-Reducing Agent Compatible (containing the BCA 
Protein Assay Reagent and BSA standards at 2 mg.mL
-1
) was purchased from Thermo 
Scientific. 
The 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Enzo Life Sciences. 
The 2´,7´-dichlorohydrofluorescin (H2DCFDA) and dihydroethidium (DHE) were 
purchased from Life Sciences. TRITC (tetramethylrhodamine isothiocyanate)-conjugated 
phalloidin was purchased from Sigma. 
 
3.1.6. Buffers, reagents and chemical products 
PorGal8 and PcGal16 were synthesized by Doctor Sandrina Silva in the Porphyrins 
and Phthalocyanines Materials Research Group, Department of Chemistry, University of 
Aveiro, Portugal. Por 1-albumin bioconjugates and Por 1-mAb anti-CD104 were 
synthesized as described in Part II. 
Sodium Chloride (NaCl), Triton X-100, formaldehyde (PFA) and sodium azide 
(NaN3) extra pure were from Merck. Tris Base ULTROL Grade was from CalbioChem. 
Protease inhibitor cocktail tablets were purchased from Complete Mini. 
Glycerol electrophoresis reagent, DL-dithiothreitol 99%, bromophenol blue salt 
solution, sodium dodecyl sulfate (SDS), ethylene glycol tetraacetic acid (EGTA), 
iodoacetamide (IAD), phenylmethanesulfonyl fluoride (PMSF), sodium deoxycholate 
(DOC), Tween 20, DMSO Hybri-Max™, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT), ammonium persulfate, TEMED electrophoresis reagent, 
glycine, D(+)Galactose, L-histidine, L-cysteine, poly(2-hydroxyethyl methacrylate) poly-
HEMA and agarose were purchased from Sigma-Aldrich. 
The trypan blue stain 0.4% was from BioWhittaker Reagents, Lonza. The 2-propanol 
was from J.T.Baker BAKER ANALYZED™ A.C.S reagents. The methanol (MeOH) was 
from EMSURE, Merck. The hydrochloric acid (HCl) 37% was from Panreac. 
The acrylamide/Bis 20% solution was from BIO-RAD. The ECL reagent was from 
Amersham Biosciences. 
The Glycergel was purchased from DAKO. The VectaSHIELD mounting medium 
with DAPI was purchased from VECTOR.  
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Table 4.8. Buffers used in the biological studies. All buffers were prepared in Milli-Q water unless 
other solvent is mentioned. 
 Buffer name Composition pH 
 PBS buffer 
137 mM NaCl, 27 mM KCl, 81 mM Na2HPO4, 15 mM 
KH2PO4 
7.30 
 
1% SDS lysis 
buffer 
1% (v/v) SDS , Prepared in PBS buffer 7.00 
 RIPA buffer 
150 mM NaCl, 50 mM Tris base, 5 mM EGTA, 1% (v/v) 
Triton X-100, 0.5% (m/v) DOC, 0.1% (m/v) SDS, 2 mM 
PMSF, 2 mM IAD, 1 tablet of protease inhibitor cocktail 
7.50 
 
6x Laemmli 
buffer 
350 mM Tris-HCl, pH 6.8, 30% (m/v) glycerol, 10% (m/v) 
SDS, 600 mM DTT, 0.012% (m/v) bromophenol blue 
6.80 
 
1.5 M Tris-HCl 
buffer 
1.5 M Tris base 8.80 
 
0.5 M Tris-HCl 
buffer 
0.5 M Tris base 6.80 
 Fixation buffer 4% (v/v) PFA, Prepared in PBS buffer 7.30 
Western Blot 
Running buffer 25 mM Tris base, 192 mM Glicyine, 0.1% (m/v) SDS 8.80-8.50 
Transfer buffer 
25 mM Tris base, 192 mM Glycine, 20% (v/v) MeOH, 0.005% 
(m/v) SDS 
8.00-8.50 
Tris Buffer Saline 
Tween20 (TBST) 
buffer 
20 mM Tris base, 150 mM NaCl, 0.1% (v/v) Tween 20 7.60 
Blocking buffer 
5% (v/v) non-fat milk or 3% (v/v) BSA, Prepared in TBST 
buffer 
7.60 
Immunofluorescence 
Blocking buffer 
5% (v/v) BSA or 1:10 (by volume) goat serum, Prepared in 
PBS buffer 
 
Permeabilization 
buffer 
1% (v/v) Triton X-100, 0.02% (m/v) BSA, 0.02% (m/v) NaN3, 
Prepared in PBS 
7.30 
PBS Triton X-100 
(PBST) buffer 
0.25% (v/v) Triton X-100, 1% (m/v) BSA, 0.02% (m/v) NaN3, 
Prepared in PBS 
7.3 
Washing buffer 0.02% (m/v) BSA, 0.02% (m/v) NaN3, Prepared in PBS 7.3 
 
 
3.1.7. Softwares 
Paint Shop Pro
TM
 (v.6.00, Jasc Software) was used for the treatment of the images 
obtained in microscopy. 
ImageJ 1.42n (Wayne Rasband, National Institutes of Health, USA) was used for the 
quantification of the proteins expression on western blotting assays. 
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GraphPad Prism (v.5.00, GraphPad Software) was used for most of the displayed 
graphs, as well as for the statistical analysis.  
 
3.1.8. Statistical Analysis 
The results are presented as mean ± standard deviation (S.D.) with n indicating the 
number of experiments. Statistical significance among two conditions was assessed using 
the nonparametric Mann-Whitney test. Statistical significance among three conditions was 
assessed by the nonparametric Kruskal-Wallis test. Statistical significance among several 
conditions was assessed with the Friedman test. P-value was considered at the 5% level of 
significance to deduce inference of the significance of the data. 
 
 
 
3.2. Protocols 
 
3.2.1. Maintenance of UM-UC-3 and HT-1376 bladder cancer cell lines 
Principle 
Animal cell lines, obtained from certain cancer cells and from genetic engineering, 
under the appropriate nutrients and strict aseptic conditions grow and replicate in culture 
[11]. 
 
Protocol: Defrosting Cells 
The human bladder carcinoma cell lines were frozen in 1 mL vials in liquid nitrogen. 
The vial content was thawed, as fast as possible, in 37 ºC water bath and transferred to 5 
mL of prewarmed EMEM medium. After centrifugation at 1,000 x g during 5 min, 
appropriate aliquots of cell suspension were added to new 25 cm
2
 or 75 cm
2
 cell culture 
flasks. Cells grown in monolayer at 37 ºC in a humidified incubator gassed with 5% carbon 
dioxide (CO2) and 95% air. 
 
Protocol: Subculturing 
After 1 week or 3 days, respectively, HT-1376 and UM-UC-3 cell layers were 
normally confluent, and subculturing was necessary. The EMEM medium was removed 
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from culture flasks by aspiration and discarded. The cell layers were rinsed with 5 mL of 
warm sterile PBS, in order to remove traces of serum which would inhibit the action of the 
trypsin. UM-UC-3 and HT-1376 cells were treated with 0.033 mL.cm
-2
 of trypsin Tryple 
Express or 0.040 mL.cm
-2
 of trypsin-EDTA, respectively. The trypsinization progress was 
monitored under an inverted microscope. Flasks were incubated at 37 ºC until the cells 
rounded up and the cell layer begun being dispersed: 5 min or 8 min to 10 min for the cell 
line UM-UC-3 and HT-1376, respectively.
 
EMEM medium (0.1 mL.cm
-2
) was added to 
inhibit further tryptic activity and the cells were dispersed by repeated pippeting over the 
surface bearing the monolayer.
 
The cells suspensions were then centrifuged at 1,000 x g for 
5 min. The supernatant was removed, the cells were re-suspended in EMEM medium and 
appropriate aliquots of cells were added to new 25 cm
2 
or 75 cm
2 
culture flasks. Cells were 
examined carefully every day by eye on an inverted microscope, for signs of contamination 
and the EMEM medium was changed two or three times per week.
14
 UM-UC-3 and HT-
1376 cells were subcultivated at a ratio of 1:4 to 1:10 or 1:2 to 1:6, respectively, in the 
conditions described above. 
 
Protocol: Freezing Cells 
UM-UC-3 and HT-1376 cells were stored frozen as stocks in liquid nitrogen using 
EMEM medium containing 10% (v/v) DMSO at a density of 2-4 x 10
6
 cells.mL
-1
. Cells 
were also frozen at -80 ºC for short times. Cells were harvested in the same manner used 
for routine subculture. The cell pellet was re-suspended in EMEM medium to give a final 
concentration of about 3 x 10
6
 cells.mL
-1
 and 900 µL were aliquot into each sterile vial 
containing 100 µL of sterile DMSO. The cells were frozen in a -80 ºC freezer prior to 
transfer to liquid nitrogen. 
 
 
3.2.2. HT-1376 sphere-formation assay  
Principle 
Cancer stem-like cells (CSCs) can be isolated from the HT-1376 cell line using the 
sphere-formation assay in ultra-low attachment surfaces. The general idea of the sphere-
formation assay is that each sphere derived from a single cell is clonal. For that assay, HT-
                                                             
14 The cells HT-1376 were growing slowly and only half the medium was removed and replaced. 
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1376 cells are trypsinized and single cells are plated in non-adherent conditions in serum-
free supplemented with epidermal growth factor (EGF) and basic fibroblast growth factor 
(bFGF). A small population of cells will began to divide, forming spheres of proliferating 
cells. To show self-renewal, the formed spheres are dissociated and cultured again in the 
presence of EGF and bFGF, with a subset forming secondary spheres. 
The spheres obtained with this method were designated CSCs HT-1376.  
 
Protocol: Coating cell culture plates 
The 6-wells or 96-wells cell culture plates were coated with 50 µL per cm
2
 of 10% 
(m/v) poly-HEMA solution prepared in 95% ethanol or 1% (m/v) of agarose prepared in 
Milli-Q autoclaved water. The plates were dried at RT overnight and sterilized under UV 
light for at least 2 h. The plates were then rinsed with sterile warm PBS. 
 
Protocol: Culturing HT-1376 cells as spheres 
Adherent HT-1376 cells growing in EMEM medium
15
 were detached with trypsin 
and plated in N2 medium with 1% (m/v) methylcellulose, at a density of 4,200 cells.cm
-2
 in 
6-wells or 96-wells coated cell culture plates (according to the experiment). Spheres were 
formed in suspension at 37 ºC in a humidified incubator gassed with 5% carbon dioxide 
(CO2) and 95% air. The EGF and bFGF growth factors 10 ng.mL
-1
 were added twice a 
week.
16
 After 5 to 7 days in culture, the first generation spheres were expanded. For that, 
they were removed from the 6-wells cell culture plates and centrifuged at 1,000 x g for 5 
min. After washing with warm PBS, the supernatant was removed and the cells were re-
suspended in N2 medium (without methylcellulose) containing 2% (v/v) FBS. The cells 
were allowed to attach to adherent 25 cm
2
 flask surfaces as described above (Part III, 
3.2.1). After reaching 60% to 80% confluence (10-12 days), the expanded cells were re-
seeded in stressful growth conditions for the formation of secondary generation spheres. 
For that, the cells were detached with trypsin and plated in N2 medium with 1% (m/v) 
                                                             
15 The cells should have about 80% of confluence and only cells with viability above 90% were used in all 
experiments. For these experiments, the tryptic digestion was inhibited with 1 mL of EMEM medium (with 
low FBS concentration, 0.02% v/v) because the addition of the serum results in cells differentiation and their 
growth as an adherent layer. 
16 The cells were evaluated daily to follow sphere formation, to ensure that they were derived from single 
cells and that they did not become confluent and adherent during the experiment. 
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methylcellulose, at a density of 4,200 cells.cm
-2
 in 6-wells coated cell culture plates (2 mL 
per well). 
Protocol: Counting the spherical colonies 
The total number of spherical colonies obtained at each passage was determined by 
platting the cells in N2 medium with 1% of methylcellulose, at a density of 4,200 cells.cm
-
2
 in 96-wells coated cell culture plates (100 µL per well). After 5-7 days in culture, the 
spheres were counted using a light microscope. The results were expressed as follows: 
                                
                        
                            
    . 
 
 
3.2.3. Preparation and treatment of UM-UC-3, HT-1376 and CSCs HT-1376 
cells with photosensitizers  
Principle 
UM-UC-3, HT-1376 and CSCs HT-1376 cells in exponential growth (in 
conventional monolayer culture) are treated with working sterile solutions of PSs.  
 
Protocol: Preparing PSs working solutions  
Stock solutions of the PSs at a concentration of 2 mM were prepared in DMSO and 
stored at 0-4 ºC in dark conditions. Freshly working solutions
 
were prepared from the 
respective stock solution in sterile PBS, accounting their water solubility range. The 
concentration of DMSO was always lower than 0.45% (v/v), in all working solutions. 
 
Protocol: Preparing UM-UC-3 and HT-1376 bladder cancer cell lines, and CSCs 
HT-1376 
UM-UC-3 and HT-1376 adherent cells were detached with trypsin as described 
before (Part III, 3.2.1).  
HT-1376 second generation spheres were dissociated with accutase during 3 min. 
EMEM medium was then added to inhibit accutase/trypsin activity and cells were 
dispersed by repeated pippeting up and down for 4 min. The cells suspensions were then 
centrifuged at 1,000 x g for 5 min.  
The cells were re-suspended in EMEM medium and seeded into cell culture plates 
(plates of 6, 12, 24, or 96-wells according to the experiment) at a density of 9.4 x 10
4
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cells.cm
-2   17
 and incubated overnight in an incubator at 37 ºC with 5% CO2 and 95% air to 
promote cell adhesion. 
 
Protocol: Treatment of UM-UC-3 and HT-1376 bladder cancer cell lines, and 
CSCs HT-1376 with photosensitizers 
After seeding the cells overnight, the EMEM medium was removed and the cells 
were washed with PBS.
18
 The cells were incubated in dark conditions at various periods of 
time with increasing concentrations of PSs in sterile PBS. 
 
 
3.2.4. Determination of intracellular photosensitizer concentration by 
fluorimetry 
Principle 
Taking into account the fluorescence properties of the porphyrin and phthalocyanine 
PSs, their concentration inside the cancer cells can be determined by fluorimetry (after cell 
lysis) and normalized to total protein quantity. 
The concentration of proteins in a sample can be measured spectrophotometrically 
using the Bicinchoninic Acid Assay (BCA assay), also known as the Smith assay [12]. The 
procedure involves two steps. The first is the biuret reaction, whose faint blue color results 
from the reduction of cupric ion (Cu
2+
) to cuprous ion (Cu
+
) by peptide bonds in protein, in 
an alkaline environment. Therefore, the amount of reduced Cu
2+
 is proportional to the 
amount of protein present in the solution. The second is the chelation of two molecules of 
BCA with one cuprous ion, resulting in an intense purple-colored product that strongly 
absorbs light at the wavelength of 562 nm. The BCA-copper complex exhibits a strong 
linear absorbance at 562 nm with increasing concentration of protein. The purple color can 
be measured at any wavelength between 550 nm and 570 nm with minimal loss of signal. 
 
 
 
                                                             
17 The concentration of viable cells per milliliter of cell supession was calculated using the Trypan Blue 
Staining (described on the Part III, 3.2.7.2). Only cells with viability above 90% were used in all 
experiments. 
18 This washing step allows the elimination of serum proteins that are able to interact with the PSs. 
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Protocol: Determination of intracellular photosensitizer fluorescence by 
fluorimetry 
UM-UC-3, HT-1376 and CSCs HT-1376 cells were seeded into 96-wells cell culture 
plates at a density of 3 x 10
4
 cells per well (final volume of 100 µL per well) and incubated 
overnight in an incubator at 37 ºC with 5% CO2 and 95% air. On the following day, 
immediately after PSs incubation (as described in Part III, 3.2.3), cells were washed twice 
with PBS. Cells were mechanically scrapped in 130 µL of 1% (m/v) SDS solution in PBS 
(pH 7.0) and the plate was stirred on an automatic plate shaker in the dark at RT. One 
hundred µL of this cell suspension was transferred to 96-wells black plates and the 
intracellular fluorescence of the PSs was determined by ﬂuorometric measurement, using 
standard PSs solutions for calibration. For the porphyrin based PSs, the intracellular 
fluorescence was determined using the plate reader fluorometer in combination with its 
software. For these PSs, the excitation and emission filters used were 360/40 nm and 
645/40 nm, respectively. For the phthalocyanine based PSs, the intracellular fluorescence 
was determined using the IVIS Lumina XR equipment. For these PSs, the excitation and 
emission filters used were 675 nm and 695-770 nm, respectively. The PS concentration in 
the samples was directly obtained by plotting the average of the fluorescence for each PS 
standard in function of its concentration (µM). 
 
Protocol: Determination of total protein 
In a 96-wells plate, the following solutions were pipetted into each well: 
- 25 µL of sample buffer: 1% (m/v) SDS in PBS (pH 7.0), 
- 25 µL of sample, blank (sample buffer), standard (prepared in the sample buffer at 
concentrations ranging from 12.5-800 µg.mL
-1
 using the BSA standard at 2 mg.mL
-1
), 
- 200 µL of BCA working Reagent (50 parts of BCA reagent A mixed with one part 
of BCA reagent B). 
The plate was incubated at 37 ºC for 30 min. Then, the absorbance at 570 nm was 
measured in the plate reader spectrophotometer. The protein concentration in the samples 
was directly obtained by plotting the average of the absorbance at 570 nm for each BSA 
standard in function of its concentration (µg.mL
-1
). 
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Protocol: Calculations 
The PS uptake curves were obtained by non linear regression analysis (using 
GraphPad), accordingly to the following equation: 
                                  
         
       
. 
The Bmax is the maximum extrapoled value of the PS uptake (nmol of PS per mg of 
protein) and Kd is the PS concentration needed to achieve a half maximum uptake at 
equilibrium. 
 
3.2.5. Determination of intracellular photosensitizer fluorescence by 
fluorescence microscopy 
Principle 
Based on the fluorescence properties of the porphyrin and phthalocyanine based PSs, 
their distribution inside the cells can be evaluated by fluorescence microscopy. 
 
Protocol 
Coverslips (three coverslips per well in 12-wells culture plates) were coated with 
poly-L-lysine (diluted 1:10, by volume, in sterile PBS) for 1 h at RT. The coverslips were 
allowed to dry completely at RT. The UM-UC-3 and HT-1376 cells were plated carefully 
at a density of 1.8 x 10
5
 cells or 3.6 x 10
5
 cells per well (2 mL per well), respectively, in 
12-wells culture plates for 24 h before treatment. After photosensitizer uptake and 
washing, cells were fixed
 
with 4% PFA for 10 min at RT. The samples were washed with 
PBS (3 x 5 min). The coverslips were mounted using the VectaSHIELD mounting 
medium,
19
 sealed with nail polish and stored at 4 ºC until visualization under the 
fluorescence microscope. 
 
3.2.6. Photodynamic assays  
Principle 
The excitation of a potential PS (previously accumulated in cancer cells) with light at 
a specific wavelength induces cell toxicity, which is mediated by ROS generation. It is 
expected that, besides the preferential accumulation of the PS in cancer cells, they produce 
                                                             
19 The mounting medium is applied on a slide and the coverslip with cells on top is added. 
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toxicity just after activation by light. Thus, it is important to evaluate both the PS toxicity 
in the absence of light and after light irradiation. 
 
Protocol: Irradiation 
After PSs incubation (as described in Part III, 3.2.3), the cells were washed twice 
with PBS
 
and covered with 100 µL of fresh medium. In a dark room, the cells were 
irradiated for variable times with a LEDs array system emitting white light with two 
emission peaks at λ = 450 ± 20 and λ = 550 ± 50 nm. The cell culture plates were placed 
above the LEDs. Under these conditions, most of the light was emitted at a potency of 8.4 
mW.cm
-2
. After irradiation, cells were incubated for selected time points in the humidified 
incubator gassed with 5% CO2 and 95% air. 
 
 
3.2.7. Cell viability assays 
3.2.7.1. MTT colorimetric assay 
Principle 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT, yellow-
colored) is added directly to the medium in the wells and incubated for 2-4 h. In living 
cells, MTT is reduced to an insoluble formazan (giving a blue purple colour), being this 
reduction proportional to the mitochondrial enzyme succinate dehydrogenase activity [13].  
 
Protocol  
For the MTT colorimetric assays, the UM-UC-3, HT-1376 and CSCs HT-1376 cells 
were plated at a density of 3 x 10
4
 cells per well (100 µL per well), in 96-wells culture 
plates for 24 h before treatment. Next, the cells were treated with the photosensitizer and 
the photodynamic treatment was performed, as described before (Part III, 3.2.3 and 3.2.6). 
Twenty four, 48, or 72 h after treatments, 50 µL of the medium was removed and 10 µL of 
MTT stock solution (3 mg.mL
-1
 in PBS buffer) was added to each well at a final 
concentration of 0.5 mg.mL
-1
. The plates were then wrapped in aluminium foil and 
incubated in the darkness at 37 ºC for 4 h. The resulting purple needle-shaped crystals were 
dissolved by the addition of 200 µL acidic isopropanol (0.04 M HCl in absolute 
isopropanol). To solubilise completely the converted dye, repetitive pipetting was applied 
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and the plate was stirred on an automatic plate shaker in the dark at RT. The absorbance 
was measured at 570 nm (using 620 nm as the background wavelength), using a plate 
reader spectrophotometer. The percentage of absorbance for each treated sample was 
normalized to that of the untreated control cells.  
 
Calculations 
For each well, the absorbance was expressed as:  
                                   . 
The results were expressed as percentage of MTT reduction:  
                  
                       
                       
     . 
The IC50 values (i.e. concentration of PS that reduces cell survival by 50%) were 
calculated using non-linear regression analysis, sigmoidal dose-response curves (using 
GraphPad Prism) as shown in the equation below: 
                          
          
                                
. 
Herein, Bottom represents the maximum value of response (maximum percent of 
MTT reduction) and Top is the minimum value of response (minimum percent of MTT 
reduction). The log IC50 is the log of the PS concentration ([PS]) that responses midway 
between Top and Bottom. The Hillslope is the steepness of the curve. 
 
3.2.7.2. Trypan blue assay 
Principle 
Trypan blue is an organic amine dye that is excluded by living cells with intact 
membranes, whereas dead or dying cells with compromised plasma membrane integrity 
take up the dye. Therefore, all the cells that exclude the dye are considered viable and 
appear brilliant under the microscope. By contrast, cells with damaged membranes appear 
with a distinctive blue color readily observed under the microscope [11]. 
 
Protocol  
To check cell viability before plating the cells, they were trypsinized and 
resuspended in medium (as described in Part III, 3.2.1 and 3.2.2). Then, 20 µL of cell 
suspension and 20 µL of trypan blue stain were gently mixed, and the cells were counted 
using a haemocytometer. The percentage of viable cells and the concentration of viable 
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cells per milliliter of cell suspension were calculated. Only cells with viability above 90% 
were used in all experiments. To check cell viability after PDT experiments, the UM-UC-3 
and HT-1376 cells were plated at a density of 8.9 x 10
4
 cells per well (259 µL per well), in 
48-wells culture plates for 24 h before treatment. Next, the cells were treated with the 
photosensitizer and the photodynamic treatment was performed, as described in Part III, 
3.2.3. Twenty four, 48, or 72 h after treatments, the cell suspension was diluted in the 
trypan blue stain and the cells were counted. 
 
Calculations 
Viable (bright cells) and nonviable cells (cells stained in blue) were counted and 
summed for the total number of cells. The viability was calculated as follows:  
                 
                      
                     
    . 
The concentration of viable cells per milliliter in the cell suspension was calculated 
considering the average of viable cells (VCs) per each counting square, the dilution made 
and the volume of each counting square:
20
 
            
  
 
                   
      
. 
 
 
3.2.8. Galactose blocking assays 
Principle 
The possible involvement of galectins (galactose binding proteins) in the uptake (and 
consequent phototoxicity) of PSs conjugated with galactose molecules can be indirectly 
assessed by “blocking” the galectin binding sites with galactose.  
 
Protocol  
The UM-UC-3 and HT-1376 cells were plated at a density of 3 x 10
4
 cells per well 
(100 µL per well), in 96-wells culture plates for 24 h before treatment. On the following 
day, the cells were incubated in the presence of 50 nM galactose in PBS for 1.5 h, in an 
incubator at 37 ºC with 5% CO2 and 95% air. The uptake of the galacto-conjugates was 
determined by fluorometry, as described in Part III, 3.2.4. The effect of galactose on cell 
                                                             
20 Considering the volume of each counting square to be 0.1 mm3, the same as 1 x 10-4 mL. 
Methods and Materials                                                                                                In vitro biological assays 
139 
 
viability was evaluated 24 h after photodynamic therapy by the MTT viability assay, as 
described in Part III, 3.2.7. 
 
 
3.2.9. Intracellular levels of Reactive Oxygen Species after Photodynamic 
assays 
Principle 
The ROS generation after PDT can be detected using the dichlorofluorescein 
(H2DCFDA) [14] and the dihydroethidium (DHE) [15] probes, by fluorescence 
microscopy and fluorescence spectroscopy techniques. H2DCFDA is able to cross the cell 
membrane and their acetate groups are removed by intracellular esterases, producing 
H2DCF. H2DCF reacts with several cytotoxic oxygen species producing DCF that can be 
used as a measure of intracellular ROS levels. DHE probe diffuses across cell membrane, 
exhibiting blue fluorescence. In the presence of ROS (particularly superoxide anion) this 
probe is oxidized to ethidium, which intercalates within the cell´s DNA, staining the 
nucleus with bright red fluorescence.  
The intracellular fluorescence of the probes was normalized to total protein quantity. 
 
Protocol: Reactive oxygen species evaluation by fluorimetry 
The UM-UC-3 and HT-1376 cells were plated at a density of 3 x 10
4
 cells per well 
(100 µL per well), in 96-wells black plates for 24 h before treatment. Immediately after 
photodynamic treatment and washings, cells were incubated with either 2 μM or 5 μM of 
H2DCFDA or DHE
21 
in PBS (in dark conditions) for 1 h at 37°C. The excitation and 
emission filters used for the H2DCFDA probe were 485/20 nm and 528/20 nm, 
respectively. For the DHE probe, the excitation and emission filters used were 485/20 nm 
and 590/35 nm, respectively. After fluorometric measurement, cells were lysed with 1% 
(m/v) SDS solution in PBS (pH 7.0) and total protein concentration was determined as 
previously described (Part III, 3.2.4).  
 
 
                                                             
21 H2DCFDA and DHE were prepared in DMSO as stock solutions with a concentration of 5 mM, under a 
nitrogen atmosphere. The stock solutions were then kept in the dark at -20 ºC. 
Methods and Materials                                                                                                In vitro biological assays 
140 
 
Protocol: Reactive oxygen species evaluation by fluorescence microscopy  
Coverslips were coated with poly-L-lysine (diluted 1:10, by volume, in sterile PBS) 
for 1 h at RT. The UM-UC-3 and HT-1376 cells were plated carefully at a density of 1.8 x 
10
5
 cells or 3.6 x 10
5
 cells per well (2 mL per well), respectively, in 12-wells culture plates 
for 24 h before treatment. The cells were treated with the photosensitizer and the 
photodynamic treatment was performed. After PDT treatments, cells were incubated with 5 
μM of H2DCFDA or DHE in PBS (in dark conditions) for 1 hour at 37°C. The cells were 
washed twice for 5 min each in PBS. After that, the cells were fixed in 4% PFA for 10 min 
at RT. The samples were washed with PBS (3 x 5 min). The coverslips were mounted 
using the VectaSHIELD mounting medium, sealed with nail polish and stored at 4 ºC until 
visualization under the fluorescence microscope. 
 
 
3.2.10. Redox quenching assays 
Principle 
The role of type I and type II oxidative mechanisms in cell toxicity after PDT, can be 
evaluated using specific quenchers of 
1
O2 (sodium azide [16] and histidine [17]) and free 
radical scavengers (cysteine [18]), respectively. 
Protocol 
The UM-UC-3 and HT-1376 cells were plated at a density of 3 x 10
4
 cells per well 
(100 µL per well), in 96-wells black plates for 24 h before treatment. Immediately after PS 
uptake, the cells were washed and the redox quenchers (sodium azide, histidine and 
cysteine at concentration of 50 nM in growth culture medium) were added to the cells. 
After incubation with the redox quenchers for 10 min, the photodynamic treatment (in the 
presence of the redox quenchers) was performed. The effect of the presence of quenchers 
on cell viability was evaluated 24 h after photodynamic therapy by the MTT viability 
assay.  
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3.2.11. F-actin staining after Photodynamic assays 
Principle 
The changes induced by the photo-activated PS on actin microfilaments can be 
determined using the fluorescent conjugate tetramethylrhodamine isothiocyanate (TRITC)-
labelled phalloidin[19]. Phalloidin is a fungal toxin that binds to polymeric and oligomeric 
forms of F-actin and stabilizes the actin filaments.  
 
Protocol 
Coverslips were coated with poly-L-lysine (diluted 1:10, by volume, in sterile PBS) 
for 1 h at RT. The UM-UC-3 and HT-1376 cells were plated carefully at a density of 1.8 x 
10
5
 cells or 3.6 x 10
5
 cells per well (2 mL per well), respectively, in 12-wells culture plates 
for 24 h before treatment. The cells were treated with the photosensitizer and the 
photodynamic treatment was performed. After PDT treatments, the cells were fixed in 4% 
PFA for 10 min at RT. The samples were washed with PBS (3 x 5 min). To visualized F-
actin staining, the cells were incubated in darkness with 0.20 µM of TRITC-phalloidin in 
PBS for 40 min at room temperature. After washing with PBS, coverslips were mounted 
using the VectaSHIELD mounting medium, sealed with nail polish and stored at 4 ºC until 
visualization under the fluorescence microscope. 
 
 
3.2.12. Western Blotting assays 
Principle 
The presence of specific proteins in a complex mixture extracted from cells can be 
performed by Western Blotting using specific antibodies. Moreover, with this technique it 
is possible to quantify the levels of the proteins. For that, denaturated proteins present in 
the mixture are separated in a polyacrylamide gel by electrophoresis, accordingly to their 
size, following the methodology of Laemmli [20]. Then, the separated proteins in the gel 
are electrotransferred to a membrane using the method of Towbin [21] and a specific 
unlabeled antibody is used to stain the target antigen. After wash, a labeled secondary 
antibody is used to detect the presence of the primary antibody, and thus the target protein. 
The proteins can be visualized as bands, using the ECL (enhanced chemiluminescence) 
detection method. For ECL detection, the horseradish peroxidase (HRP), which is 
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conjugated with the secondary antibody, in the presence of hydrogen peroxide and an 
enhancer, catalyzes the oxidation of luminol, emitting light. The emitted light can be 
detected using a CCD camera for light capture. 
 
Protocol: Sample preparation of UM-UC-3 and HT-1376 cells (adherent cells) 
For immunodetection of proteins associated to cell death after PDT, the HT-1376 
cells were plated at a density of 4 x 10
5
 cells or 8 x 10
5
 cells per well (2.5 mL per well), 
respectively, in 6-wells culture plates for 24 h before treatment. The cells were then treated 
with the photosensitizer and the photodynamic treatment was performed. After treatment, 
the cells were washed twice with ice-cold PBS and lysed by addition of ice-cold RIPA 
buffer with fresh protease inhibitors (500 µL of buffer was used per 5 x 10
6
 cells, per 60 
mm of Petri dish or per 75 cm
2
 flask). The cell lysates were then transferred to microtubes 
with the help of a rubber policeman (cell scrapper) and incubated on ice during 30 min. 
During incubation, samples were vortexed 10 sec every 10 min.
22
 The total cell lysates 
were centrifuged at 18,000 x g for 16 min, at 4 ºC. The supernatant was transferred to a 
new microcentrifuge tube. The supernatants were used for protein concentration 
determination, followed by denaturation with Laemmli buffer. 
  
Protocol: Sample preparation of CSCs HT-1376 (cells growing in suspension) 
The cells were pipetted into a fresh conical tube and placed on ice. The cells were 
centrifuged on low speed at 4 ºC and the medium was aspirated. Ten mL of ice cold PBS 
was added to the cell pellet and the tube was gently inverted to wash the cells. The cells 
were again centrifuged on low speed and the supernatant was aspirated. The washing and 
aspiration was repeated. Ice cold RIPA buffer with fresh protease inhibitors was added to 
the cells (500 µL of buffer was used per 60 mm of Petri dish or per 75 cm
2
 flask). The cell 
suspension was transferred to a clean microtube and incubated on ice during 30 min. 
During incubation, samples were vortexed 10 sec every 10 min. The cell lysates were 
clarified by spinning for 16 min at 18,000 x g, at 4 ºC. The supernatant was transferred to a 
new microcentrifuge tube and the supernatants were used for protein concentration 
determination, followed by denaturation with Laemmli buffer. 
 
                                                             
22 These vortex steps are important for the cell disruption. 
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Protocol: Determination of total protein 
The protocol used for the determination of protein concentration was the same as 
described in Part III, 3.2.4, with some differences: 
The samples were diluted in RIPA buffer 1:9 (by volume) and in a 96-wells plate, the 
following solutions were pipetted to each well: 
- 25 µL of sample buffer: RIPA buffer, 
- 25 µL of sample, blank (sample buffer), standard (prepared in the sample buffer at 
concentrations ranging from 12.5-800 µg.mL
-1
 using the BSA standard at 2 mg.mL
-1
), 
- 200 µL of BCA working Reagent (50 parts of BCA reagent A mixed with one part 
of BCA reagent B). 
 
Protocol: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis and 
Blotting 
After determination of protein concentration, the samples were denaturated with 6x 
Laemmli buffer. The samples were heated at 37 ºC for 30 min, or boiled during 5 min at 95 
ºC. Sixty µg of protein samples was loaded on 10% or 12% polyacrylamide gels and the 
proteins were separated by electrophoresis. The electrophoresis was stopped when the dye 
front reached the bottom of the gel.  
Following gel electrophoresis, the separated protein mixtures were transferred to a 
solid support for further analysis. The polyvinylidene difluoride membranes (PVDF) were 
first activated with 100% MeOH, and then soaked in Milli-Q water and equilibrated in 
transfer buffer. All the material used in the blotting (sponges, sheets of filter paper), as well 
as the gels were also equilibrated in transfer buffer. The gel and the PVDF membrane were 
assembled into a sandwich along with sheets of filter paper and sponges. The separated 
proteins were then transferred to the PVDF membranes (using ice cold transfer buffer) for 
90 min under agitation, with the tank in ice (and using a cooling coil inside the tank). At 
the end, the baking of the membranes was performed by incubation at 50 ºC for 20 min. 
 
Protocol: Antibodies incubations, detection and quantification 
The membranes were placed into blocking buffer for 1 h at RT with gentle agitation. 
The membranes were incubated with the primary antibody (diluted in the blocking buffer) 
for 2 h at RT, under low agitation. After incubation, the membranes were rinsed in TBST 
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(3 x 10 min) at RT. The appropriate secondary antibody conjugated with the enzyme 
horseradish-peroxidase diluted 1:10,000 (v/v) in 2.5% non-fat milk (prepared in TBST) 
was added, and the membranes were incubated for 1 h at RT, under moderate agitation. 
After incubation with the secondary antibodies, the membranes were washed in TBST (3 x 
10 min), with agitation. To demonstrate equivalent protein loading, all the membranes 
were re-probed for the protein β-actin. For the detection, the membranes were placed on 
the chemiluminescence detection system
23
 (proteins side up), incubated with the substrate 
solution (1:1, by volume, mixture of luminol/enhancer and peroxide buffer) for 1 min 
following manufacturer instructions, and then the images were acquired. The intensity 
signal of the bands was quantified using the software ImageJ 1.42q and the fold change in 
protein levels was expressed as follows and then normalized to the control situation: 
                                  
                    
                    
. 
 
 
3.2.13. Immunofluorescence assays 
Principle 
The distribution of specific proteins through the sample can be visualized by 
immunocytochemistry. First, the cells are fixed to retain their shape and structure 
(morphology) and location of all cellular proteins and to disable intrinsic proteolytic 
enzymes. The cells are then permeabilized with a mild detergent, so the antibodies could 
have access to the cytoplasm. After that, specific unlabeled primary antibody binds to the 
target molecule, and the secondary antibody (covalently attached to a fluorophore) 
recognizes the primary antibody. At the end, the images can be obtained using a 
fluorescence microscope, showing the subcellular distribution of the protein of interest. 
 
Protocol: Sample preparation, adherent cells (UM-UC-3 and HT-1376 cells) 
Coverslips were coated with poly-L-lysine (diluted 1:10, by volume, in sterile PBS) 
for 1 h at RT. UM-UC-3 and HT-1376 cells were plated at a density of 1.8 x 10
5
 cells or 
3.6 x 10
5
 cells per well (2 mL per well), respectively, in 12-wells culture plates for 24 h 
                                                             
23 To prevent drying, the membranes were placed in a nylon transparent sheet. 
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before treatment. For the treatments with the PSs, the cells were treated and the 
photodynamic treatment was performed. 
  
Protocol: Sample preparation, suspension cells (CSCs HT-1376) 
The HT-1376 spheres growing in suspension were collected to a microtube and 
centrifuged at 3,300 x g during 5 min. The cell pellet was washed twice with warm PBS. 
 
Protocol: Fixation, permeabilization, blocking and incubation with the 
antibodies 
After washing with PBS, the cells were fixed
 
in 4% PFA for 10 min at RT. The 
samples were washed with PBS (3 x 5 min). The cells were treated with permeabilization 
buffer during 10 min. Then, the cells were washed with washing buffer, for 5 min. The 
cells were incubated with the blocking buffer
24
 for 30 min, in a humidified chamber. After 
blocking, the cells were incubated with the primary antibody diluted in PBST buffer during 
1 h at RT, in a humidified chamber. The primary antibody solution was decanted and the 
samples were washed with washing buffer (3 x 5 min). The cells were incubated with the 
secondary antibody and DAPI (1 µg.mL
-1
) diluted in PBST buffer for 1 h (at RT) in a 
humidified chamber in the dark. The cells were washed in the dark three times with the 
washing buffer, 5 min each wash. The coverslips were mounted using the glycergel 
mounting medium and sealed with nail polish. The samples were stored in an appropriate 
box at 4 ºC until acquisition of images by fluorescence microscopy. 
 
 
                                                             
24 For the antigen CD44, the blocking buffer was goat serum. For the other antigens, the blocking buffer was 
BSA. 
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